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Protein glycosylation is a well-established post translational modification occurring in all forms 
of life. In the past two decades, protein glycosylation has been extensively studied in bacterial 
pathogens underscoring its importance in virulence and colonisation. However, despite the 
wealth of information regarding protein glycosylation in bacterial pathogens, little is known 
about this process in gut commensal bacteria. The gut microbiota has co-evolved with and is 
largely adapted to its host, leading to mutually beneficial interactions. These interactions often 
involve the adhesion of the bacteria to the gastrointestinal tract using specialised adhesins. 
Lactobacillus reuteri is a common gut symbiont found in a wide range of vertebrate hosts. As 
such, it is used as a model organism to study the co-evolution between gut commensal bacteria 
and their hosts. Here, we used L. reuteri 100-23 (rodent isolate), ATCC 53608 (pig isolate) and 
MM4-1a (human isolate) to study the glycosylation of proteins in gut commensal bacteria. An 
initial bioinformatics approach to identify putative glycosylation clusters suggested the presence 
of two putative O-glycosylation systems (gtf1/gtf2 and secA2/Y2) that could be involved in post 
translational modification of proteins in L. reuteri strains. Further genetic and biochemical 
analyses suggested that Gtf1 is involved in a general glycosylation system targeting multiple 
proteins in L. reuteri, whereas proteins encoded form the secA2Y2 cluster are dedicated to the 
glycosylation of a serine rich repeat protein (SRRP). Lectin screening of the secreted proteins 
from L. reuteri combined with mass spectrometry analysis identified the mucus binding protein 
MUB53608, SRRP53608 and SRRP100-23, the major adhesins of L. reuteri ATCC 53608 and 100-23, 
respectively, as glycoproteins. MUB53608 is a putative target of Gtf1-mediated glycosylation. The 
glycans present on this adhesin were biochemically characterised and found to carry α-galactose 
and galactofuranose epitopes that could be involved in interactions with the host immune 
system. The glycosylation of the SRRPs was studied by mass spectrometry and biochemical 
assays. SRRP53608 harboured GlaNAcα-GlcNAc moieties, whereas SRRP100-23 was found to be 
glycosylated with Glc-Glc-GlcNAc trisaccharides. The data produced in this work provided novel 
insights into the L. reuteri glycosylation systems, the nature of glycoproteins and the structure 
of their glycans, furthering our understanding of the underpinning mechanisms behind their 
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AFM Atomic force microscopy 
AIM Auto induction medium 
Amp Ampicillin 
AP Alkaline phosphatase 
Ara Arabinose 
Araf arabinofuranose 
aSecA Accessory secretion system 
Asp Aspartic acid 
Asp1-5 Accessory secretion protein 1-5 
asp2 Gene encoding Asp2 
AST Alanine-serine-threonine rich domain 
BR Binding (or basic region) 
CAZyme Carbohydrate active enzyme 
Cb Carbenicillin 
CHAPS (3-[(3-cholamidopropyl) dimethylammonio]1-propanesulfonate) 
CM Cell membrane 
Cm Chloramphenicol 
ConA Concanavalin A 
CPS Capsular polysaccharide 
Cys Cysteine 
DC-SIGN Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-
integrin 
DHB 2,5-dihydroxy-benzoic acid 
DMSO Dimethylsulfoxide 
DSF Differential scanning fluorimetry 
DSS Dextran sodium sulfate 
dTDP Deoxythymidine diphosphate 
DTT Dithiothreitol 
DUF Domain of unknown function 
ECM Extracellular matrix 
EF-Tu Elongation factor Tu 
EPEC Enteropathogenic E. coli 
EPS Exopolysaccharide 
ER Endoplasmic reticulum 
Ery Erythromycin 
FbpA Fibrinogen binding protein A 
FITC Fluorescein isothiocyanate 
FITC- (f-) lectin Fluorescein isothiocyanate-labelled lectin 
Ftf Fructosyltransferase 








GAPDH Glyceraldehyde 3-phosphate dehydrogenase  
GC-MS Gas chromatography – mass spectrometry 
gDNA Genomic DNA 
GF Germ-free 





GluC Endoproteinase C 
GPC Gel permeation chromatography 
GSL-I B4 Griffonia simplicifolia Lectin I isolectin B4 
GT Glycosyltransferase 
Gtf1 Glycosyltransferase 1 
gtf1 Gene encoding Gtf1 
GtfA Glycosyltransferase A 
gtfA Gene encoding GtfA 
GtfB Glycosyltransferase B 
gtfB Gene encoding GtfB 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Hex Hexose 
HexNAc N-acetyl-hexosamine 
h-Int1 Human intelectin 1 
HPLC High performance liquid chromatography 
HRP Horseradish peroxidase 
IEC Intestinal epithelial cells 




LB Luria Bertani 
LCR Low complexity region 
LDM II Lactobacillus defined medium II 
LDS Lithium dodecyl sylphate 
Leg Legionaminic acid 
LPS Lipopolysaccharide 
Lr100-23 Lactobacillus reuteri 100-23 
LrATCC 53608 Lactobacillus reuteri ATCC 53608 
LrMM4-1a Lactobacillus reuteri MM4-1a 
LTA Lipoteichoic acid 
LTL Lotus tetragonolobus lectin 
MAL I Maackia amurensis lectin I 
MALDI-ToF Matrix assisted laser desorption/ionisation – time of flight 
Man Mannose 
ManNAc N-acetyl-mannosamine 
MPL Maclura pomifera lectin 
MRS deMan-Rogosa-Sharpe 




MucBP Mucus binding protein domain 
MurNAc N-acetyl-muramic acid 
MW Molecular weight 
Neu5Ac N-acetyl-neuraminic acid 
Neu5Gc N-glycolyl-neuraminic acid 




PAS Periodic acid/Schiff stain 
PBS Phosphate buffered saline 
PBST Phosphate buffered saline – Tween-20 
PCR Polymerase chain reaction 
PG Peptidoglycan 
PNA Peanut agglutinin 
Pse Pseudaminic acid 
PTM Post translational modification 
PTS Phosphostransferase system 
PUL Polysaccharide utilization loci 
RCA Ricinus communis agglutinin 
Rha Rhamnose 
SCFA Short chain fatty acids 
SecA2 Accessory secretion system protein A 
secA2 Gene encoding SecA2 
Ser Serine 
SlpA Surface layer protein A 
SM Spent media 
SNA Sambucus nigra agglutinin 
S.O.C. Super optimal broth with catabolite repression 
SPase Signal peptidase 
srr Gene encoding SRRP 
SRRP Serine rich repeat protein 
Suc Sucrose 
TFA Trifluoroacetic acid 
Thr Threonine 
Tm Melting temperature 
TMB 3,3',5,5'-Tetramethylbenzidine 
tMUB1063N Truncated MUB53608 from L. reuteri 1063N 
Treg Regulatory T-cells 
Trp Tryptophan 
TTP Triple phase partitioning 
Tyr Tyrosine 
UDP Uridine diphosphate 
UEA Ulex europaeus agglutinin 
WB Western blot 
WT Wild type 











1.1. Gut Microbiota 
1.1.1. Occurrence in the gastrointestinal tract 
Microbes can be found on any surface of the human body, such as the skin, the oral cavity and 
the respiratory tract, as well as the gastrointestinal (GI) tract and the urogenital system. The 
largest population of microorganisms, however, is found in the GI tract, which harbours 
hundreds of trillions of microbes per gram of tissue, collectively referred to as the gut 
microbiota. An uneven distribution of the microbial population is observed along the GI tract; 
while a few thousands cells per gram of tissue survive the highly acidic conditions of the 
stomach, more than 1011 cells per gram of tissue reside in the colon (Figure 1) (1). 
 
Figure 1. Distribution of the gut microbiota throughout the GI tract (adapted from (1)). 
The gut microbiota is comprised mainly of bacteria, but archaea, Eukaryotes and viruses are also 
part of the microbial community (2). The composition of the gut microbiota is highly dynamic 
and depends on many environmental and genetic factors, thus it differs greatly between 
individuals, as well as within a single host.  
The colonisation of the GI tract begins at birth - some studies suggest even earlier (3) - and 
changes throughout life, with different genera prevailing at different stages [reviewed in (4)]. 
The great majority of bacterial gut symbionts found in healthy humans fall into the phyla of 
Firmicutes and Bacteroidetes, and a minor proportion of the microbiota consists of 




While related individuals share some similarity in terms of microbiota composition (6), a core 
microbiota, i.e. a group of species that are common across the population, is considered unlikely 
to exist. In contrast, common functions between different individuals’ microbiota have been 
identified and this has led to the hypothesis of a core microbiome, which includes genes that 
perform conserved functions across all microbiota (7). This also implies that functional 
redundancies exist between different sets of species (8), favouring the phylogenetic diversity of 
the microbiota between and within individuals. Phenotypic diversity is considered to be an 
advantage in evolution, as it provides organisms with various traits which may benefit them 
under environmental challenges, such as in the gut environment. 
1.1.2. Factors affecting the microbiota composition 
1.1.2.1. Mode of delivery 
The initial colonisation of the GI tract plays a pivotal role in shaping the future composition of 
the microbiota (5). The method of delivery greatly affects the initial microbiota composition; 
children born pre-termly or by cesarean section are exposed mainly to nosocomial microbes, 
such as Clostridia, Staphylococci and Streptococci, as well as skin related species. In addition, 
Jacobsson et al. (2014) showed that children delivered by C-section had a decreased microbiota 
diversity and that colonization of the gut by members of the Bacteroidetes phylum, one of the 
predominant phyla in adult microbiota, was significantly delayed (9). In contrast, naturally born 
babies, as well as those that did not require the administration of antibiotics showed high 
numbers of Lactobacilli, a species that dominates the vaginal flora, as well as increased numbers 
of Bifidobacteria and Bacteroides (5,10).  
1.1.2.2. Diet  
Diet is one of the primary driving forces that shapes the microbiota composition. After birth, the 
environment of the gut favours the colonisation of facultative anaerobic bacteria, and bacteria 




to lactose, breast milk contains short oligosaccharides that act as prebiotics to promote 
colonization by specific species, such as Bifidobacteria and Bacteroidetes, which preferentially 
utilize these carbohydrates (11–14). In contrast, formula-fed children are colonized by 
Bacteroides fragilis, Clostridium coccoides and Lactobacilli (12) and show greater microbial 
diversity (10,15). In addition to providing nutrients for early colonisers, breast milk also carries 
a plethora of bacterial species that babies get exposed to during lactation; the composition of 
this group of bacteria changes throughout the lactation period (16,17). Once the oxygen is all 
consumed, strictly anaerobic bacteria take the opportunity to colonise the large intestine (4) 
and by the age of one year old, and after the introduction of solid food, bacteria that can digest 
dietary carbohydrates emerge and the microbiota diversity increases (5,18). At the age of 2-3 
years old, the gut microbiota matures and resembles that of an adult (18,19). 
In an adult-like microbiota, the spatial distribution of bacteria differs, not only in the number of 
microbial cells found in each part of the GI tract, but also in the type of bacteria. For instance, 
the small intestine harbours facultatively anaerobic bacteria that can adhere onto the host tissue 
and feed on simple or short sugars (20,21). In contrast, strictly anaerobic bacteria that exploit 
complex and -otherwise- indigestible carbohydrates live in the large intestine (20). 
Even though an adult-like microbiota is considered relatively stable, it is very dynamic and 
responds to changes in environmental factors such as the diet. A common trend is that a diet 
rich in dietary fibres favours the colonisation and growth of Bacteroidetes, whereas a diet rich 
in fat promotes the growth of Firmicutes (22,23). In addition, high-fat diets promote the growth 
of bacteria that are bile-acid tolerant, like Alistipes sp. and Bilophila sp, as bile acids are 
bactericidal for many species (24,25). 
However, it is difficult to establish a clear connection between diet and specific bacterial species, 
as most studies report changes at the phylum level. For example, a study by Wu et al. (2011) 




Firmicutes and Proteobacteria benefited from a fibre-rich diet (26). Similarly, murine microbiota 
from mice on a low-fat diet showed higher abundance of Firmicutes, in contrast to those on 
high-fat diet that showed increased numbers of Bacteroidetes (27). Such differences were also 
reported using specific oligosaccharides, such as iso-maltooligosaccharides (IMOs) which have 
been shown to either benefit Bifidobacteria in rats (28,29), or lead to a decrease in their 
population (29). In addition, different dietary fibres seem to benefit different species. For 
instance, inulin promotes growth of Bifidobacteria (28,30) whereas IMOs favour the growth of 
Lactobacilli (28). Interestingly, Lactobacillus species that are adapted to the GI tract can utilize a 
wider range of carbohydrates compared to those isolated from food sources (31).  
It is apparent that the way various bacterial species respond to changes in diet is inconsistent 
between individuals. As there is functional redundancy between different microbiota and even 
different species, it is likely that a specific diet will select for a microbiome rather than a 
microbiota. For example, a fibre-rich diet will select for genes that can digest complex 
carbohydrates rather than specific bacterial species. Such genes can be found in members of the 
Bacteroidetes or the Firmicutes phyla (19). This could account for the differences observed 
between studies, where identification of the different bacteria reaches down to the species 
level, but does not inform about the genetic repertoire of the strains. 
1.1.2.3. Host genetics 
It has been proposed that the genetic profile of a host plays a role in shaping the gut microbiota. 
This arose from studies showing that related individuals have more similar microbiota than 
unrelated ones (7,32,33). Host genes encoding proteins involved in bile acid metabolism (34), 
antimicrobial peptide production (35), metabolism and mucin glycosylation have been shown to 
affect the microbiota composition (Figure 2). Most of our understanding on how specific genes 




have linked genes associated with metabolism (e.g. Apo-E1 and leptin) with differences in the 
microbial community (36–38). 
 
Figure 2 Host genetics affect the microbiota composition by mucin production, to provide binding sites and nutrients 
to the commensal bacteria, by regulating the immune system to tolerate or attack commensal or pathogenic bacteria, 
respectively, or by secretion of bile acids, which promote the survival of bile-acid tolerant bacteria (adapted from 
(39)). 
The mucus layer is a gelatinous layer that covers the GI tract and is comprised mainly of mucins, 
large glycoproteins in which the glycans account for more than 80% of their mass. Mucin  
O-glycosylation (see section 1.4.1.1) occurs in the Golgi apparatus where mucins are modified 
by carbohydrate chains that consist of N-acetyl-galactosamine (GalNAc), N-acetyl-glucosamine 
(GlcNAc) and galactose (Gal), and are often capped by sialic acid and/or fucose (Fuc) (40).  In 
early life, the profile of the capping monosaccharides is the same in the mucus across the GI 




observed from the small intestine to the colon in humans (29). Mucin glycosylation can affect 
bacterial colonization by either selectively providing adhesion sites to bacteria expressing the 
right repertoire of adhesins (40) or by providing carbohydrates as nutrients that only certain 
bacteria can utilize (41). It is well documented that mouse models with altered or deficient 
mucin glycosylation show changes in the microbiota composition (42). For example, deletion of 
FUT2, a fucosyl-transferase responsible for capping mucin glycans with Fuc, results in lower 
microbial diversity and altered microbiota composition in mice (43). An earlier study with Finnish 
individuals showed a link between FUT2, the presence of ABO antigens in the mucus and the 
microbiota composition, with differences in the populations of Bifidobacteria, Bacteroides and 
Clostridia between individuals with different antigens (44).  
The increased sialic acid content found in the large intestine also contributes in shaping the 
microbiota. As sialic acid protects the mucin carbohydrates, it requires specific bacteria 
expressing sialidases to release it and expose the underlying glycans. Upon release, other 
bacteria can either use free sialic acid or the rest of the glycan to feed (45,46). Recently, a new 
type of sialidase was discovered in strains of the gut commensal Ruminococcus gnavus, which 
released a modified sialic acid that the bacteria can preferentially metabolise, providing an 
ecological advantage to this species (41). A similar synergy between bacterial species is observed 
in cases where bacteria rely on degradation or metabolic products of other species to survive, 
as for example with species that utilize short chain fatty acids (SCFAs) as carbon source (47).  
Genes encoding proteins that are involved in the regulation of the immune system also 
contribute to the selection of the gut microbiota. These include, antimicrobial peptides, 
proteins, such as defensins, various types of lectins, cell-wall degrading enzymes and immune 
modulators, all of which are part of the innate immune system and directly interact with 
microbes. Some of these, such as RegIIIγ, can lead to disruption of the cell wall or membrane 




amount in the mucus interacts with bacteria and contribute to biofilm formation, minimizing 
exposure of the epithelium to the bacteria  (51). 
Bile acids, although their primary role is the emulsification of fats, are also part of the innate 
immune system, owing to their antimicrobial properties (52). As such, they play a direct role in 
shaping the microbiota community, by stressing the bacteria, damaging their membranes or 
leading to protein misfolding (52,53), thus selecting for strains that are bile acid tolerant. 
Bacterial species that feed on bile acids can also be selected. For example, mice fed a high milk-
derived-fat diet led to production of bile acids conjugated with taurine to more effectively 
emulsify the fats. This, in turn, increased the availability of organic sulfur and sulfite-reducing 
bacteria, such as Bilophila wadsworthia, causing colitis in mice (27).  
1.1.2.4. Antibiotics  
Antibiotics, which are often used to treat infectious diseases, target a wide range of bacteria, 
regardless of their pathogenicity; thus, gut symbionts are also affected. Depending on the 
mechanism of action of a given antibiotic, different bacterial classes are affected. For example, 
a recent study showed a strong increase in damaged Firmicutes when cell wall synthesis 
inhibitors were used, such as ampicillin or vancomycin (54). Interestingly, while vancomycin 
specifically targets Gram-positive bacteria, it was found that the Bacteroides population was 
substantially reduced (55,56), suggesting a complex interplay between different species. In the 
same study, members of the Enterobacteriaceae family, which is normally under-represented in 
the gut microbiota, dominated the population following antibiotic treatment (55). Also, 
antibiotics can disturb the balance of commensal bacteria and reduce their diversity (57). This 
causes a disruption to the normal gut microbiota also known as “dysbiosis”, but also exposes 




1.1.3. The role of the gut microbiota in human physiology 
It is now clear from analysis of metagenomics studies that there is a significant correlation 
between the composition of the gut microbiota and the health or disease state of individuals  
(58). Human gut bacteria play a crucial role in our health and well-being, by affecting various 
levels of the human physiology, as discussed below. 
1.1.3.1. Food digestion 
The gut microbiota is essential in processing otherwise indigestible polysaccharides from our 
diet. For example, several Ruminococcus species are able to digest insoluble carbohydrates like 
cellulose and resistant starch (59) whereas Bacteroidetes species are characterized by a number 
of polysaccharide utilization loci (PUL) clusters (60). These species, along with others from the 
Bacteroidales and the Clostridiales orders, can convert these polysaccharides into SCFAs, which 
can be utilized by the host (60,61). These SCFAs provide up to 10% of the daily energy 
requirement (62). When the diet is rich in simple sugars and depleted in dietary fibres, SCFA 
producers, such as Prevotella, are diminished (26). Additionally, bacteria that feed on dietary 
fibres will consume host sugars when fibres are not available from the diet (63), leading to a thin 
mucus layer and eliciting an immune response from the host (64). Therefore, the gut microbiota 
can enhance the host’s ability to extract energy and nutrients from the food. As a consequence, 
an imbalance in microbiota composition has been associated with nutritional disorders, such as 
diabetes (61,65) and obesity (36). Also, conventionalization of germ-free (GF) mice leads to an 
increase in body mass and insulin resistance (65) and the transfer of microbiota from obese mice 
into lean donors can result in a phenotypic change of these mice (66). In addition, the gut 
microbiota is able to increase the host’s monosaccharide uptake from the gut lumen, and, at the 




1.1.3.2. Vitamin production 
Humans only carry limited biosynthetic pathways for vitamins. To cover our needs in all essential 
vitamins, we rely on vitamins available in the food or provided by members of the gut microbiota 
that can synthesise them. It has been shown, for example, that members of the Bifidobacteria 
genus can de novo synthesise folate, while Lactobacillus reuteri strains can produce vitamin B12, 
the only vitamin exclusively produced by bacteria, and closely related analogues (67,68). Gut 
bacteria have also been implicated in the de novo synthesis of riboflavin (69), vitamin K (70), 
biotin (68,71). 
1.1.3.3. Short-chain fatty acids production 
The most important SCFAs are acetate, propionate and butyrate. These are small molecules that 
act as signals in the GI tract and regulate various processes. They are end products of the 
anaerobic fermentation of dietary fibres by the microbiota, which takes place mainly in the 
proximal colon (72). Bacteroidetes produce mainly acetate and propionate, whereas butyrate 
mainly results from Firmicutes activity (73). In addition to their role in energy provision, SCFAs 
are involved in regulation of appetite (74) as well as fatty acid, glucose and cholesterol 
metabolism (72). In addition, anti-inflammatory and anti-cancerous properties have been 
attributed to butyrate (75) and the gradient of butyrate that is formed between the lumen of 
the gut and the bottom of the crypts has been proposed to mediate cell apoptosis at the tip of 
the villi and cell proliferation at the bottom of the crypt, thus contributing in the regeneration 
of the brush border epithelium (76). Butyrate was also shown to enhance the tight-junction 
assembly (77), probably by increasing the production of IL-18, which is responsible for 
maintaining epithelial integrity (78) and mucin production (79).  
1.1.3.4. Maturation of the immune system 
In addition to contributing to the food digestion capacity of the host, the gut microbiota is also 




revealed various malfunctions, reflecting an immature immune system. For instance, GF mice 
show defective development of lymphoid tissue, and administration of gut bacteria restored its 
proper function (80).  Insufficient microbial exposure in early life can result in an alteration of 
the gut microbiota in adulthood and a defective or allergy-susceptible immune system (81). Anti-
inflammatory immune responses establish tolerance against non-pathogenic microbes, and the 
gut microbes play a pivotal role in maintaining this tolerance, by regulating responses of the 
innate immune system (82). For instance, it has been shown that microbes producing butyric 
acid, one of the main SCFAs, can induce colonic regulatory T cells (Treg), which are a key 
component in inflammation and allergy suppression (83). In another study, administration of a 
cocktail of three commensal bacteria in mice resulted in higher counts of Treg cells, which led to 
increased IL-10 and TGFβ production, which are known for their anti-inflammatory activity (84). 
Similarly, polysaccharide A from Bacteroides fragilis showed a protective activity against colitis 
in mice, by inducing Treg differentiation, while reducing the level of pro-inflammatory cytokines 
(85). It was recently shown that Lactobacillus reuteri strains was necessary for the differentiation 
of CD4+ CD8αα+ double-positive intraepithelial lymphocytes (86), cells that are involved in the 
suppression of inflammation in the gut (87).  
Interestingly, host-specific microbiota composition is required for the proper development of a 
mature immune system. It was recently shown that only GF mice colonised by mouse-derived 
microbiota could develop a fully mature immune system, in contrast to mice colonised with 
human- or rat-derived microbes (88), supporting the concept  of co-evolution between the gut 
microbiota and its host.  
Members of the gut microbiota can also promote restoration of damaged epithelial tissue in an 
ex vivo model of intestinal epithelial cells (89). In addition, it is well established that certain 




thicker mucus layer (90), or change the glycosylation profile of mucins (41,91), thus protecting 
the host against infections (92). 
1.1.3.5. Competition against pathogens 
The protective effects of the gut microbiota also derive from the ability of gut symbionts to 
compete with pathogens for available nutrients and binding sites. For example, commensal E. 
coli can outcompete Citrobacter rodentium in nutrient utilisation in mice, as they both utilise 
similar carbon sources. The same effect was also observed with B. thetaiotaomicron (93).  In 
addition, the imbalance in the gut microbiota composition caused by antibiotics administration 
or gut inflammation in mice can provide enteric pathogens, such as Salmonella typhimurium or 
Clostridium difficile a greater opportunity to infect the host (45,94). Commensal bacteria can 
also prevent adherence of pathogens to the host tissue, as shown by reduced the adherence of 
enteropathogenic E. coli (EPEC) to epithelium following pre-treatment with L. reuteri strains, 
due to the occupation of available binding sites (95). 
To assist the host fight against pathogens, commensal bacteria can also produce antimicrobial 
compounds, known as bacteriocins, which can have potent inhibitory effects on harmful 
microbes (96). It has also been postulated that commensal bacteria may exclude pathogens by 
forming aggregates and trapping them into it, thus preventing invasion in the host (97), They 
can also protect the host from viral infections (for a review see (98)). 
Another protective property of gut commensal bacteria comes from their ability to metabolise 
unabsorbed bile acid conjugates, which act as germinants in spore germination of C. difficile, 
using bile acid hydrolases. These enzymes remove the amino acid conjugate and release primary 
bile acids that competitively inhibit germination (99).  
1.1.3.6. Probiotic effects 
To confer the beneficial effects listed above, the gut microbiota is in a constant 




come in contact with the host tissue, mainly via surface proteins or carbohydrates, or indirectly, 
via the action of secreted proteins or other molecules. These interactions often trigger a 
response cascade which either exerts an immune response (pro-inflammatory effect) or 
attenuates the immune system (anti-inflammatory effect). Gut-derived microbes can be used as 
probiotics (i.e. live organisms that, when administered in adequate amounts, confer a health 
benefit on the host, according to the World Health Organization (100)) in order to exploit these 
immunomodulatory effects. Probiotics can either suppress immune responses to mitigate 
chronic inflammation or elicit a stronger immune response against pathogens. They are also 
actively involved in metabolism, directly compete with pathogens and maintain the epithelium 
integrity (Figure 3).  
 




1.2. Lactobacillus reuteri: Occurrence in the GI tract and its impact on 
host health 
The Lactobacillus genus is one of the most commonly represented genus in the gut microbiota 
across vertebrates and one of the first to colonise the mammalian GI tract (4) as it is often found 
in breast milk (101). It includes facultative anaerobic, Gram-positive, rod-shaped bacteria. L. 
reuteri, in particular, is a wide-spread bacterial species commonly found in the gut of humans 
(101,102), as well as other vertebrates, including rodents, pigs and chicken (103). 
L. reuteri strains from different hosts show a great level of host-specificity (104). For example, 
murine isolates were found to be the most successful colonisers of the murine GI tract, 
compared to strains isolated from different hosts (103,105,106). Similar results were observed 
for poultry strains, when colonizing the chicken GI tract (107). This evolutionary adaptation of 
different L. reuteri strains to their respective hosts was first reported by Oh et al. (2010) (108) 
and many genes and gene clusters specific to strains from the same host have since been 
identified (108,109). An important feature of host adaptation is the difference in the nature and 
the number of large cell-surface adhesins between human, porcine, poultry and rodent isolates. 
The specialization of different strains towards specific hosts has been shaped evolutionally by 
various events of horizontal gene transfer and deletions of genes (103). 
Lactobacilli have been used in a range of human intervention studies as probiotics, to investigate 
their health promoting effects (110). For instance, L. reuteri DSM 17938 was used in clinical trials 
against infant colic and showed important improvement in the treated groups compared to the 
placebo group (111,112). In addition, administration of L. reuteri ATCC 55730 resulted in milder 
cystic fibrosis symptoms by reducing pulmonary exacerbations caused by infection or 
inflammation, and also by reducing the infections of the upper respiratory tract (113). L. reuteri 
RC-14, along with L. rhamnosus GR-1, was used in a study of HIV-infected patients in sub-Saharan 




probiotics had a 15% increase in CD4+ cells and also showed a significant improvement in 
symptoms like clinical diarrhea and nausea (114). In addition, many L. reuteri strains have 
demonstrated anti-inflammatory properties in animal studies. For example, administration of L. 
reuteri DSM17938 increased Foxp3+ Treg cells in an induced necrotizing enterocolitis (NEC) mouse 
model (115) and reduced lipopolysaccharide (LPS)-induced gut inflammation (116).  L. reuteri 
anti-inflammatory properties were also shown in a C. rodentium infection mouse model (117).  
The results showed that infected mice that were also exposed to stress exerted a stronger 
immune response compared to infected-only mice. But infected/stressed mice that were given 
L. reuteri as a probiotic showed normal immune responses, i.e. higher levels of β-defensin 3 and 
reduced expression of CCL2 (which recruits inflammatory monocytes to the colon) and TNF-α 
(117). While L. reuteri was not able to outcompete C. rodentium, there was a decreased 
translocation of the pathogen to the spleen, probably due reduced loosening of the tight 
epithelial junctions  (117). L. reuteri was also tested for its ability to reduce inflammation in the 
GI tract. A mixture of four L. reuteri strains was found to protect mice against dextran sodium 
sulfate (DSS)-induced colitis (118). More specifically, administration of L. reuteri R2LC, JCM 5869, 
ATC PTA 4659 and ATCC 55730 prior to and during the DSS treatment showed a protective 
effect, by significantly reducing mucosal damage in the Lactobacilli-treated mice. In addition, p-
selectin, a protein associated with colitis, was found to be expressed in “healthy” levels in 
Lactobacilli-treated mice, whereas it was significantly elevated in DSS-treated mice (119). 
Other strains of L. reuteri have shown potent activity against infectious diseases in preliminary 
experiments conducted in vitro or in animals. For example, the human strain L. reuteri L22 
produces bacteriocins that kill and inhibit the growth of methicillin-resistant Staphylococcus 
aureus in vitro (120). Reuterin, one of the L. reuteri L22 bacteriocins produced, can reduce the 
growth of Salmonella pullorum ATCC 9120 in vitro, while L. reuteri ATCC 55730, another reuterin 
producer, exhibits a protective role in a Salmonella-induced pullorum disease model chicken. 




that the protective role of L. reuteri ATCC 55730 could not be attributed to reuterin exclusively 
(121). Table 2 summarises some of the studies testing L. reuteri strains as a probiotic in various 
diseases, ranging from infectious diseases to genetic disorders. The results of these studies 
suggest that L. reuteri strains have anti-inflammatory properties, as in most cases they attenuate 
immune responses. 
Table 2 Summary of studies on the in vivo probiotics effects of L. reuteri strains 
Strain Host Condition Outcome Ref. 
L. reuteri DSM 17938 Human Infant colitis Reduction in crying time (111) 
L. reuteri ATCC 55730 Human Cystic fibrosis Reduction of pulmonary 
exacerbations, reduction of 
upper respiratory tract 
infections 
(113) 
L. reuteri RC-14,  
L. rhamnosus GR-1 
Human HIV infection No effect in white blood 
cells, increased CD4+ cells, 
reduction of clinical 
diarrhea and nausea 
(114) 
L. reuteri DSM 17938 Human T2Diabetes No change in glycated 
haemoglobin,  
improved insulin sensitivity 
in a subset of participants 
(122) 
L. reuteri DSM 17938, 
L. reuteri ATCC PTA 6475 
Human Helicobacter 
pylori infection 
Reduced side effects, 
reduced gastrin-17, 
increased rate of 
eradication 
(123) 
L. reuteri DSM 17938 Mouse Necrotising 
enterocolitis 
Increased Foxp3+ Treg cells, 
reduced LPS-induced gut 
inflammation 
(115) 
 L. reuteri ATCC 23272 Mouse C. rodentium 
infection/stress 
Decreased translocation of 
C. rodentium to the spleen,  
(117) 
L. reuteri R2LC,  
L. reuteri JCM 5869,  
L. reuteri ATC PTA 4659,  
L. reuteri ATCC 55730 
Mouse DSS-induced 
colitis 
Reduction of mucosal 
damage, normal expression 
of p-selectin 
(118) 
L. reuteri TB-B11 Mouse Ovalbumin-
induced food 
allergy 
Reduction of diarrhea, 
reduction of ovalbumin-
specific IgE titre 
(124) 




Increase in survival rate of 
the model organism 
(121) 




No significant protective 






Although the exact mechanisms underpinning the health promoting effects of L. reuteri remain 
undefined, immunomodulatory effects and the ability to colonise the human intestine are 
considered as key elements of these properties.  
1.3. Lactobacillus cell surface: role in adhesion to the host 
The ability of gut commensal bacteria and probiotics to colonise the host is one of the key steps 
in symbiosis and health promotion. One of the mechanisms mediating a specific interaction with 
the host is via specific surface structures, such as exopolysaccharides (EPS) and cell wall or 
surface proteins (Figure 4), which can bind to components of the epithelium, the mucus or the 
extracellular matrix (ECM), depending on the niche the bacteria colonise in the GI tract. In Gram-
positive bacteria, these proteins are anchored on the peptidoglycan (PG) layer, via specific cell-





Figure 4 Architecture of the surface of Lactobacilli species. The cell membrane (CM) is protected by a thick layer of 
peptidoglycan (PG) covered with exopolysaccharides (EPS) and surface layer proteins. Adhesins and other surface 
proteins are anchored onto the PG layer by various domains such as SH3 and LysM, as well as LPxTG motifs. Wall 
teichoic (WTA)- and lipoteichoic acids (LTA) are bound onto the PG and the CM, respectively (125). 
1.3.1. Exopolysaccharides 
EPSs are high molecular weight carbohydrate polymers that are produced by bacteria and 
secreted into their microenvironment to form the EPS layer. They have a diverse composition, 
even within the same species, and range in size from 10 to 1000 kDa (126). The EPS layer is a 
multifunctional structure, involved in bacterial aggregation, as well as adhesion to the host, 
among other biological roles. EPS is believed to play either a direct role in adhesion by acting as 
a ligand that mediates adhesion and co-aggregation or indirectly by holding surface proteins in 
place (127). Bacterial aggregation can also enhance adhesion to host tissue, by increasing 




which may result from exposure of proteins involved in adhesion to the microenvironment 
(129). For instance, mutants of Lactobacillus johnsonii that do not produce EPS showed greater 
biofilm formation and adhesion to chicken gut explants, as compared to the wild-type strain, 
probably due to exposure of hydrophobic components on their surface (130). Similar results 
have been observed with the pathogen Streptococcus pneumoniae, where removal of the 
capsular polysaccharide led to the exposure of lectins that were responsible for agglutination of 
human red blood cells (131). These seemingly contradicting results suggest that there are 
different mechanisms in bacterial adhesion and aggregation, where EPS may favour or impede 
cell-cell interactions. 
1.3.2. Teichoic acids 
Wall-teichoic acid (WTA) and lipoteichoic acid (LTA) are cell wall glycopolymers characteristic of 
Gram-positive bacteria (132). WTA is attached to the PG layer whereas LTA is anchored via a 
lipid moiety to the cell membrane (133).  Both WTA and LTA have been implicated in adhesion 
of pathogenic bacteria to host tissue, and specifically to scavenger receptors and C-type lectins 
expressed on the surface of macrophages, dendritic cells and epithelial tissue of the host (132). 
An early study by Granato et al. (1999) showed that treatment of Caco-2 cells with pure LTA 
decreased binding of L. johnsonii to the cells (134), suggesting a direct interaction between LTA 
and the cells. This interaction between LTA and Caco-2 cells may be mediated by the 
carbohydrate component of LTA (which could also be found on other glycoconjugates), or by 
the lipid moiety, which could also be involved in other functions (e.g. protein-protein 
interactions), by occupying hydrophobic pockets. However, a more recent study also suggested 
that LTA may be directly involved in adhesion, as Listeria monocytogenes that lacked the D-
alanine modification of LTA adhered inadequately to Caco-2 cells, compared to the wild-type 
strain (135). Despite the original view that LTA only had an indirect role in adhesion, these data 




1.3.3. Cell surface adhesins 
Surface proteins, such as adhesins or lectins, are an important class of cell surface molecules 
that are involved in adhesion of gut bacteria to the host tissue, especially the gut epithelium and 
mucus layer, by interacting with host proteins or glycoconjugates.  
The mucus layer is a thick mixture of glycoproteins (mainly mucins), immunoglobulins, 
antimicrobial peptides and other intestinal proteins, lipids and electrolytes (40), covering the GI 
tract. Many bacterial adhesins have been experimentally shown to bind mucus components 
such as mucins, mucin glycans or immunoglobulins (40). These include moonlighting proteins, 
surface appendages like pili and flagella, as well as specialized surface adhesins that bind to host 
tissue components (summarized in Table 3). 
Table 3 Summary of the main characterised adhesins in Lactobacillus species. 
Adhesin Organism Ref. 
32-Mmubp L. fermentum BCS87 (136) 
CmbA L. reuteri JCM1112 (137) 
DnaK L. agilis (138) 
EF-Tu L. johnsonii La1, L. reuteri JCM1081,  (139–141) 
Enolase L. johnsonii, L. agilis (138) 
Formyl-CoA transferase L. johnsonii (138) 
GAPDH L. acidophilus, L. plantarum (142–144) 
GroEL L. johnsonii La1 (145) 
Lam29 L. mucosae ME-340 (146) 
Lar_0958 L. reuteri MM4-1a (147) 
MapA L. reuteri 104R (148) 
MBF L. rhamnosus GG (149) 
Msa L. plantarum WCFS-1 (150) 
Mub L. reuteri, L. plantarum, L. acidophilus (151–157) 
Peptidase C1 L. johnsonii (138) 
phosphofructokinase L. johnsonii (138) 
Phosphoglycerate kinase L. agilis (138) 
Phosphoglycerolmutase L. johnsonii (138) 
Pili L. rhamnosus GG (158) 
SRR L. reuteri (pig and rodent isolates) (109,159) 





1.3.3.1. Moonlighting proteins 
Moonlighting proteins are proteins with more than one functions.  Many moonlighting proteins 
that have been experimentally shown to bind mucus have no apparent mucus binding domains 
or a signal peptide necessary for secretion. Elongation factor Tu (EF-Tu) is a well-studied example 
of moonlighting proteins involved in bacterial adhesion to the host tissue. Its primary role is 
believed to be in the translation of mRNA, where it carries the amino acyl-tRNA to the ribosome 
(160). However, studies have shown its involvement in the formation of bacterial cytoskeleton 
(161), as well as to adhesion to host tissue (139,140,162). In particular, EF-Tu was found to be 
upregulated when Lactobacilli strains were grown in presence of mucin and soluble EF-Tu 
inhibited binding of Lactobacilli as well as E. coli and Salmonella enterica strains (163). In some 
cases though, EF-Tu may be masked by EPS, thus its contribution to adhesion is limited (129). 
EF-Tu from L. reuteri JCM1081 was found to bind to mucin sulphated glycans (141). Other similar 
examples of mucin binding, moonlighting proteins include the heat shock protein GroEL (145),  
the enzyme GAPDH (143), enolase and DnaK, all of which can be found both intracellularly and 
on the bacterial surface (125,138). 
1.3.3.2. Surface appendages 
Pili and flagella are large polymeric proteins that form long surface structures which are involved 
in bacterial adhesion. Although rare in Gram-positive bacteria, pili have been identified in 
Lactobacillus rhamnosus GG, where they confer binding to mucus (164) and are predicted to 
exist in other Lactobacilli species, based on genomics analyses (125). Flagellar proteins have 
been extensively studied in pathogens but not in commensal bacteria. For example, flagellar 
proteins of the enteropathogenic and enterohaemorrhagic E. coli as well as those of 
Campylobacter sp. have been shown to be important components of adhesion to host tissue 
(165,166). A few Lactobacilli species have the potential to produce flagella which can induce pro-




1.3.3.3. Cell-surface adhesins 
This group of adhesins contains proteins that have been primarily characterized for their ability 
to bind components of the host tissue, such as collagen, fibronectin and mucus. The Collagen 
Binding Protein from L. reuteri NCIB  11951, (168) and L. crispatus JCM 5810 (169,170), as well 
as Fibronectin binding protein A (FbpA) from L. acidophilus NCFM (171) and Surface Layer 
Protein (SlpA) from L. brevis ATCC 8287 (172) are examples of this group. The latter comprises 
the majority of the bacterial surface protein load and plays key roles in aggregation and binding 
to mucus or ECM (125,173).  
Many adhesins are cell surface-bound; they include a signal peptide at the N-terminus that 
directs their secretion by specialized secretion systems, as well as a C-terminal cell-wall 
anchoring motif through which they are covalently bound onto the cell wall by specific enzymes 
called sortases (174). Lar_0958 from L. reuteri MM4-1a is such a protein, containing a YSIRK 
signal motif at the N-terminus, as well as a LPxTG anchoring motif at the C-terminus. This protein 
family was recently identified as a major adhesin of human L. reuteri isolates (147). In addition 
to the signal and anchoring motifs, these proteins were shown to contain a varying number of 
repeating domains, the presence of which correlates with the capacity of the microorganism to 
adhere to mucus. The crystal structure of this repeat showed structural similarities with 
internalins from L. monocytogenes, proteins that are suggested to mediate adhesion to the GI 
mucus (147). Other examples of major cell-surface adhesins from Lactobacilli are detailed below. 
1.3.3.3.1. Mucus binding protein 
Mucus Binding proteins (MUBs) containing Mub repeats have been identified primarily in lactic 
acid bacteria (125) and are more common in those colonizing the GI tract (155); no mucus 
binding protein has been identified in food-derived Lactobacilli (31). MUB53608 from L. reuteri 
ATCC 53608 is one of the most studied examples of mucus adhesins (154). It is a high molecular 




(Mub2), based on sequence homology. Each repeat is further divided into two domains, a mucin 
binding (MucBP) domain and an immunoglobulin binding (Ig-binding protein) domain  (155,156) 
(Figure 5). The Mub repeats mediate binding to mucin glycans, through interactions with 
terminal sialic acid (152,156), and immunoglobulins in a non-antigenic manner (155). In addition, 
MUB53608 presents a C-terminal LPxTG anchoring motif, and an N-terminal secretion signal 
peptide. MUB53608 has the shape of a long, fibre-like structure, of around 180 nm in length, and 
forms appendices similar to pili found in pathogenic and, more rarely, other commensal 
bacterial species. This elongated structure allows for the exposure of all 14 repeats, each of 
which has the capacity to bind onto mucus components. This is proposed to allow the bacteria 
to firmly adhere to their host, in contrast to many pathogenic adhesins which only show 
adhesion capacity at the N-terminal tip (156). In addition, MUB53608 was recently shown to 
interact with elements of the immune system in vitro, as it elicited immune responses from 
monocyte-derived dendritic cells, leading to increased levels of pro-inflammatory cytokines and 
CD83 (175). Proteins containing one or more copies of MucBPs have been identified across most 
species of the Lactobacillus genus, as well as proteins containing Mub repeats (40). 
 
Figure 5 Graphic representation of MUB53608 from L. reuteri ATCC 53608. Six Mub1 and eight Mub2 repeats comprise 
MUB53608. Each repeat has two domains, an Ig binding domain at the N-terminus and a mucin binding domain (MucBP) 
at the C-terminus. Adapted from (156) 
1.3.3.3.2. Serine rich repeat proteins 
Another recently identified type of adhesin in Lactobacilli belongs to the serine-rich-repeat 
protein (SRRP) family. This protein family was originally identified in Gram-positive oral 




be important for adhesion to host tissue and virulence (180). As a result, most of our knowledge 
on these adhesins is derived from studies conducted with SRRPs from pathogenic species. These 
include SraP from Staphylococcus aureus COL, Srr1 and Srr2 from Streptococcus agalactiae NCTC 
10/84 and COH1, respectively, Hsa from Streptococcus gordonii DL1, GspB from Streptococcus 
gordonii M99, Fap1 from Streptococcus parasanguinis FW213 and PsrP from Streptococcus 
pneumoniae TIGR4 (summarised in Table 4). 




Lactobacillus reuteri 100-23 SRR Forestomach epithelium (103) 
Staphylococcus aureus COL SraP Surface molecules of blood 
platelets 
(181) 





Srr1 Platelet fibrinogen (177,184) 
Streptococcus agalactiae 
COH1 
Srr2 Fibrinogen (184) 
Streptococcus gordonii DL1 Hsa Sialic acid containing MUC7, 




Fap1 Saliva coated-tooth model (185) 
Streptococcus pneumoniae 
TIGR4 











The srr gene encoding SRRP is located in a genomic island that encodes for proteins that form 
an accessory secretion system, dedicated to the glycosylation and secretion of SRRP. The 
secretion system typically consists of two translocases, SecA2/SecY2, three to five accessory sec 
system proteins (Asp1-5), and a variable number of glycosyltransferases, ranging between two 
to eight (190,191).  
The SRRPs are composed of distinct subdomains: a cleavable and unusually long signal peptide 
which, in some cases, is followed by an alanine-serine-threonine rich (AST) motif, a short serine 




of basic amino acids), a second and much larger serine rich repeat region, and a cell wall 
anchoring motif (Figure 6) (192).  
 
Figure 6 Schematic representation of the SRRP domain organisation. There is an unusually long signal peptide that 
blocks secretion from the canonical SecA system, followed by an alanine-serine-threonine (AST) domain and a short 
serine-rich repeat region (SRR1). The binding region (or basic region; BR) is followed by a second, larger serine-rich 
repeat domain (SRR2) and the cell wall anchoring motif (CWA) LPxTG is found at the C-terminus (193). 
Substrates for the various SRRPs characterised to date include a tooth surface model for 
streptococcal Fap1 and staphylococcal SraP (185,194), which implies its importance in dental 
diseases such as caries and periodontitis, the platelet surface for the staphylococcal SraP, and 
the streptococcal Hsa and GspB (181,183,195), suggesting a role in transport to heart valves and 
bacterial endocarditis, as well as various keratins that can be found in the lungs for the 
pneumonococcal Srr-1 and PsrP (177,186,188). In addition, SrpB and SrpC from the oral 
commensal S. salivarius JIM8777 were found to specifically bind to epithelial cells and ECM, 
respectively, suggesting a role in colonisation of the oral cavity (189). The binding or the SRRPs 
to their substrates is mediated by the binding region (BR). However, different substrate 
specificities can be observed within the same BR domain. For instance, PsrP was shown to bind 
keratin 10 in mice lungs, as well as other PsrP molecules to promote aggregation, but different 
regions in the BR domain were responsible for each interaction (188). While binding of PsrP to 
keratin-10 is not glycan mediated, it was found to bind various Lewis blood group related glycans 
in a sialic acid independent manner (131), further suggesting different binding specificities for a 




to bind extracellular DNA during biofilm formation, which greatly expands the nature of 
substrates this protein binds onto, using a single BR domain (187). Pyburn et al. (2011) also 
observed distinct binding domains within the BR region of GspB by X-ray crystallography (196), 
supporting the idea that there may be different binding sites in a BR domain. In addition, 
defective glycosylation of SRRPs also leads, in many cases, to impaired binding of these adhesins 
onto their respective substrates. This suggests that the glycans have a role in adhesion, either 
by mediating glycan-protein interactions, or by contributing to proper folding and stability of the 
adhesin.  
The mechanism of secretion of SRRPs is not yet fully understood, and seems to vary slightly from 
one organism to another. The two translocases along with the Asps are important for the export, 
as SecA2 and SecY2 form the channel through which SRRP is secreted (Figure 7). Deletion of either 
secA2 or secY2 leads to accumulation of GspB in Streptococcus gordonii (180), but the deletion of 
secY2 in Streptococcus parasanguinis did not fully abolish Fap1 export (197). SecA2 was shown 
to interact with GspB via three glycine residues found in a hydrophobic region of the N-terminal 
signal peptide to mediate secretion, and when these residues are mutated export occurs 
through the canonical SecA system (198). In addition, SecA2 was found to readily interact with 
the N-terminal of the AST motif, but interaction with the C-terminal of the same motif occurs 
only when the Asps are present (199). Deletion of any of the asp genes results in the defective 
export of SRRPs (200), showing the importance of these proteins in the secretion process. Asp3 
appears to have a central role in the coordination of the export machinery, as it was found to 
interact with the other Asps, as well as with SecA2 and SRRP (201,202). The interaction with SRRP 
occurs in the SRR regions, prior to complete glycosylation, so mutations in asp2 or asp3 also lead 
in altered glycosylation of the SRRP (197,202,203). It was recently shown that in addition to its 
role in export of GspB, Asp2 is also an acyltransferase that O-acetylates GlcNAc residues found 




secretion of SRRP through the SecA2/Y2 system does not depend on the glycosylation of SRR, but 
this modification blocks export through the canonical SecA system (205).  
 
 
Figure 7 Predicted model of the SecA2/Y2 export mechanism. Asp1-3 (purple) target SRRPs (black) to the accessory 
SecA2 protein (red). During the translocation process through the SecY2 channel across the cell membrane (CM), Asp2 
and 3 modify the glycan composition and complete the glycosylation of SRRPs (brown dots). A signal peptidase (SPase) 
cleaves the signal peptide adapted from (206). 
To date, secA2/Y2 clusters have been identified in the genomes of various Lactobacillus species 
(159). In L. reuteri, the cluster has only be found in isolates of murine or porcine origins, and it 
appears to be absent from isolates of human origin (103,159). The cluster in the murine isolate 
L. reuteri 100-23 is crucial for adhesion of the bacteria to the forestomach epithelium of the 
murine GI tract, as shown by colonisation experiments in mice with L. reuteri 100-23 and 
mutants lacking putative adhesins. Mutants lacking the secA2 gene showed defective adhesion, 
whereas mutants lacking srr showed the most reduced colonisation, compared to other putative 
adhesins (109) tested. 
1.4. Protein glycosylation 
Protein glycosylation, i.e. the covalent attachment of a carbohydrate moiety onto a protein, is a 
highly ubiquitous protein modification in nature, and considered to target the most diverse 




it was originally believed to be restricted to eukaryotic systems and later to archaea, it has 
become apparent nowadays that protein glycosylation is a common feature in all three domains 
of life. In fact, it is now believed that at least 70% of eukaryotic and 50% of prokaryotic proteins 
are glycosylated by post-translational modification (208).  
1.4.1. Mechanisms of protein glycosylation 
Protein glycans are secondary gene products, as they are synthesized in a no-template manner 
by the sequential action of multiple enzymes, called glycosyltransferases (GTs) (209). These 
enzymes transfer monosaccharides from activated sugar nucleotides (donor) onto a lipid carrier, 
or the target protein (acceptors). The nature of the primary acceptor defines the glycosylation 
mechanism that each species has developed. Two distinct glycosylation mechanisms have been 
identified to date. In the first one, the glycan is first synthesized onto a lipid carrier (dolichol in 
Eukaryotes and undecaprenol in Prokaryotes), and then transferred as a whole onto the 
acceptor protein. In the second mechanism, the glycans are built directly onto the acceptor 
protein. In Eukaryotes, in most cases, an initial, en bloc glycosylation occurs, followed by further 
extension of the glycans directly onto the protein. 
Of the 20 amino acids found in proteins, only six of these have been found to accommodate 
glycans, with asparagine (Asp, N), serine (Ser, S), threonine (Thr, T) being the most common 
ones, whereas tyrosine (Tyr, Y), cysteine (Cys, C) and tryptophan (Trp, W) and glutamine (Gln, 
Q) have only been identified as glycosylated in very few and specific cases. On these amino acids, 
the glycans can be found on the nitrogen of the Asp or Gln amido group (N-linked glycans), the 
oxygen of the Ser, Thr, or Tyr hydroxyl group (O-linked glycans), the sulfur of the Cys thiol (S-
linked glycosylation) or the C2 of the Trp indol ring. 
1.4.1.1. Protein glycosylation in Eukaryotes 
Protein glycosylation in eukaryotic systems is a process that occurs co-translationally, as well as 




reticulum (ER), where six GTs catalyse the synthesis of the core Mannose5N-acetyl-glucosamine2 
(Man5GlcNAc2) on dolichyl-pyrophosphate on the outer membrane of the ER. Man5GlcNAc2 is 
then flipped towards the ER lumen and expanded by four Man and three glucose (Glc) 
molecules. The complete Glc3Man9GlcNAc2 glycan is then transferred by the Stt3b active subunit 
of the oligosaccharyl-transferase (OST) complex onto the asparagine of the highly conserved 
consensus sequon Asp-Xxx-Ser/Thr, (where Xxx can be any amino acid, other than proline) (210). 
The glycoproteins are then subjected to further modifications by two ER α-glucosidases that 
remove the Glc3, and sometimes by an α-mannosidase that removes one or two mannose units. 
Up to this point, the glycans serve as quality control markers; misfolded proteins are tagged for 
ER-degradation, whereas folded proteins are transferred to the Golgi apparatus. There, the 
glycans are further trimmed by mannosidases down to Man3GlcNAc2 and then extended with 
galactose (Gal), N-acetyl-galactosamine (GalNAc), or GlcNAc and capped with N-acetyl-
neuraminic acid (Neu5Ac) and/or fucose (Fuc) to yield complex N-glycans (211) (Figure 8). 
Mammalian systems other than humans can also cap the glycans using N-glycolyl-neuraminic 
acid (Neu5Gc) whereas yeasts generally extend the glycans with mannose only, yielding high 





Figure 8 En bloc N-glycosylation in Eukaryotes. The core glycan is synthesised on the cytosolic side of the endoplasmic 
reticulum (ER), flipped over to the ER lumen and transferred onto the acceptor protein before it is translocated to the 
Golgi apparatus where the glycan is further matured (213). 
O-glycosylation (often referred to as “mucin-type O-glycosylation”) takes place in the Golgi 
apparatus (214,215) and is characterized by the synthesis of the glycan chain directly onto the 
acceptor protein by the sequential action of multiple GTs (Figure 9). The process is initiated by 
the addition of an α-GalNAc to a Ser or Thr residue (Tn-antigen), which, under normal conditions, 
is extended by a β-1,3-Gal (T-antigen). As an exception, the Tn-antigen can be extended by β-
1,3-GlcNAc (core 3), or β-1,3 GalNAc (core 5) in intestinal epithelial cells (216). The T-antigen 
and core 3 (GlcNAcβ-1-3-GalNAcα) structures are further elongated or branched with Gal and 
GlcNAc, and capped with Fuc or Neu5Ac, similarly to N-glycans. Core 5 structures can be capped 
by an α-2,6-Neu5Ac (214). In disease states, such as cancer, the Tn- and T-antigens may not be 
extended, or immediately capped with sialic acid, generating sialyl-Tn- or sialyl-T-antigens (216). 
While no consensus sequon has been identified for O-glycosylation (in contrast to the N-X-S/T 




transferase shows a preference for Thr over Ser residues, while glycosylation is favoured by the 
presence of a proline close to the glycosylation site and may be inhibited by charged amino acids 
flanking the glycosylation site (214). 
 
Figure 9 Mucin-type protein O-glycosylation in Eykaryotes. Each GT extends the glycan directly ont the acceptor 
protein to generate diverse carbohydrate epitopes (adapted from (216)). Core structures are shown. 
To summarise, protein N-glycosylation in Eukaryotes starts during protein synthesis in the ER by 
the addition of the pre-assembled core N-glycans on the asparagine residue of the sequon N-X-
S/T. The glycans mature in the Golgi apparatus, where O-glycosylation also takes place, by 
sequential addition of monosaccharides to the extending glycan, directly onto the acceptor 




including GlcNAc, Man, Glc (only in the premature N-glycans), Gal, GalNAc, Fuc, and Neu5Ac or 
Neu5Gc. Additional modifications, such as addition of sulfates may occur under certain 
conditions (217,218). 
1.4.1.2. Protein glycosylation in bacteria 
Protein glycosylation in bacteria shares several similarities with that of Eukaryotes, but also 
shows some significant differences. Similar to eukaryotic glycosylation, bacterial glycoproteins 
can be modified primarily on Asp (N-glycosylation) or Ser/Thr (O-glycosylation). However, in 
contrast to eukaryotic glycosylation, where N-glycans are pre-assembled onto a lipid carrier 
before being transferred onto the acceptor protein and O-glycans are synthesized directly onto 
the acceptor protein, bacterial glycosylation is more diverse, both in terms of mechanisms 
employed, as well as in the nature of the carbohydrates used. In addition, while glycosylation in 
Eukaryotes occurs co-, as well as post- translationally, glycosylation in bacteria is believed to 
occur post-translationally.  
1.4.1.2.1. N-Glycosylation: The Campylobacter jejuni paradigm 
The first complete glycosylation system ever identified in bacteria, and indeed the most well 
studied, is that from C. jejuni. C. jejuni 81-176 harbours a protein glycosylation cluster (pgl) of 13 
genes (219) that are responsible for the glycosylation of various proteins (220). These genes 
encode i) enzymes that synthesise bacilosamine (2,4-diacetamido-2,4,6-trideoxyglucose) found 
at the reducing end of the glycan, ii) GTs that are involved in the production of the glycan {α-
GalNAc-(1,4)- α-GalNAc-(1,4)- [β-Glc-(1,3)-]- α-GalNAc-(1,4)- α-GalNAc-(1,4)- α-GalNAc-(1,3)-α-
diNAcBac} on undecaprenol-phosphate, iii) a transporter that flips the glycan to the periplasm 
and iv) an oligosaccharyl-transferase (N-OSTase) that glycosylates the target protein (219) (see 
Figure 10A).  
This system resembles the eukaryotic N-glycosylation pathway, as the glycan is synthesized onto 




protein. In addition, PglB, the N-OSTase, is homologous to the Stt3b subunit that glycosylates 
the newly synthesised proteins in the ER of Eukaryotes and, as such, it recognizes a similar 
consensus sequon, although extended to Asp/Glu-Tyr-Asp-Xxx-Ser/Thr (221). This may reflect 
the fact that the glycosylation site of unfolded proteins in eukaryotic systems are more flexible 
and, thus, readily accessible by the N-OSTase, whereas fully folded bacterial proteins are more 
rigid and require this extended sequon to better expose the glycosylation site to PglB. This was 
shown in in vitro glycosylation reactions were PglB was used to glycosylate native C. jejuni 
glycoproteins or bovine ribonuclease A. PglB had greater affinity for the native substrates, 
compared to folded RNase A, but could glycosylate unfolded RNase A as efficiently as the native 
proteins (222). Homologues of PglB from other organisms, however, have been shown to 
possess a more relaxed specificity towards the acceptor peptide, yet retaining the requirement 
for the Asp-Xxx-Ser/Thr motif (223). PglB has been shown to have a relaxed specificity towards 
the oligosaccharide it can transfer (224,225). The nature of the monosaccharides does not seem 
to restrict transfer, as heterologous expression and glycosylation systems have been used to 
modify proteins even with eukaryotic-like glycans (225). The length of the glycan is not strigent 
either; transfer of longer or shorter glycans has been achieved in cases were O-antigen-derived 
glycans were used for protein glycosylation (224). 
Homologues of PglB, the key enzyme of this N-glycosylation system in C. jejuni, are present in 
most δ- and ε- proteobacteria analysed to date. However, the organisation of the cluster varies 
between species and strains in terms of the number of genes and in particular the GTs 
expressed. For example, some Campylobacter and Helicobacter species contain two putative 
copies of pglB, whereas the pgl cluster in Helicobacter canadensis MIT 98-5491 is split between 
multiple loci (226). H. pylori seems to be an exception, as it lacks all homologues from the pgl 




In addition, as this type of glycosylation takes place in the periplasm, and requires flipping of the 
lipid-linked glycan across the inner membrane, this N-glycosylation system has not been 
identified or predicted to exist in any Gram-positive species. 
1.4.1.2.2. Alternative N-glycosylation in β- and γ-proteobacteria 
In contrast to the “typical” en bloc N-glycosylation system found in Campylobacter and other δ- 
and ε- proteobacteria (as described above), a different N-glycosylation system has been 
reported in γ-proteobacteria. In particular, HMW1, an adhesin in Haemophilus influenza (Hi), 
was found to undergo glycosylation in the cytoplasm by HMW1C with one or two hexose (Hex) 
molecules at over 30 sites (228). In contrast to other glycosylation systems, where one enzyme 
is responsible for adding the initial monosaccharide and other enzymes act to elongate the 
glycan, HMW1C can perform both tasks, i.e. form an N-bond between the first Hex and the 
acceptor protein, and extend the glycan by forming an O-glycosidic bond with a second Hex 
(229) (see Figure 10B). Based on its amino acid sequence, the enzyme is classified as a GT family 
41 of the Carbohydrate Active Enzymes (CAZy) database (www.cazy.org) (230), which contains 
almost exclusively O-glycosyltransferases (231). HMW1C recognises the same N-X-S/T 
consensus sequence required for the typical eukaryotic or prokaryotic N-glycosylation process, 
with a single exception in the native substrate HMW1, in which the consensus sequence appears 
to be reversed (T-F-N-V-E) (229). It is still unknown, however, if HMW1C is involved in the 
glycosylation of other proteins, or if it is solely dedicated to the modification of HMW1. 
Regarding its sugar specificity, the enzyme was shown to initiate glycosylation with either Glc or 
Gal, but the glycan was further extended with Glc or Gal only when Glc was the initiating 
monosaccharide (228). This is in contrast to other N-glycosylation systems were the reducing 
sugar is a N-acetylhexosamine (HexNAc). 
HMW1C-like proteins are predicted to exist in many families of β- and γ- proteobacteria (231). 




suggesting that the adhesins may be the target proteins, but others have no apparent 
glycosylation targets (231). Of these, HMW1C-like protein from Actinobacillus 
pleuropneumoniae (Ap), Kingella kingae and Aggregatibacter aphrophilus were experimentally 
shown to possess a function similar to HiHMW1C. Most importantly, ApHMW1C-like protein was 
shown to have a relaxed specificity towards the glycosylation site, which also included Ser or Gln 
residues (232).  
 
Figure 10 N-glycosylation pathway in Prokaryotes. A) The en bloc glycosylation system in C. jejuni. Synthesis of 
diNAcBac is mediated by the enzymes PglFED. The heptasaccharide is assembled onto udecaprenol-phosphate by the 
GTs PglCAJH, before flipped to the periplasmic space by PglK and transferred onto the target protein by PglB. B) The 
sequential N-glycosylation system in Haemophilus influenzae. HMW1 is glycosylated in the cytoplasm by HMW1C, 
and is then secreted through the SecYEG and HMW1B channels (233).  
1.4.1.2.3. N-glycosylation in mycoplasmas 
While the family of enzymes involved in cytoplasmic N-glycosylation appears to be restricted to 
limited classes of Gram-negative proteobacteria, similar glycosylation mechanisms cannot be 
excluded from Gram-positive bacteria. In fact, evidence for N-glycosylation in mycoplasmas 
species has emerged. Mycoplasmas are Gram-positive bacteria with a unique surface structure. 
In a recent study, Asn and Gln residues outside of the N-glycosylation consensus sequence were 
found to carry a single Hex in Mycoplasma pulmonis and Mycoplasma arthritis, which could 
suggest a similar glycosylation mechanism to that found in H. infuenzae (234). However, no 




extracellularly. In addition, it was shown that the bacteria could use free oligosaccharides from 
the growth media, without the need to synthesise glycans internally to use for protein 
glycosylation (234). 
1.4.1.2.4. O-glycosylation in bacteria 
Similarly to Eukaryotes, bacteria also have mechanisms to perform O-glycosylation by modifying 
protein targets with glycans on Ser or Thr residues, and, like prokaryotic N-glycosylation, two 
mechanisms have been identified: either en bloc transfer of a pre-assembled lipid-linked 
oligosaccharide, or modification of the acceptor protein directly, by the sequential action of GTs 
(235). In the first case, the mechanism is identical to that of the N-glycosylation system, i.e. the 
glycan is synthesised on undecaprenol, the lipid carrier found in bacteria, flipped over to the 
periplasmic space and transferred onto the acceptor protein by the action of an O-
oligosaccharyltransferase (O-OTase). In the second case, multiple GTs act directly on the 
acceptor protein to extend the glycan, using sugar nucleotides as donors. 
En bloc O-glycosylation 
Several Gram-negative species have been identified to harbour genes encoding O-
oligosaccharyltransferase (O-OTase), including Neisseria, Pseudomonas, Aeromonas and 
Burkholderia spp (209). The most well studied example of en bloc O-glycosylation is that of 
Neisseria gonorhoeae, where PglO, the active O-OTase, glycosylates multiple proteins with a O-
acetylated (OAc)-Gal-Gal-diNAcBac (236–238). Often, the O-OTase utilises lipid-linked glycans 
used in O-antigen biosynthesis (239), as in the case of PilO from Pseudomonas aeruginosa 
(240,241) and Francisella tularensis (242). In this case, the O-antigen subunit is built on an 
undecaprenyl phosphate lipid carrier on the cytosolic side of the inner membrane, as in the case 
of N-glycosylation, by the sequential action of a varying number of GTs. Then it is flipped across 
the membrane to the periplasmic space by the transmembrane flippase Wzx. At this stage, 




(243), or the O-OTase uses the synthesised subunit to transfer the glycan onto a glycoprotein 
(Figure 11A) (239).  
 
Figure 11 O-glycosylation in Gram-negative bacteria. A) En bloc O-glycosylation of Neisseria meningitis pili; after the 
synthesis of the necessary nucleotide-activated monosaccharides, the glycan is assembled onto undecaprenol 
phosphate, before flipped in the periplasmic space, where it is transferred onto the target protein. B) Sequential O-
glycosylation of the C. jejuni flagella; the glycan is synthesised directly onto the target protein in the cytoplasm, before 
the glycosylated protein is secreted. 
As Neisseria species lack O-antigens (244), their glycosylation clusters may be dedicated to 
protein glycosylation. Burkholderia cenocepasia also has an O-glycosylation system that is 
independent of the O-antigen biosynthesis and can transfer HecNAc-HexNAc-Hex moieties onto 
acceptor proteins (245). Most of these systems have been studied in the context of flagellar or 
pili glycosylation in their respective organisms, and it is not clear whether flagellar subunits are 
the only targets of glycosylation. Recent studies have shown that the O-glycosylation systems in 
B. cenocepasia and N. gonorrhoeae can target multiple proteins (237,245), whereas PilO from 
P. aeruginosa was found to target proteins other than pilins, when heterologously expressed in 
E. coli, suggesting that it could potentially glycosylate other periplasmic proteins (246). The N. 
gonorrhoeae glycoproteins were found to be modified in low-complexity regions (LCRs), rich in 
Ala, Ser and Pro residues (237), suggesting there may be some structural features that are 




O-OTases were identified in Acinetobacter baylyi ADP1, one being specific to pilin glycosylation, 
whereas the other one could target several proteins (247).  
While the specificity of the enzymes towards the acceptor protein is not yet fully understood, it 
is clear that O-OTases from different organisms can transfer a wide range of sugars. For instance, 
PglL from N. meningitidis and PilO from P. aeruginosa can transfer, in addition to their native 
glycans, the C. jejuni glycan synthesised during N-glycosylation, as well as the E. coli O7 antigen. 
It is worth mentioning that while PglL could facilitate O-glycosylation using glycans comprised of 
more than three repeating units of the E. coli O7 antigen, PilO was not active when more than 
two repeats were used (244). In addition, PglL was also able to glycosylate a pilin subunit using 
UDP-diNAcBac, but not UDP-GlcNAc or UDP-GalNAc, as donor in vitro. However, this donor is 
not present in the periplasmic space, where this reaction naturally takes place, so it is considered 
unlikely for this reaction to occur in vivo (248). Putative O-OTases from Burkholderia 
thailandensis and Vibrio cholerae identified and expressed heterologously were shown to be 
active, when provided with the right combination of glycan donor and protein acceptor (249).  
O-glycosylation by sequential action of GTs 
In addition to the en bloc O-glycosylation systems, many bacteria encode enzymes that mediate 
mucin-type O-glycosylation, where the acceptor protein is modified intracellularly by the direct 
action of a priming GT, followed by extension of the glycan by the action of additional GTs. In its 
simplest form, the acceptor protein is modified by a single monosaccharide, with no further 
elongation of the glycan, as in the case flagellar proteins from C. jejuni and C. coli which are 
modified by a single pseudaminic acid (Pse) or legionaminic acid (Leg) or their derivatives, 
respectively (Figure 11B). In both cases, the genes coding for enzymes involved in the 
biosynthesis and subsequent transfer of the sugar onto the protein are all located downstream 




Examples of this O-glycosylation mechanism have also been described in a range of Gram-
positive species. For example, strains of C. difficile glycosylate their flagella with two types of 
glycans: Type A is composed of an O-GlcNAc modified with a thr via a phosphodiester bond (Thr-
P) and Type B of an O-GlcNAc, extended with two rhamnose (Rha) molecules, occasionally 
methylated, and capped with a unique sulfonated peptidyl fucosamine (252,253). Glycosylation 
with the Type A glycan is mediated by the action of a GT encoded by CD0240 (254), followed by 
the addition of the pre-formed Thr-P at C-3 of the GlcNAc moiety by CD242, before CD243 
methylates the amine on the thr (255). The synthesis of Type B glycans requires the action of 
five gene products: GT1 initiates glycosylation by adding the reducing GlcNAc, GT2 extends the 
glycan by adding two Rha residues and methylating either or both Rha, whereas GT3 adds the 
non-reducing terminal peptidyl-modified fucosamine, which is synthesised by the action of 
CDR20291_0245 and 0246 (252). In contrast to C. difficile, C. botulinum glycosylates its flagella 
with a single hexuronic acid or Leg derivative per glycosylation site (256). Bacillus antharacis and 
the closely related Bacillus cereus glycosylate their spore protein with 3-O-Me-Rha-α-1,2-Rha-α-
1,3-GalNAc, capped either with anthrose or cereose, respectively, sugars characteristic for each 
strain (257). A distinct glycosylation system is found in L. monocytogenes, where the flagella is 
modified on several amino acids by a single β-Ο-linked GlcNAc (258). This is unexpected as it 
resembles the cytosolic O-GlcNAcylation mechanism that is involved in signalling pathways 
(259), rather than the typical O-glycosylation pathways where the reducing sugar is most often 
in α-configuration (see section 1.4.1.1). 
The accessory secretion system SecA2/Y2 glycosylation pathway 
As described above (1.3.3), several pathogenic Gram-positive bacteria possess an auxiliary 
secretion system (aSecA), in addition to the canonical SecA system. This system contains the 
necessary genes encoding proteins that facilitate the expression, glycosylation and subsequent 
secretion of serine-rich-repeat containing proteins (SRRPs) (for details see 1.3.3). The cluster 




studied SecA2-mediated glycosylation system is that of Streptococcus parasanguinis 
(191,205,260–265) which shows some unique features, not found in other glycosylation 
systems. In total this cluster contains six GTs. First, glycosylation of Fap1, the SRRP in S. 
parasanguinis FW213, is initiated by the combined action of two GTs, GtfA and GtfB. These 
enzymes interact with the acceptor SRRP and with each other through a conserved domain 
DUF1975 and mediate the addition of the reducing GlcNAc. GtfA acts as the active GT, whereas 
GtfB interacts with the acceptor protein, acting as a chaperone (266,267). An enzyme previously 
annotated as a sugar nucleotide synthase like protein (NSS) extends the glycan by adding a 
glucose unit (thus this enzyme has been renamed GtfC). dGT1 contains two distinct GT domains 
(DUF1792 in N-terminus, which is a recently described GT-D type glycosyltransferase fold, and a 
GT-A type GT fold in C-terminus (262)) and creates a branching point by adding a Glc and a 
GlcNAc residue on Glc. GalT2 adds a Rha residue onto the second glucose and the glycosylation 
is completed by the addition of a Glc residue onto GlcNAc by Gly (Figure 12) (191).  
Recently, the SecA2/Y2 glycosylation system from S. pneumoniae TIGR4 was elucidated (268). 
This cluster contains ten GTs. Glycosylation of PsrP, the respective SRRP in this organism, is 
initiated by the addition of GlcNAc by GtfA and GtfB. GtfA was recently shown to belong to GT 
family 4, suggesting the addition of an α-O-GlcNAc (267). Gtf3 catalyses the second step in 
glycosylation by adding a Glc unit, similarly to the Fap1 glycosylation. The third step is catalysed 
by GlyD, GlyG or GlyE. Similarly to dGT1, GlyD is also composed of two GT domains: a DUF1792 
at the N-terminus and a GT8 domain at the C-terminus. GlyDDUF1792 primarily mediates the third 
step in PsrP glycosylation by adding either a Glc or a Gal residue. When GlyG, a GT family 2 
glycosyltransferase, mediates the third step, the glycan is extended with Glc, whereas GlyE, a 
GT8 enzyme, adds a Gal residue. These three enzymes, in addition to GlyA can also mediate the 
fourth glycosylation step; in particular, GlyG can add an additional Glc to the extending glycan, 
whereas GlyDGT8, GlyE and GlyA can extend the glycan with a Gal residue. GlyDDUF1792 can 




no activity has been attributed to GlyB, GlyC and GlyF, although GlyB was shown to possess 
hydrolytic activity against both UDP-Glc and UDP-Gal, whereas GlyF was more active against 
UDP-Gal (268).  
 
Figure 12 SRRP Glycosylation mechanism of Fap1 in Streptococcus parasanguinis FW213 (top) and PsrP in S. 
pneumoniae TIGR4 (bottom). The adhesin is glycosylated intracellularly, by the sequential action of a number of GTs. 
The glycosylated product is secreted through the SecA2/Y2 export machinery. During secretion the signal peptide (SP) 
is cleaved and Asp2 acetylates GlcNAc residues on the SRRPs. 
Glycosylation of the S. agalactiae Srr-1 is mediated by the GTs found in the SecA2/Y2 cluster. 
However, it shows great glycan heterogeneity and the role of each GT is not yet understood. 
Importantly, a novel modification was identified in the Srr-1 glycan: some HexNAc residues also 
carry an additional O-acetyl group, probably on the O-6 position (269). This modification had 
previously been identified on GlcNAc in the peptidoglycan layer of various Lactobacilli species, 
where it protects the PG from enzymatic hydrolysis  (270). However, while OatB was responsible 
for generating the O-Acetylated GlcNAc (O-AcGlcNAc) used in the peptidoglycan, Asp2 was 




Recently, a functional SecA2/Y2 cluster has been identified in the oral commensal Streptococcus 
salivarius JIM8777, which harbours genes encoding three SRRPs and four GTs (189). In contrast 
to other studied SecA2/Y2 systems, GtfA and GtfB in the cluster were not involved in glycosylation 
of the SRRPs. Instead, two genetically linked GTs found outside of the cluster were shown to act 
on the SRRPs, as well as other surface and secreted proteins (189). SRRPs in this cluster were 
found to be glycosylated with O-acetyl-HexNAc, HexNAc and HexNAc-Hex residues, only in the 
serine rich repeat regions (189), in contrast to Srr-1 from S. agalactiae in which glycopeptides 
from the N-terminal domain were identified (269). 
Table 5 SPPR glycosylation in bacteria. 
SRRP Organism Glycans 




Fap1 Streptococcus parasanguinis FW213 Glc-GlcNAc-(Rha-Glc)-Glc-GlcNAc 
Srr1 Streptococcus agalactiae H36B N.D.* 
Contain HexNAc, O-AcHexNAc, Hex  
GspB Streptococcus gordonii M99 N.D.* 
Contain HexNAc, O-AcHexNAc 
*N.D: Not determined 
1.4.1.3. Protein glycosylation in gut commensal bacteria 
While protein glycosylation has attracted much interest in pathogenic bacteria underscoring the 
role of glycans in virulence and pathogenicity in many clinically important bacterial species, the 




Various glycoproteins have been identified in B. fragilis, one of the most studied gut commensal 
bacteria. Most proteins were shown to be fucosylated as shown using the fucose-specific Aleuria 
aurantia lectin (AAL). The bacteria could both synthesise GDP-fucose from GDP-mannose, and 
acquire Fuc from the growth media and activate it with GDP, after phosphorylation (both 
phosphorylation and subsequent activation are catalysed by a single enzyme) (271). Affinity 
chromatography with AAL followed by MS analysis identified glycoproteins of various functions, 
including peptidases, chaperones and proteins predicted to be involved in protein-protein 
interactions. All the identified proteins were predicted to be periplasmic or associated with the 
bacterial outer membrane (272). It was also found that glycosylation took place in the periplasm, 
which suggested an en bloc glycosylation mechanism. Indeed, a gene cluster resembling a 
capsular polysaccharide (CPS) biosynthesis cluster was identified, which lacked a polymerase 
gene. After its deletion, the protein recognition by AAL was lost, suggesting that this cluster plays 
a critical role in a general O-glycosylation system and that this system is independent of the CPS 
biosynthesis pathway. Using an antibody specific for the B. fragilis glycan against protein 
extracts of various Bacteroides species, it was suggested that most of them, including B. 
thetaiotaomicron and B. ovatus, produce similar glycans. No glycosylation was observed in B. 
vulgatus, suggesting either a lack of glycosylation, or, more likely, a different glycan structure, 
as this bacterial species contains a homologous glycosylation system (272). Interestingly, even 
though there is no consensus sequence identified for O-glycosylation, the B. fragilis O-OTase 
seems to be specific for the three-amino-acid long sequon D-(S/T)-(A/I/L/M/T/V). Mutation of 
the first Asp led to a loss of glycosylation in the proteins tested, and there was a clear 
requirement for an amino acid with at least one methy-group in its side chain in the position 
following the glycosylation site (273). Based on this sequence, more than 1000 putative 
glycoproteins were identified in B. fragilis, and by introducing this sequence to a putative α-




glycosylation, site-specific glycosylation was achieved in vivo (273). However, the structure of 
the glycan has not yet been determined. 
Lactobacillus species have been extensively studied owing to the importance of certain 
Lactobacillus strains as probiotics, evidence for protein glycosylation has recently emerged.  
In L. plantarum WCFS1, a general glycosylation system has been described (274). This system is 
very similar to that initiating glycosylation of SRRPs, i.e. two GT, named as GtfA and GtfB in L. 
plantarum, but here will be referred to as Gtf1 and Gtf2 (so as to avoid confusion with the GtfA 
and GtfB from the SecA2/Y2 cluster) are involved in the addition of a single HexNAc molecule 
onto each glycosylation site of the acceptor proteins (274); deletion of either Gtf1 or Gtf2 leads 
to a loss of protein recognition by the GlcNAc-specific lectin wheat germ agglutinin (WGA). This 
suggests that both GTs are required for protein glycosylation and that the added sugar is most 
likely GlcNAc. These two enzymes contain a DUF1975 in N-terminus which probably mediates 
the interaction between the two GTs and the target proteins and a GT domain in C-terminus, as 
described for the SRRP-specific GtfA and GtfB, suggesting a similar mode of action. In contrast 
to the L. monocytogenes flagellar glycosylation and the O-GlcNAcylation systems that add a 
single β-O-GlcNAc, this system is likely to add α-linked O-GlcNAc, as Gtf1 is highly similar to GtfA 
from S. pneumoniae (267). The muramidase Acm2 from L. plantarum WCFS1 was identified as a 
glycoprotein targeted by this glycosylation system. Analysis of the glycosylation of the 
muramidase Acm2 by MS showed that it is glycosylated by single HexNAc residues at more than 
20 sites, all found within the AST domain (275). This is in accordance to previous studies showing 
that O-glycosylation occurs in low complexity regions. By deleting the secretion signal peptide 
of Acm2, Fredrikesn et al. (2012) showed that glycosylation occurs intracellularly and therefore 
precedes secretion (275). It was also shown that glycosylation of Acm2 inhibited its enzymatic 
activity, by causing conformational changes. These were proposed to occur by interaction of 




binding the GlcNAc-rich peptidoglycan layer (276). Glycosylation also increased the resistance 
of the AST domain against trypsin (276). MS analysis of surface proteins in L. plantarum WCFS1 
revealed numerous additional proteins carrying O-GlcNAc residues, suggesting that this is a 
general glycosylation system. These proteins include among others DnaK, a chaperone involved 
in protein folding, PdhC, which is involved in the anaerobic metabolism of Lactobacilli, as well as 
a mucus binding protein, similar to MUB53608 from L. reuteri ATCC53608, probably involved in 
adhesion of the bacteria to the host surface (277). This analysis also identified a HexNAc-Hex 
moiety on gamma-D-glutamate-meso-diaminopimelate muropeptidase, which suggests that 
either the GlcNAc residues can be further extended by the action of other GTs, or that there is 
an additional glycosylation system in L. plantarum (277). In addition to WGA, Dolichos biflorus 
agglutinin, a lectin specific for α-GalNAc, and Lens culinaris lectin, which is specific for α-Man, 
were also shown to interact with L. plantarum proteins (274). This would also suggest the 
presence of additional glycosylation system(s). However, deletion of four other putative GTs 
(including one with a DUF1975), similar to GtfA from S. parasanguinis in L. plantarum WCFS1 did 
not lead to any changes in the recognition of the proteins by these lectins (274). 
The Major secreted protein 1 (Msp1) is a muramidase, similar to Acm2, found to be glycosylated 
in L. rhamnosus GG (278). It has a predicted molecular weight (MW) of 48 kDa, but was found 
to migrate at 75 kDa on SDS-PAGE and interact with Concanavalin A (ConA), a lectin specific for 
Man and Glc residues. Msp1 shows low complexity, as it consists of 23% ala residues. 
Monosaccharide composition analysis of Msp1 confirmed the presence of Man, in agreement 
with ConA affinity to Msp1 (278). As reported for Acm2, the glycosylation of Msp1 protected the 
protein against proteases. However, in contrast to Acm2, glycosylation of Msp1 did not affect 
the hydrolytic activity of the enzyme or its ability to activate the Akt signalling pathway in Caco-
2 cells (278). L. rhamnosus GG also expresses proteins that are responsible for the formation of 
pili, a rare feature in the Lactobacillus genus. These are composed of the three-protein complex 




involved in adhesion to intestinal epithelial cells (IEC) and in the attenuation of proinflammatory 
responses from these cells (279). Atomic force spectroscopy (AFM) of the pili using 
functionalised tips with lectins specific for Man and Fuc suggested the presence of these two 
monosaccharides, in contrast to the glycosylation analysis of L. rhamnosus GG Msp1, which only 
showed Man residues and no Fuc. Furthermore, the glycosylated pili were shown to interact 
with dendritic cells via the DC-SIGN lectin, an important receptor of the immune system that 
recognises primarily high-mannose structures, and induce the expression of the anti-
inflammatory cytokine IL-10, as well as IL-6 and IL-12p35 (280). While L. rhamnosus GG contains 
a pair of putative GTs containing a DUF1975, these have not been experimentally assessed for 
their involvement in glycosylation of either Msp1 or the spaCBA pilin.  
Similar to pili, flagella are also rare structures in the Lactobacillaceae family. However, they were 
recently discovered in a motile strain of Lactobacillus agilis and were shown to be glycosylated 
by means of periodic acid/Schiff (PAS) stain (281), but the nature of glycosylation was not further 
investigated.  
S-layer proteins (Slps) are expressed by many bacterial species and form a two-dimensional layer 
that surrounds the bacterial cells (282). In Gram-positive bacteria, Slps are found attached onto 
components of the PG layer, such as (lipo)teichoic acids or neutral polysaccharides (282). In 
Lactobacillus species, these proteins usually consist of a C-terminal carbohydrate-binding 
domain, used for attachment of the protein onto the cell wall, and a self-assembly N-terminal 
domain that forms the 2D layer (283). Although there are older reports of glycosylated Slps in 
Lactobacillus helveticus and L. plantarum, based on PAS stain (284), it is believed that 
Lactobacillus Slps are generally non-glycosylated (173). However, recent detailed studies of L. 
kefir strains (173), L. acidophilus (285) and L. buchneri (284) revealed glycosylated S-layer 
proteins. Screening of various L. kefir strains showed that Slp glycosylation is conserved within 




unexplored. SlpA in L. acidophilus NCFM was found to be glycosylated with glycans containing 
Man and Fuc, as shown by AFM experiments with specific lectins (285). Similarly to spaCBA pili 
from L. rhamnosus, SlpA from L. acidophilus induced the production of IL-10 from DC, by 
interacting with DC-SIGN (285). MS analysis of SlpA from L. buchneri CD034 showed that the 
protein is glycosylated on Ser residues in the sequon SSASSASSA, consistent with previous 
reports for O-glycosylation in low complexity and AST-rich regions. The glycans found on each 
glycosylation site consisted of on average 7 residues of α1-6 linked Glc. It was also suggested 
that glycosylation occurs extracellularly, as no glycosylated SlpA was found in the cytosolic 
fraction (284). In the same study a glycoside hydrolase (GH), belonging to GH family 25 according 
to the CAZy database classification, was also found to carry a modification corresponding to the 
mass of eight glucose units, suggesting that the system that is responsible for SlpA glycosylation 
may target other proteins as well (284). 
Table 6 A summary of identified glycoproteins from Lactobacillus species. 
Protein Organism Glycan Method Reference 
Msp1 L. rhamnosus 
GG 





spaCBA L. rhamnosus 
GG 
Man and Fuc- 
containing 
Lectin affinity (AFM, 
WB, ELLA) 
(280) 
FliC1/FliC2 L. agilis uncharacterised PAS-stain (281) 











Glc8 MS (284) 
Slp L. kefir uncharacterised PAS stain (284) 
Acm2 L. plantarum 
WCFS1 
GlcNAc MS, lectin affinity 
(WB)  
(275) 









GlcNAc1 MS (277) 
Lp_2260 L. plantarum 
WCFS1 









GlcNAc1 MS (277) 
PdhC L. plantarum 
WCFS1 
GlcNAc1 MS (277) 
FtsY L. plantarum 
WCFS1 
GlcNAc1 MS (277) 
Lp_2793 L. plantarum 
WCFS1 
GlcNAc1 MS (277) 
FtsK1 L. plantarum 
WCFS1 








FtsZ L. plantarum 
WCFS1 
GlcNAc1 MS (277) 
 
In addition to the characterised glycosylation systems and glycoproteins described above (Table 
6 provides a summary of the identified glycoproteins from Lactobacillus sp.), there is also 
indirect evidence for additional protein glycosylation systems in gut commensal bacteria. For 
instance, the presence of a functional SecA2/Y2 cluster in the murine isolate L. reuteri 100-23 
(103) shows that this glycosylation system is not exclusive to pathogenic bacteria. In addition, 
MUB53608 from the porcine isolate L. reuteri ATCC 53608 was recently shown to interact with DC-
SIGN via C-type lectins (175), suggesting the presence of a carbohydrate component. This, in 
addition to its aberrant electrophoretic mobility (154), suggests that that protein may be 
glycosylated. However, glycosylation of the major adhesins in L. reuteri strains has not been 
investigated. 
1.5. Aims- objectives 
The aim of this project is to analyse the secreted glycoproteome of L. reuteri strains 
isolated from different vertebrate hosts. Specific objectives include (i) identifying the 












Chemical reagents were purchased from Sigma Aldrich (UK), and enzymes were purchased from 
New England Biolabs (UK), unless otherwise stated. Antibodies with their suppliers are listed in 
Table 7. Plant lectins were purchased from Vector Labs (UK) (Table 8). Human intelectin-1  
(h-Int1) was provided by Dr. Amanda Ducan and Prof. Laura Kiessling (University of Wisconsin-
Madison, WI, USA).  
Table 7 Antibodies used in this study. 
Antibodies Specificity Supplier/Reference 
Rabbit anti-MUB53608-R5 
polyclonal ab 
MUB53608-R5 repeat (155) 
Rabbit anti-MUB53608-RI 
polyclonal ab 
MUB53608-RI repeat (155) 
Rabbit anti-SRRP53608 polyclonal 
ab 
Binding region of SRRP53608 (286) 
Mouse anti-β-O-GlcNAc 
monoclonal antibody 
Serine O-linked β-GlcNAc Millipore, UK 
Mouse anti-α-gal monoclonal 
antibody 
 




Strep-tag II peptide IBA lifesciences, 
Germany 
Goat anti-rabbit antibody, AP 
conjugate 
Rabbit antibodies Sigma Aldrich, UK 
Anti-mouse antibody, HRP 
conjugate 
Mouse antibodies Jackson 
laboratories, USA 
 
Table 8 Fluorescein-labelled plant lectins used in this study. 
Lectin Abbreviation Specificity Fluorescein/ 
protein ratio 
Concanavalin A ConA α-mannose 5:1 
Lotus tetragonolobus lectin LTL α-L-fucose 4:1 
Peanut agglutinin PNA Gal-(β-1,3)-GalNAc (T-
antigen) 
4.2:1 
Ricinus communis agglutinn RCA  Gal or GalNAc 6:1 
Sambucus nigra agglutinin SNA α-2,6-linked sialic acid 
(α-2,3-linked sialic acid 
with lower affinity) 
7.7:1 
Ulex europaeus agglutinin UEA α-L-fucose (differs from 
LTL) 
2.6:1 
Wheat germ agglutinin WGA GlcNAc or sialic acid 3.1:1 
Griffonia simplicifolia Lectin I 
isolectin B4 




Maackia amurensis lectin I MAL I Galβ-1,4-GlcNAc 8.9:1 
Maclura pomifera lectin MPL Galβ-1,3-GalNAc 3.9:1 
 




E. coli L. reuteri 
Kanamycin (Kan) 50 N/A 
Chloramphenicol (Cm) 34 10 




2.2. Media and bacterial growth 
All strains used in this study are listed in Table 10. 




Lactobacillus reuteri 100-23 wild type (WT) N/A (109) 
Lactobacillus reuteri 100-23 Δasp2 Ery Prof. Jens Walter (University of 
Alberta, Edmonton, Canada), 
(109) 
Lactobacillus reuteri 100-23 ΔsecA2 Ery (109) 
Lactobacillus reuteri 100-23 ΔgtfB Ery Prof. Jens Walter (University of 
Alberta, Edmonton, Canada) 
(109) 
Lactobacillus reuteri 100-23 Δsrr Ery (109) 
Lactobacillus reuteri 100-23 Δgtf1 N/A Dr. Rebbeca Duar and Prof. 
Jens Walter (University of 
Alberta, Edmonton, Canada) – 
This study  
Lactobacillus reuteri 100-23 Δftf Ery (287) 
Lactobacillus reuteri ATCC 53608 N/A (288) 
Lactobacillus reuteri 1063N N/A (151) 
Lactobacillus reuteri MM4-1a N/A (147) 
Escherichia coli DH5a  N/A  
Escherichia coli DH5a_pOPINF Amp/Cb  
Escherichia coli DH5a_pOPINF-gtf1 Amp/Cb This study 
Escherichia coli DH5a_pOPINF-gtf2 Amp/Cb This study 
Escherichia coli DH5a_pOPINF-gtfA Amp/Cb This study 
Escherichia coli DH5a_pOPINF-gtfB Amp/Cb This study 
Escherichia coli DH5a_pOPINF-gtfC Amp/Cb This study 
Escherichia coli DH5a_pRSFDuet-1 Kan This study 
Escherichia coli DH5a_pRSFDuet-1-gtf1 Kan This study 
Escherichia coli DH5a_pRSFDuet-1-gtf1/2 Kan This study 




Escherichia coli BL21 (DE3)_pOPINF Amp/Cb  
Escherichia coli BL21 (DE3)_pOPINF-gtf1 Amp/Cb This study 
Escherichia coli BL21 (DE3)_pOPINF-gtf2 Amp/Cb This study 
Escherichia coli BL21 (DE3)_pOPINF-gtfA Amp/Cb This study 
Escherichia coli BL21 (DE3)_pOPINF-gtfB Amp/Cb This study 
Escherichia coli BL21 (DE3)_pOPINF-gtfC Amp/Cb This study 
Escherichia coli BL21 (DE3)_pRSFDuet-1 Kan  
Escherichia coli BL21 (DE3)_pRSFDuet-1-gtf1 Kan This study 
Escherichia coli BL21 (DE3)_pRSFDuet-1-gtf1/2 Kan This study 
 
Typically, de Man-Rogosa-Sharpe (MRS; Table 11; ThermoFisher Scientific, UK) medium or 
Lactobacillus defined medium-II (LDM-II; prepared in house, Table 11), supplemented with the 
appropriate antibiotics (Table 10), was used for the growth of L. reuteri.  
E. coli strains were grown Luria-Bertani (LB) medium (Table 12), supplemented with the 
appropriate antibiotics (Table 10). Where plates were used, LB was supplemented with 1.5% 
w/v bacteriological agar. Super optimal broth with catabolite repression (S.O.C.) medium (Table 
12) was used for the recovery of E. coli strains after heat-shock transformation. Auto-induction 
medium (AIM; Table 12; Formedium, UK) was used for the overexpression of recombinant 
proteins. 
Table 11 Composition of media used for L. reuteri growth. 
LDM II 
Ingredients Amount per L Ingredients Amount per L 
K2HPO4 (anhydrous) 1.5 g Glutamic acid 50 mg 
KH2PO4 (anhydrous) 1.5 g Arginine 50 mg 
Sodium acetate 15 g Lysine 50 mg 
Sodium citrate 0.22 g Thiamine-HCl 0.2 mg 
Tryptophan 50 mg p-Aminobenzoic acid 0.04 mg 
Asparagine 50 mg Calcium pantothenic acid 0.4 mg 
Cysteine 
Glyc 






50 mg Pyridoxine-HCl 0.5 mg 
50 mg Biotin 0.05 mg 
Alanine 
 
50 mg Folic acid 0.1 mg 
Phenylalanine 50 mg Riboflavin 0.4 mg 
Histidine 50 mg Adenine sulphate 10 mg 
Isoleucine 50 mg Uracil 20 mg 
Methionine 50 mg Guanine-HCl 10 mg 
Proline 
Thre 




Threonine 50 mg Thymidine 1.6 mg 
Valine 50 mg Tween-80 1.0 ml 
Tyrosine 50 mg MgSO4 H2O 0.163 g 
Leucine 50 mg MnSO4 7H2O 23.4 mg 
Glutamine 50 mg FeSO4 7H2O 13 mg 
Aspartic acid 50 mg Sucrose 30 g 
MRS 
Ingredients Amount per L Ingredients Amount per L 
Enzymatic digest of casein 10 g MgSO4 7xH2O 0.2 g 
Meat extract 10 g MnSo4 4xH2O 0.05 g 
. Yeast extract 4 g K2HPO4 (anhydrous) 
 
2 g 
Tri-ammonium citrate 2 g 
 
Sorbitan mono-oleate 1.08 g 
Sodium acetate 5 g Glucose 20 g 
 
Table 12 Composition of media used for E. coli growth. 
LB S.O.C. 
Ingredients Amount per L Ingredients Amount per L 
Tryptone 10 g Tryptone 10 g 
Yeast extract 5 g Yeast extract 5 g 
NaCl 10 g NaCl 4 g 
AIM 
Tryptone 12 g Na2HPO4 7.1 g 
Yeast extract 24 g Glucose 0.5 g 
(NH4)2SO4 3.3 g α-Lactose 2 g 
KH2PO4 6.8 g MgSO4 0.15  
 
2.2.1. L. reuteri growth assays 
2.2.1.1. 96-well plate format assay 
To assess the growth of L. reuteri strains on different disaccharides, LDM-II (200 μl), 
supplemented with 2% w/v sucrose, maltose or lactose was added to each well on a 96-well 
plate. The wells were inoculated with 1 μl from an overnight culture of L. reuteri in MRS. Wells 
with no carbon source, or no inoculum were included as controls. The OD600 was monitored for 
24 h on an Infinite® F50 plate reader (Tecan, Switzerland) and plotted as a function of time.  
2.2.1.2. End-point growth assay 
To assess the ability of L. reuteri strains to utilise different carbohydrates, overnight cultures in 
MRS (50 μl) were used to inoculate 10 ml filter-sterilised LDM-II containing appropriate 




at 37oC for 48 h. OD600 measurements were taken after 48 h. Cultures in LDM-II supplemented 
with 2% sucrose were used as control. 
2.3. Sedimentation assay 
L. reuteri 100-23 WT and Δgtf1, or L. reuteri ATCC 53608 and 1063N were grown from glycerol 
stocks in MRS overnight. The cells were centrifuged at 4000 g for 5 min and washed twice with 
phosphate buffered saline (PBS). The OD600 was normalised to 1 unit for each sample. 2 ml of 
each sample was loaded to a cuvette. The wild type cells were inserted into the reference cell 
of a U-3010 spectrophotometer (Hitachi, UK) and the mutant cells in the measuring cell. The 
change in OD600 was monitored for 18 h. At the end of the experiment, the samples were 
vortexed and the OD600 was measured. 
2.4. Preparation of E. coli competent cells 
E. coli DH5α or BL21 (DE3) were streaked from glycerol stock onto LB agar plates, containing 
appropriate antibiotics, if needed. The plates were incubated overnight at 37oC. A single colony 
was used to inoculate 25 ml LB broth and the culture was grown for 6 h, until the OD600 was 
approximately 0.8-1. The culture was placed on ice for 10 min and then centrifuged at 3000 g 
and 4oC for 3 min. The pellet was resuspended in ice-cold CaCl2 0.1M and incubated on ice for 
20 min. The cells were centrifuged again and after removal of the supernatant were 
resuspended in 5 ml ice-cold CaCl2 0.1 M in 15% glycerol. The suspension was aliquoted and 
stored at -80oC. 
2.5. Transformation of E. coli 
An ice-thawed aliquot of E. coli DH5α or BL21 (DE3) competent cells (100 μl) was mixed with 1 
μl of plasmid (Table 13), or all of the In-Fusion® reaction (see 2.7.2.2) and the cells were kept on 
ice for 15 min. The cells were then heat shocked at 42 oC for 45 s and then put back on ice for 2 




aliquot (typically 100 μl) was plated onto LB plates supplemented with appropriate antibiotics 
and the culture was incubated overnight at 37oC.  
2.6. Heterologous expression in E. coli 
Glycerol stock of E. coli recombinant clones (Table 10) was used to inoculate 10 ml LB broth 
supplemented with appropriate antibiotics (Table 9). The culture was incubated for 16 h at 37oC 
and 250 rpm. This culture was used to inoculate either LB or AIM, with the necessary antibiotics 
at 1% vol/vol. The cultures were incubated at 37oC for 2.5 h and 16oC for 3 days at 250 rpm. If 
LB was used, IPTG was added to the culture before temperature decrease at a final 
concentration of 1 mM. 
2.7. DNA/RNA manipulation 
2.7.1. Polymerase chain reaction (PCR) 
PCR reactions were performed using Q5 DNA polymerase (New England Biolabs, UK), following 
the manufacturer’s instructions. Typically, PCR reactions were set up at a final volume of 50 μl 
and contained 10 μl of reaction buffer, 1 μl of 10 mM dNTPs, 2.5 μl of each primer, 1 μl of 
template DNA, and 0.5 μl of Q5 polymerase. H2O was used to adjust the volume to 50 μl. When 
the PCR product was only required for agarose electrophoresis (e.g. colony PCR or RT-PCR), the 
PCR reactions were scaled down proportionally to a final volume of 10 μl. PCR reactions were 
performed on using Veriti Thermal Cycler (ThermoFischer Scientific, UK). A typical protocol 
consisted of an initial DNA denaturation step at 98oC for 30 s, followed by 35 cycles of 
denaturation at 98oC for 10 s, annealing between 55 and 68oC for 20 s, depending on the 
properties of the primers used, and extension at 72oC for 30 s/kb. The reaction was completed 
with a final extension step for 5 min. For a list of primers, see Table 15. The PCR products were 
analysed on an agarose gel (1% w/v agarose in 1x Tris-acetic acid-EDTA (TAE; 40 mM, 20 mmM 
and 1 mM, respectively) buffer, at 100 V for 30 min. For RT-PCR products, 1.2% w/v agarose was 




2.7.2. Preparation of recombinant plasmids 
2.7.2.1. Plasmid preparation 
Plasmids were extracted from 1.5 ml of overnight E. coli cultures, using the Monarch® Plasmid 
Miniprep Kit (New England Biolabs, UK), following the manufacturer’s instructions.  
2.7.2.2. Cloning 
Restriction digests of the purified plasmids were performed using High Fidelity® (HF) restriction 
enzymes (New England Biolabs, UK) for 15 min at 25-37oC, depending on the enzyme used. 
Typically, a reaction contained a maximum of 1 μg DNA, 2 μl CutSmart® reaction buffer, and 0.5 
μl of the required restriction enzyme in a final volume of 20 μl. The reaction products were 
analysed by agarose electrophoresis, and digested DNA was purified using the Monarch® PCR 
and DNA Cleanup Kit (New England Biolabs, UK). The digested vectors were mixed in 1:1 ratio 
with the desired insert before addition of the In-fusion buffer and enzyme (Clonetech 
laboratories, USA), as instructed by the manufacturer. The reaction was incubated at 50oC for 
15 min and then quenched on ice. The reaction was used to transform E. coli DH5α cells, as 
described in section 2.5. After plating and growth at 37 oC for 16 h, three colonies were picked 
and grown in LB medium with the appropriate antibiotic for 6 h.  Plasmids were prepared from 
the three cultures and digested with appropriate enzymes to confirm insertion. The reaction 
products were analysed by agarose electrophoresis, as described above. Positive clones were 
sequenced to confirm correct orientation and fidelity. The plasmids were then used to transform 
E. coli BL21 (DE3), as described in section 2.5. 
Table 13 Plasmids used in this study 
Plasmid Selection marker Restriction enzymes used 
for cloning and plasmid 
analysis 
Reference 
pRSFDuet-1 Kan  Dr. Susan 
Schlimpert (John 
Innes Centre, UK) 
pRSFDuet-1_gtf1 
(first position) 
Kan PstI/HindIII This study 
pRSFDuet-1_gtf1/2 
(second position) 




pOPIN-F Amp/Cb   
pOPIN-F_gtf1 Amp/Cb HindIII/KpnI This study 
pOPIN-F_gtf2 Amp/Cb HindIII/KpnI This study 
pOPIN-F_gtfA Amp/Cb HindIII/KpnI This study 
pOPIN-F_gtfB Amp/Cb HindIII/KpnI This study 
pOPIN-F_gtfC Amp/Cb HindIII/KpnI This study 
pET28b_GH89 (α-
GlcNAcase) 
Kan  Dr. Lucy Crouch and 




2.7.3. DNA extraction from L. reuteri 
Genomic DNA (gDNA) was extracted from L. reuteri grown in MRS for 18 h, using the GeneJET 
Genomic Purification Kit (ThermoFischer Scientific, UK), following the manufacturer’s 
instructions for preparation of DNA from Gram-positive bacteria, with minor modifications, 
including the addition of 10 U/ml mutanolysin in the lysis buffer and extension of the incubation 
period to 1 h. DNA preparations were stored at -20oC until needed. 
2.7.4. RNA extraction from L. reuteri 
L. reuteri 100-23 and ATCC 53608 cultures in MRS were used to inoculate fresh MRS and LDM-
II, respectively, at 1 % vol/vol. The cultures were incubated under static conditions at 37oC for 
24 h. An aliquot (1.5 ml) was collected from each culture after 7 h incubation, when the OD600 
reached 1.2. the cells were centrifuged at 5000 g for 10 min and after removal of the spent 
media (SM), the cell pellets were treated with RNAprotect, (Qiagen, USA), following the 
manufacturer’s instructions. The treated cells were centrifuged at 5000 g for 5 min and the 
supernatant was removed. The cell pellet was stored at -20oC overnight. A second aliquot was 
collected after 24 h of growth, and treated in the same way. RNA was extracted from the cell 
pellets using the RNeasy Mini Kit (Qiagen, USA). The cells were resuspended in lysis buffer (100 
μl, Tris-HCl 30 mM, EDTA 1 mM, pH 8), containing 10 μl Qiagen Proteinase K, 20 mg/ml lysozyme 
and 5 U/ml mutanolysin) and the lysis reaction was incubated on an Eppendorf thermomixer C 
at 25oC, 1000 rpm for 1 h. RLT buffer (700 μl) was added to the samples. These were transferred 




cells were mechanically disrupted 3 times for 1 min at 6.5 m/s on a FastPrep®-24 Classic 
homogeniser (MP Biomedicals, USA). Cells were kept on ice for 2 min in-between runs. The 
samples were centrifuged at 17000 g for 10 s. Ethanol (80%, 590 μl) was added to the 
supernatant, the lysate was loaded onto an RNeasy Mini spin column and centrifuged for 15 s 
at 17000 g. The column was washed with 350 μl RW1 buffer. On column DNA digestion was 
carried out, using Qiagen DNase I, following the manufacturer’s instructions. The column was 
then washed with 500 μl RPE buffer and RNA was eluted twice with 50 μl RNase-free H2O. The 
concentration was measured on a NanoDrop 2000 (ThermoFisher Scientific, UK) and the 
recovered RNA was further treated with TURBO™ DNase (ThermoFisher Scientific, UK), following 
the manufacturer’s instructions. The RNA samples were stored at -20oC until needed. 
2.7.5. RT-PCR analysis 
RNA purified from L. reuteri 100-23 and ATCC 53608 was treated with TURBO DNase 
(ThermoFischer Scientific, UK), following the manufacturer’s instructions. cDNA was synthesised 
from the recovered RNA, using the Quantitect Reverse Transcription kit (Qiagen, USA), following 
the manufacturer’s instructions. Briefly, 12 μl of RNA was treated with 2 μl gDNA wipeout at 
50oC for 15 min, before addition of the reverse transcription buffer, the primers and the reverse 
transcriptase. Initially, the random hexamers provided with the Reverse Transcription kit was 
used as primers. When the RT-PCR did not yield any products, gene specific reverse primers 




Table 14 Primers used for RT-PCR. 
Primer name Sequence (5’-3’) DNA template Intergenic region targeted 
10023gtfc-f-op ACTTTGCACGCTTGATCC 
L. reuteri 100-23 
2500070887-2500070888 (gtfC-secY2) 
10023secy2-r-op GCACAGGAACGGTACAACC 
10023secy2-f-op TGATTGTAATGTTTATGCAGG 2500070888-2500070889 (secY2-asp1) 
10023asp1-r-op AGTTAATTGGTTTAATTTAGTGG 
10023asp1-f-op CATTAATCAAGGATTAGATTATTTCC 2500070889-2500070890 (asp1-asp2) 
10023asp2-r-op ATCCGCTAATTTGGTCC 
10023asp2-f-op GAAAGCTAATAAGGCAATCC 2500070890-2500070891 (asp2-asp3) 
10023asp3-r-op GAGTTATGAAACTCAACACTAGC 
10023asp3-f-op CCATTACTGCCAGCTACTACTTGG 2500070891-2500070892 (asp3-SecA2) 
10023secA2-r-op GCCGCAAATGCCCGTGG 
10023secA2-f-op ATAATTTGATGCTGAGTACC 2500070892-2500070893 (secA2-gtfA) 
10023gtfA-r-op AAGTCAGCGATATTATTTCC 
10023gtfA-f-op TGCTGACTTGACTAAATTCC 2500070893-2500070894 (gtfA-gtfB) 
10023gtfB-r-op AAAATTTAATGGGAGATTCC 
10023gtfB-f-op TAGCTAGTGAAGTTAGTGTCC 2500070894-2500070895 (gtfB-gtfBC-term) 
70895-r-op TGAGCGAAAACTTACAGG 
70895-f-op TGCTCTTGATTTTGATATTGG 2500070895-2500070896 (gtfBC-term- gtfD) 
70896-r-op TATCGTAATTTGCGCATAGG 
70896-f-op ATTGGTAAGAATAAGCATACG 2500070896-2500070897 (gtfD-gtfE) 
70897-r-op CGTAGATTTTGACATCACG 
70897-f-op TGGCGAATAAGCATACC 2500070897-2500070898 (gtfE-gtfFN-term) 
70898-r-op AACGATTAATATTCACAAACC 





70899-f-op GCCCTTGCTTGTTGTAGAGAC 2500070899-2500070900 (tnase- gtfFC-term) 
70900-r-op TTTGCTAAAATTTGTTGATTATGAC 
70900-f-op GGTATGCTTATTCTTTAACTT 2500070900-2500070901 (gtfFC-term-RTase) 
70901-r-op TTTACCTTCACCATAATCG 
70901-f-op CTTATGAATATGTCCAAGACG 2500070901-2500070902 (RTase-srr) 
70902-r-op AAAAGAGTTTGAAGAAGCG 
70902_int-F CCAGTGCATCTACCAGTACCTCG 2500070902 (srr, internal region) 
70902_int_R GAGGCTAGGGCAGCATTCG 
SRR-ts-F TTTCGATGAGTGAAAGTCTCAGC 
L. reuteri ATCC 53608 
 LRATCC53608_0906 (srr, internal region) 
SRR-ts-R TTGGTAGTCTTAAGACCATTCCC 
srr-F-op TGGTAATGAAAAGCATTCAACGG LRATCC53608_0906 - LRATCC53608_0907 (srr – gtfC) 
 nss-R-op GGCAATTTGATTTTGAGCAATT 
op_nss_f AATGAAATGGTCCAACGAG LRATCC53608_0907 - LRATCC53608_0908 (gtfC-secY2) 
 op_secY2_r TGTCGAAATGTTAACTAATGGC 
op_secY2_f GATTGTAATGTTTATGCAGGG LRATCC53608_0908 - LRATCC53608_0909 (secY2-asp1) 
 op_asp1_r TTGCGTTGGTGAGATCG 
op_asp1_f GCAAATTTCTGATATCAATAAGGG LRATCC53608_0909 - LRATCC53608_0910 (asp1-asp2) 
 op_asp2_r CTGGACGCCTTCTGTAATTATC 
op_asp2_f CTATTTGTTAGTAAAGGATTTCC LRATCC53608_0910 - LRATCC53608_0911 (asp2-asp3) 
 op_asp3_r GGACCAATTTAGTTGCC 
op_asp3_f CTTTCCACCATCAATGCAG LRATCC53608_0911 - LRATCC53608_0912 (asp3-SecA2) 
 op_secA2_r CGTGGTAAGATATCATCAACTG 
op_secA2_f AAACTATCAGTTATCGTTCAGC LRATCC53608_0912 - LRATCC53608_0913 (secA2-gtfA) 
 op_gtfA_r AATCTGATCAGCATTAAAACC 
op_gtfA_f ACTGAAGATTGGAGTAATTCAC LRATCC53608_0913 - LRATCC53608_0914 (gtfA-gtfB) 





Table 15 Primers used for gene expression. The underlined sequences indicate the overlapping region of the insert and the plasmid. 
Primer 
name 
Sequence (5’-3’) DNA template Region targeted Vector used 
0089-F AAGTTCTGTTTCAGGGCCCGATGCTTTTTTTCCTAAACGATAATA 
















EcoRI -Gtf1-F GCCAGGATCCGAATTCGATGCTTTTTTTCCTAAACGATAATA 
gtf1 
pRSFDuet-1 




























2.8. Protein purification  
2.8.1. Spent media (SM) Protein preparation from L. reuteri 
L. reuteri strains were grown from glycerol stocks in MRS, overnight at 37oC under static 
conditions. This culture was used to inoculate fresh MRS or LDM-II (289), supplemented with 2% 
sucrose, unless otherwise stated, at 0.2 % vol/vol. The fresh cultures were incubated under static 
conditions at 37oC overnight. Cells were centrifuged at 4000 g for 5 min. The SM fraction was 
concentrated 10-fold by spin filtration using Vivaspin protein concentrator 10 kDa MWCO 
(Sartorius, UK) and proteins were extracted by addition of 1.33 vol of chloroform and 2.67 vol 
of methanol. The supernatant was removed after centrifugation at 17,000 g for 10 min and 
proteins were resuspended in H2O and stored at -20 oC. 
2.8.2. Purification of MUB53608 and SRRP53608 from L. reuteri ATCC 53608 
Glycerol stock of L. reuteri ATCC 53608 was used to inoculate MRS medium. The culture was 
incubated under static conditions overnight and was used to inoculate 1 L of LDM-II at 1% 
vol/vol. The fresh culture was grown under anaerobic and static conditions at 37oC for 24 h. The 
cells were removed by centrifugation at 10000 g, 4oC and SM proteins were precipitated upon 
addition of ammonium sulfate, at a final concentration of 60%. The precipitate was dissolved in 
H2O and the proteins were extracted in a step-wise manner, using a triple phase partitioning 
(TTP) system. Ammonium sulphate was again added to the sample to a final concentration of 
20% and one volume of tert-butanol was added to the sample. After thorough mixing by 
vortexing, the sample was centrifuged at 5000 g for 10 min. The upper phase was removed, the 
protein pellet in the interphase was recovered and dissolved in H2O and CHAPS (3-[(3-
cholamidopropyl) dimethylammonio]1-propanesulfonate) was added to the sample at 0.5% w/v 
final concentration. MUB53608 was purified from this fraction by gel permeation chromatography 
(GPC), using a Superose 6 10/30 GPC column (GE Healthcare, UK). PBS supplemented with 0.5% 
CHAPS was used as the elution buffer, at a flow rate of 0.4 ml/min. The collected fractions were 




and dialysed in a 100 kDa MWCO dialysis membrane against 50 mM ammonium bicarbonate for 
48 h, with 4 changes of buffer. The dialysed sample was loaded onto an agarose-bound wheat 
germ agglutinin (aWGA) affinity column (Vector labs, UK), which was pre-conditioned with 10 
vol of lectin washing buffer [10 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 
pH 7.5, 150 mM NaCl]. The column was washed with 5 vol of lectin washing buffer. The flow-
through and wash fractions containing MUB53608 were concentrated by spin-filtration using a 100 
kDa MWCO Vivaspin 2 spin filter. Bound SRRP53608 was eluted with 3 vol of wash buffer, 
supplemented with 0.5 M GlcNAc. The eluant and the concentrated wash fraction were dialysed 
using a 100 kDa MWCO dialysis membrane against 50 mM ammonium bicarbonate for 48 h, with 
four changes of buffer, and stored at 4oC. 
For purification of truncated MUB1063N (tMUB1063N), a similar workflow was followed, with the 
following modifications. L. reuteri 1063N was grown in MRS.  After GPC, the fractions containing 
tMUB1063 were pooled and were not further purified by affinity chromatography.  
2.8.3. Purification of SRRP100-23 from L. reuteri 100-23 
An overnignt culture of L. reuteri 100-23 in MRS was used to inoculate 1 L of LDM-II, 
supplemented with 2% maltose. The culture was incubated under static conditions overnight at 
37oC and then the cells were removed by centrifugation at 10000 g for 10 min. SRRP100-23 was 
purified from the supernatant by an aWGA affinity chromatography column, as described for 
SRRP53608 (section 2.8.2). The eluted protein was dialysed extensively in ammonium bicarbonate, 
to remove the excess of GlcNAc and then stored at -20oC.  
2.8.4. IMAC purification of recombinant proteins 
After induction of the expression (see section 2.6), cells were pelleted by centrifugation at 5000 
g and washed twice with Tris buffer (50 mM Tris, 150 mM NaCl, pH 7.5). Cells were either lysed 
using the BugBuster® reagent (EMD Millipore), following the manufacturer’s instructions, or 




break on ice), using a Soniprep 150 (MSE, UK). The cell debris and insoluble material were 
removed by centrifugation at 12000 g for 15 min and the soluble and insoluble fractions were 
analysed by SDS-PAGE. Where the target protein was found in the soluble fraction, this was 
loaded onto a His-bind® resin (Bio-Rad, UK) column, charged with Ni2+, following the 
manufacturer’s instructions. The unbound material was washed with 10 column vol of Tris buffer 
supplemented with 10 mM imidazole. The bound protein was eluted with 6 column vol of Tris 
buffer supplemented with either 250 mM imidazole or 100 mM EDTA. The eluted protein was 
concentrated by spin filtration, using a 10 kDa MWCO Vivaspin® Turbo 15 spin filter (Sartorious, 
UK) and buffer exchanged into Tris buffer using a PD-10 desalting columns (GE Healthcare 
Lifesciences, UK), following the manufacturer’s instructions. 
2.9. Protein analysis 
2.9.1. SDS-PAGE 
Typically, 6.5 μl of protein was mixed with 2.5 μl lithium dodecyl sulphate (LDS) buffer 4x 
(ThermoFischer Scientific, UK), and 1 μl dithiothreitol (DTT; 100 mM).  The samples were heated 
at 70oC for 7 min and were then loaded onto 4-12% Bis-Tris NuPAGE polyacrylamide gel 
(ThermoFischer Scientific, UK). The electrophoresis was typically performed at 200 V for 50 min. 
The gel was then washed in H2O before staining with InstantBlue (Expedeon, UK), for 30 min, 
before being washed with H2O.  Alternatively, the gel was used for western blotting. 
2.9.2. Western blot analysis 
Proteins from SDS-NuPAGE gels were blotted onto an Amersham™ Hybond® P Western blotting 
PVDF membrane (GE Healthcare Lifesciences, UK), using the XCell II Blot module (ThermoFischer 
Scientific, UK), following the manufacturer’s instructions for assembly and run with the following 
modifications: no methanol was used in the transfer buffer and transferring was performed for 
2 h for large proteins (> 300 kDa). The membrane was blocked with Pierce protein-free PBS 
blocking buffer (ThermoFisher Scientific, UK) for 1 h and then immersed in 10 ml PBS blocking 




The probed membrane was then washed three times with PBS, supplemented with 0.1% 
Tween®20 (PBST) and then probed with the appropriate secondary antibody (Table 7), before 
being washed again three times with PBST. When horseradish peroxidase (HRP)-conjugated 
antibody was used, the blots were visualised by the addition of the chromogenic 1-step 3,3',5,5'-
Tetramethylbenzidine (TMB) blotting substrate solution (ThermoFisher Scientific, UK), until 
bands appeared. The blot was then washed extensively with H2O. When alkaline phosphatase 
(AP)-conjugated antibody was used, the membrane was first washed once with 10 ml Tris-HCl 
0.1 M, pH 9.6, before 10 ml of the visualisation solution (40 μM MgCl2, 0.1 mM nitroblue 
tetrazolium, 0.1 mM 5-bromo-4-chloro-3indolyl-phosphate toluidine) was added until bands 
appeared. The blots were then washed extensively with H2O. After colour development, the 
blots were air-dried and then scanned on a GS-800 calibrated densitometer (Bio-Rad, UK). 
Alternatively, PBS blocking buffer supplemented with 5 μg/ml of an appropriate fluorescein 
isothiocyanate FITC- labelled lectin (f-lectin; Table 8) was used instead of primary antibodies for 
1 h. The membrane was then washed with PBST three times and scanned using a Pharos-FXTM 
Plus molecular imager (Bio-Rad, UK), using excitation and emission wavelengths of 495 and 520 
nm, respectively.  
2.9.3. Slot blot 
Slot blots were performed using a Hoefer™ PR648 blotting manifold (ThermoFischer Scientific, 
UK). The protein sample was loaded onto a prewet Amersham™ Hybond® P Western blotting 
PVDF membrane (GE Healthcare Lifesciences, UK), followed by two washes with PBS. The 
membrane was blocked and probed with f-lectins or antibodies, as described in section 2.9.2. 
2.9.4. Trypsin digestion and mass spectrometry 
Protein bands of interest were excised from SDS-NuPAGE gels and cut up to small cubic pieces. 
The gel plugs were washed twice with 200 μl of ABC buffer (200 mM aqueous ammonium 




of ACN was removed and the gel plugs were air-dried for 15 min. A DTT solution (200 μl, 10 mM 
in 50 mM ammonium bicarbonate) was added and the samples were incubated at 60oC for 30 
min. Then, the DTT solution was removed and, upon addition of 200 μl iodoacetamide solution 
(10 mM in 50 mM ammonium bicarbonate), the plugs were incubated at room temperature in 
the dark for 30 min. The iodoacetamide solution was removed and the washing steps were 
repeated. Trypsin Gold (10 μl; 10 ng/μl; Promega, UK) was added to the gel plugs along with 
equal amount of 10 mM ammonium bicarbonate. After incubation at 37oC for 3 h, 20 μl of 1% 
formic acid was added and the samples were further incubated at room temperature for 10 min. 
The solution was then transferred to a clean tube and tryptic peptides were further extracted 
from the gel plugs by addition of 40 μl of 50% ACN and incubation for 10 min at room 
temperature. The two samples were pooled together and dried on a Vacufuge® Plus vacuum 
concentrator (Eppendorf, UK). The peptide mixtures were analysed by nLC MS/MS, using and 
Orbitrap Fusion trihybrid mass spectrometer coupled with a nano flow UHPLC system 
(ThermoFischer Scientific, UK). The peptides were separated, after trapped on a C18 pre-column, 
using a gradient of 3-40% ACN in 0.1% formic acid (vol/vol), over 50 min at a flow rate of 300 
nL/min, at 40°C. The peptides were fragmented in the linear ion trap by a data-dependent 
acquisition method, selecting the 40 most intense ions. Mascot (Matrix Science, UK) was used 
to analyse the raw data against an in-house maintained database of the L. reuteri proteome. The 
tolerance on parent ions was 10 ppm and on fragments was 0.5 Da. Carboxymethylation of 
cysteine was selected as fixed modification and oxidation of methionine as variable 
modification. One miscleavage was allowed. 
2.9.5. Endoproteinase C digest 
Endopeptidase C (GluC; 5 μg) was added to 5 μl purified protein (MUB53608 or SRRP53608; 5 μl) in 
50 mM Tris-HCl, pH 8, containing 0.5 mM glutamate-glutamate. The reaction was incubated at 
37oC for 16 h and quenched by the addition of LDS loading buffer. The reaction products were 




2.9.6. Differential scanning fluorimetry (DSF) 
DSF was used to assess glycosyltransferase – sugar donor interactions by measuring changes in 
the melting temperature (Tm) of the protein, upon interaction with the sugar nucleotides. The 
reactions were set up at a final volume of 20 μl in Tris-HCl 50 mM, pH 7.5. Proteins were used at 
a final concentration of 10 μM and SYPRO Orange (ThermoFischer Scientific, UK), the fluorescent 
dye used in the assay was used at 5x final concentration. Ligand and ion concentration ranged 
from 0-50 mM. The reactions were initially kept at 10oC for 10 min and then the temperature 
increased in a step-wise manner, with increments of 0.5oC every 15 s, up to 90oC. Measurements 
of the fluorescence were taken every 15 s on a Bio-Rad CFX96 Touch™ Real-Time PCR Detection 
System. The results were analysed using CFX Manager 3.5 (Bio-Rad, UK). 
2.10. Enzymatic assays 
2.10.1. N-acetyl-glucosaminidase assay 
Purified SRRP100-23 or SRRP53608 (3 μl) was mixed with 2 μl reaction buffer (sodium acetate 200 
mM, NaCl 100 mM, pH 5), 5 μl α-GlcNAcase (cloned and expressed in-house) at a final 
concentration of 0.17 U/μl and/or 1 μl of β-N-acetyl-hexosaminidasef (0.5 U/μl; New England 
Biolabs, UK). The reaction was incubated at 25oC, 37oC, or 42oC for 24 h. The reaction was 
quenched by addition of 3.5 μl LDS loading buffer supplemented with DTT and the samples were 
analysed by western blot, using f-WGA and anti-SRRP53608 antibodies (see section 2.9.2, and 
Table 7).  
2.10.2. Sialidase assay 
Protein sample (5 μl) was mixed with 0.6 μl of GlycoBuffer 1 (New England Biolabs) and 0.4 μl 
neuraminidase A (~1.5 U/μl final concentration). The reaction was incubated at 37oC for 16 h, 
quenched by the addition of 2.5 μl LDS buffer and 1 μl DTT 100 mM and analysed by western 




2.10.3. MUB53608 enzymatic deglycosylation assay 
Purified MUB53608 (125 μl) was mixed with 100 μl reaction buffer (sodium acetate 200 mM, NaCl 
100 mM, pH 4.4) and 0.3 μl α-galactosidase and/or β-galactosidase at 1 mU/ml final 
concentration. The reaction was incubated at 25oC for 16 h and the products were analysed by 
western blot using f-RCA and anti-MUB53608 antibodies. 
2.11. Glycan analysis 
2.11.1. Monosaccharide composition analysis 
2.11.1.1. Methanolysis of glycoproteins and trimethyl-silylation of monosaccharides 
SM proteins (~100 μg;) were precipitated as described in section 2.8.1 and resuspended in H2O. 
Myo-inositol (2.5 μg) was added to the suspension, which was then lyophilised. The dried sample 
was resuspended in 0.5 ml methanolic HCl 1N and incubated at 80oC for 16 h. The methanolysed 
sample was cooled down to 25oC and silver carbonate (~50 mg) was added, followed by 100 μl 
addition of acetic anhydride. The N-acetylation reaction was incubated at room temperature for 
24 h. The sample was centrifuged at 3000 g for 5 min and the supernatant was transferred into 
a clean vial and dried under a gentle stream of nitrogen. Tri-Sil HTP reagent (200 μl; 
ThermoFischer Scientific, UK) was added to the sample and the derivatisation reaction was 
incubated at 80oC for 30 min. The sample was dried again under nitrogen, resuspended in 1 ml 
hexane and sonicated for 15 min. After centrifugation at 3000 g for 5 min, the supernatant was 
transferred into a clean vial and dried under nitrogen. The dried sample was dissolved into 100 
μl dichloromethane and transferred to a GC-compatible vial.  
2.11.1.2. GC-MS chromatography 
The samples were analysed on an Agilent 7890B GC-MS system paired with an Agilent 5977A 
mass spectrometry detector (Agilent, UK), using an BPX70 column (SGE Analytical Science, 
Australia). Helium was used as the carrier gas. The inlet was maintained at 220oC, 12.9 psi, and 




increased initially from 100oC to 120oC over 5 min, followed by a second increase from 120oC to 
230oC over 40 min.  
2.11.2. Sialic acid release, labelling and HPLC-based analysis 
Protein sample (100 μl) was mixed with 100 μl acetic acid (4 M) and incubated at 80oC for 2.5 h. 
The reaction mixture was dried using a centrifugal evaporator and the sample was dissolved in 
100 μl DMB labelling reagent (14 mM 1,2-diamino-4,5-methylenedioxybenzene, 3 mM acetic 
acid, 1.5 mM β-mercaptoethanol, 36 mM sodium hydrosulphite). An aliquot of the Glyko® sialic 
acid reference panel (Prozyme, USA) was used as a positive control. The reaction was incubated 
for 3 h at 55oC and the mixture was transferred in an HPLC vial. The products were analysed on 
a Luna® 5μm C18(2) 100 A column (250x4,6 mm; Phenomenex, UK), using a Shimadzu 
Prominence HPLC system (Shimadzu, UK). The solvents used were H2O (A), ACN (B) and 50% 
methanol (C). Sialic acids were separated on a gradient from 82:4:14 A/B/C to 75:11:14 over 40 
min, followed by a wash step with 30:70:0 A/B/C for 10 min and an equilibration step with the 
starting solvent for 10 min. 
2.11.3. Glycan release, permethylation and mass spectrometry analysis 
For MS analysis of protein glycosylation, purified protein (~100 μg) in ammonium bicarbonate 
was freeze-dried and dissolved in 200 μl 50 mM NaOH, containing 1 M NaBH4. The β-elimination 
reaction was incubated at 45oC for 16 h and quenched by addition of acetic acid, until 
effervescence stopped. The sample was desalted in a DOWEX 50WX8 column (H+ form, 100-200 
mesh) and glycans were eluted with 3 ml acetic acid 5% (vol/vol). The recovered sample was 
then freeze-dried and reconstituted in H2O containing 0.1% trifluoroacetic acid (TFA; vol/vol). 
The sample was further desalted using a graphitized carbon NuTip (Glygen, USA), prewashed 
with 80% ACN containing 0.1% TFA, and 0.1% TFA. Hydrophilic contaminants were washed with 
sequential washes with 0.1% TFA and 0.1% TFA in 10% ACN. Glycans were eluted with 0.1% TFA 
in 25%, 50% and 80% ACN. The elution fractions were pooled and dried on a Vacufuge® Plus 




(DMSO), followed by the addition of ~20 mg NaOH and 400 μL iodomethane. The 
permethylation reaction was incubated at room temperature for 60 min under vigorous shaking 
and quenched by the addition of 1 ml of 5% (vol/vol) acetic acid. The permethylated glycans 
were purified using a Hydrophilic-Lipophilic Balanced (HLB) copolymer Oasis cartridge (Waters, 
UK), prewet with 4 ml of methanol and equilibrated with 5% (vol/vol) methanol in H2O. Salts and 
other hydrophilic contaminants were washed with 5 ml of 5% methanol and permethylated 
glycans eluted with 3 ml of 100% methanol. The samples were dried under a gentle stream of 
nitrogen, dissolved in 10 μl of TA30 [30% (vol/vol) ACN, 0.1% (vol/vol) trifluoroacetic acid] and 
mixed with equal amount of 2,5-dihydroxybenzoic acid (DHB; Sigma-Aldrich, UK; 20 mg/ml in 
TA30), before being spotted onto an MTP 384 polished steel target plate (Bruker, UK). The 
samples were analysed by MALDI-ToF, using the Bruker Autoflex™ analyzer mass spectrometer 
(Bruker, UK) in the positive-ion and reflectron mode. 
2.11.4. Force spectroscopy 
The interactions between MUB53608 and h-Int1 or RCA were examined by covalently attaching 
lectin molecules to atomic force microscopy (AFM) tips and MUB53608 to the glass slides to enable 
binding interactions to be measured in a specific manner (290). Silicon nitride AFM tips (PNP-TR, 
Nanoworld AG, Switzerland) and freshly cleaned glass slides were functionalized using a four-
step procedure (carried out at 21 oC): the first step involved incubation in a 2% solution of 3-
mercaptopropyltrimethoxy silane (MTS, Sigma–Aldrich, UK) in toluene (dried over a 4Å 
molecular sieve) for 2 h, followed by washing with toluene and then chloroform. In the second 
step, the silanised tips were incubated for 1 h in a 1 mg/ml solution of a heterobifunctional 
linker: MAL-PEG-SCM, 2 kD (Creative PEGWorks, USA) in chloroform. The silanised glass slides 
were incubated in 5 mM N g -maleimidobutyryl-oxysuccinimide ester (GMBS) in ethanol 
(ThermoFisher Scientific, USA). The tips and slides were rinsed with chloroform/ethanol, 
respectively, and then dried with argon. The third step involved covalent attachment of the 




1 h at 21 oC, followed by a PBS washing step. The fourth step involved incubation of the 
functionalized cantilevers/slides in a 10 mg/ml solution of glycine in PBS to ‘amine’-cap any 
unreacted succinimide groups, followed by washing in PBS. Binding measurements were carried 
out in PBS using a MFP3D BIO AFM (Asylum Research Inc., USA). The experimental data were 
captured in ‘force-volume’ (FV) mode at a rate of 2 mm/s in the Z direction and at a scan rate of 
1 Hz and a maximum load force of 150-300 pN (pixel density of 32x32). Adhesion in the force 
spectra was quantified using a bespoke Excel macro (291) which fits a straight line to the baseline 
of the retract portion of the force-distance data. In order to explore the specificity of the binding 
interactions, the force measurements were repeated after addition of 100 mM galactose (for 









glycosylation in  






L. reuteri is a common gut commensal bacterial species that colonises the gastrointestinal (GI) 
tract of a wide variety of vertebrate hosts, including humans, rodents, birds, and livestock 
(103,292). L. reuteri 100-23 (Lr100-23) is a rat isolate that naturally colonises the stratified 
squamous epithelium of the forestomach (103), whereas L. reuteri ATCC 53608 (LrATCC 53608) 
is a pig isolate that colonises the porcine small intestine mucosa (292). L. reuteri MM4-1a 
(LrMM4-1a) was isolated from human breast milk (www.biogaia.com). The localisation of L. 
reuteri in the GI tract suggests that it preferentially feeds on simple sugars that are available 
from the diet of the host, rather than dietary polysaccharides which are normally fermented by 
the microbiota in the large intestine (60). As L. reuteri strains are often used for their probiotic 
properties, research is focused on understanding the colonisation process of these bacteria in 
the GI tract. A key step in bacterial colonisation is adhesion of the bacteria to the mucus or the 
epithelium via specific surface adhesins. It is often reported that surface adhesins are 
glycosylated, but information on protein glycosylation in beneficial microbes and, in particular, 
in L. reuteri is lacking. 
The building blocks of the glycans found on glycoproteins are sugar nucleotides. These are 
monosaccharides conjugated onto a nucleotide, most often uridine diphosphate (UDP). The 
synthesis of sugar nucleotides requires the phosphorylation of a monosaccharide, its 
subsequent conjugation with the nucleotide and further modifications of the sugar moiety that 
lead to diversification of the nature of the sugar. Key enzymes in this process are kinases that 
phosphorylate monosaccharides, thus enabling their subsequent activation by nucleotides 
(243). Alternatively, in bacteria, carbohydrates can be phosphorylated by specialised, sugar 
specific systems like the phosphoenolpyruvate: sugar phosphotransferase system” (PTS) 
(293,294). The PTS system consists of three enzymes in most cases: Enzymes I and II (EI and EII) 




and are responsible for the phosphorylation of the sugars. In contrast, Enzyme II is comprised of 
three, or, rarely, four subunits, and forms a sugar-specific permease (Figure 13) (294). 
 
Figure 13 Phosphorylation of monosaccharides by cytosolic kinases or the phosphotransferase system (PTS) and 
subsequent activation with nucleotides. Adapted from (295). 
The enzymes that mediate the synthesis of the protein glycan are called glycosyltransferases 
(GTs). GTs belong to a large group of carbohydrate active enzymes (CAZymes). CAZymes are 
divided into subgroups, based on their activity [e.g. GTs, glycoside hydrolases, (GH)]. Each 
subgroup is further divided into families, based on the amino acid sequence of the enzymes 
(296). Members of each family share significant similarities, which can often provide useful 
insights regarding the activity, mechanism, as well as sugar specificity of CAZymes. GTs are 
divided into two large categories, based on the sugar donor: GTs that utilise sugar nucleotides 
are called Leloir-GTs, whereas GTs that utilise other donors, such as lipid-linked oligosaccharides 
(e.g. PglB involved in N-glycosylation) are called non-Leloir GTs. Further information on each 
family of GTs can be found in the CAZy database (www.cazy.org). In addition, based on the 
mechanism they employ for glycosylation, they are divided into inverting and retaining GTs. 
Retaining GTs transfer the glycan onto the acceptor with the same conformation it had on the 




glycosylation.  For example, a retaining GT that uses a α-linked sugar nucleotide donor, will 
generate a glycoconjugate with an α-linked glycan (Figure 14). 
 
Figure 14 Schematic representation of the retaining glycosylation mechanism. Adapted from (230). 
In bacteria, genes encoding for GTs are often grouped together in clusters encoding proteins 
involved in the biosynthesis of glycans. These include examples for protein glycosylation or 
exopolysaccharide (EPS) biosynthesis. However, it is often the case that GTs do not act on a 
single biosynthesis pathway, and can be involved in the formation of different glycoconjugates. 
3.2. Results 
3.2.1. In silico analysis of L. reuteri carbohydrate metabolism 
In silico analysis of Lr100-23, LrATCC 53608 and LrMM4-1a genomes was carried out, in order to 
identify potential enzymes involved in sugar nucleotide biosynthesis and GTs involved in protein 
glycosylation. 
The annotated genomes were first analysed in order to identify sugar kinases or sugar-specific 
PTS components. The analysis revealed the presence of predicted kinases for simple 
monosaccharides such as glucose (Glc; EC 2.7.1.2), galactose (Gal; EC 2.7.1.6) and fructose (Fru; 
EC 2.7.1.4) (Figure 15). Lr100-23 and LrATCC 53608, but not LrMM4-1a, also harbour genes 
encoding a xylose (Xyl) isomerase (EC 5.3.1.5) and a xylulose kinase (EC 2.7.1.17), suggesting that 
these strains can also utilise this pentose (297), which may reflect an adaptation of the strains 




acetyl-hexosamines (HexNAcs) were found. Components of Glc-, lactose (Lac)- and galactitol-
specific PTS systems were identified in all three strains. While all three strains harbour genes 
encoding proteins involved in the utilisation of Glc and Lac, no genes involved in galactitol 
metabolism were identified. As galactitol can be converted to Gal by the reverse action of an 
aldehyde reductase, the Lr100-23 genome was also inspected for genes encoding proteins with 
similarity to known aldehyde reductases. The closest candidate was found to be a gene (gene 
ID: 2500069715) encoding a predicted aldo/keto reductase related to diketogulonate reductase, 
that shared ~45% identity (E-value < 1.0-100), with an aldehyde reductase (EC 1.1.1.21) from the 
β-proteobacterium Cupriavidus nantongensis. This gene was also present in LrATCC 53608 and 
LrMM4-1a and it is possible that its product may be involved in galactitol metabolism. 
The lack of genes encoding HexNAc-specific kinases or N-acetyl-glucosamine (GlcNAc)-specific 
PTS was further confirmed by performing a BLAST search with the amino acid sequences of 
known GlcNAc kinases and GlcNAc-specific PTS, against the predicted proteome of Lr100-23, 
LrATCC 53608 and LrMM4-1a. The in silico analysis of these three L. reuteri strains revealed 
genes encoding enzymes that are predicted to be involved in the synthesis of UDP-GlcNAc from 
Glc, as well as its modification and conversion into UDP-N-acetyl-muramic acid (MurNAc), which 
is used in cell wall synthesis, or UDP-N-acetyl-mannosamine (ManNAc), but not UDP-N-acetyl-
galactosamine (GalNAc), the monosaccharide found at the reducing end of mammalian O-
glycans (Figure 15). Despite the predicted ability of these strains to produce UDP-ManNAc, they 
all lack the downstream enzymes required for the biosynthesis of sialic acid (Neu5Ac) or N-
acetyl-mannosaminuronic acid, which raises questions about the role of UDP-ManNAc in the 
physiology of L. reuteri strains. Enzymes involved in the synthesis of guanidyl-mannose (GDP-
Man) from fructose were also identified. However, the analysis did not identify genes involved 
in the synthesis of GDP-fucose (Fuc), a monosaccharide often employed by microbes to 




Furthermore, all three strains carried a gene encoding a predicted galactopyranose mutase 
(Figure 15), an enzyme that can convert UDP-Gal to UDP-galactofuranose (UDP-Galf), which is 
often found in fungal cell walls and glycoproteins (298), as well as carbohydrate structures in 
important human parasites and bacterial pathogens (299–301). In addition, a gene involved in 
the conversion of UDP-arabinose (UDP-Ara) to UDP-arabinofuranose (UDP-Araf) was identified 
in the three genomes analysed, but no genes encoding enzymes involved in UDP-Ara synthesis 
could be found. While most sugar nucleotide biosynthetic pathways were common between the 
three L. reuteri strains, Lr100-23 was also found to carry genes encoding proteins necessary for 
the synthesis of thymidyl-rhamnose (TDP-Rha), while LrATCC 53608 and LrMM4-1a only 
harboured part of the biosynthetic gene cluster (Figure 15).  
In addition to the kinases, and the other enzymes involved in sugar nucleotide metabolism, the 
three L. reuteri strains carry genes that encode glycoside hydrolases, and specifically α-
glucosidases, α- and β-galactosidases and endo-galactanases (data not shown). Notably, no 
hydrolase specific for Neu5Ac or Fuc -monosaccharides naturally found in the host glycans of 
the small intestine- were identified in any of the three strains. Taken together, these 
observations suggest that Lr100-23, LrATCC 53608 and LrMM4-1a may rely on diet-derived, 
rather than host-derived, carbohydrates and can utilise free, short oligosaccharides, such as 
lactose, which is naturally found in excess in milk. In addition, the presence of genes involved in 
sugar nucleotide biosynthesis suggests that these strains can diversify the repertoire of 





Figure 15 A simplified map of the “Amino sugar and nucleotide sugar metabolism” KEGG pathway for L. reuteri. The 
Enzyme Commission (EC) numbers of the enzymes required in each pathway are noted in the boxes. Green boxes 
indicate enzymes predicted to be produced from the genomes of Lr100-23, LrATCC 53608 and LrMM4-1a, whereas 
the yellow box indicates the TDP-Rha biosynthetic pathway predicted to be expressed only in Lr100-23. Red boxes 
indicate enzymes that are not encoded in the three L. reuteri genomes. Underlined are the sugar nucleotides 
predicted to be expressed from these Lr100-23, LrATCC 53608 and LrMM4-1a strains. *EC 4.2.1.46 and 1.1.1.133 are 





3.2.2. In vitro analysis of L. reuteri growth on carbohydrates 
To complement the results from the bioinformatics analysis, and as there have been reports of 
GlcNAc utilisation, without the requirement of a functional GlcNAc kinase in E. coli (302), the 
growth of each L. reuteri strain was tested in the presence of lactose, sucrose (Suc), maltose, 
Xyl, 2-fucosyl-lactose (2’FL), 3-fucosyl-lactose (3’FL), 6-sialyl-lactose (6’SL), GlcNAc or GalNAc as 
sole carbon source. Overnight cultures in deMan-Rogosa-Sharpe (MRS) medium were used to 
inoculate Lactobacillus-defined-media-II (LDM-II) (154) supplemented with 2% (w/v) of the 
carbon source. The cultures were grown for 24 h and OD600 measurements were taken every 30 
min, for the disaccharide-containing growth media, or at 24 h for the HexNAc, Xyl or 
trisaccharide-containing media.  
All three strains grew in the disaccharide-containing media, however, the growth rate and the 
preference for a carbohydrate differed between strains (Figure 16). In particular, Lr100-23 grew 
best in the presence of maltose, in terms of the highest OD600 value, as well as the rate of growth, 
as it reached stationary phase after 6 h. In contrast, there was an extended lag phase when 
Lr100-23 was grown in lactose, reaching stationary phase after 13 h, and the growth was 
impaired in sucrose, showing an OD600 of 0.05 units at stationary phase, compared to 0.3 units 
when grown in maltose. This may suggest that Lr100-23 cannot metabolise Fru as efficiently as 
Glc. It is also possible that sucrose is hydrolysed by a fructosyltransferase (ftf, gene no. 
2500071010, EC 2.4.1.10), generating Glc, which becomes available to the bacteria for growth, 
and using fructose to synthesise levan (287), making it unavailable to use in metabolism. This is 
also supported by the significantly impaired growth of a Lr100-23 Δftf mutant in the presence of 
sucrose as a carbon source (data not shown). 
LrATCC53608 grew optimally in the sucrose-containing medium, reaching stationary phase 
(OD600 = 0.8) after 8.5 h. Its growth was mediocre in maltose, as it reached stationary phase 
(OD600 =0.6) after 11 h and significantly impaired in lactose, as it only reached an OD600 of 0.2 




growth in presence of sucrose, which raises questions about the different sucrose metabolism 
pathways employed by Lr100-23 and LrATCC 53608. LrMM4-1a showed comparable growth in 
all three disaccharides. However, growth in lactose was slower, as it reached stationary phase 
after 12 h, compared to 6 h in maltose and sucrose. LrMM4-1a does not have a gene encoding 





Figure 16 Growth rates of Lr100-23, LrATCC 53608 and LrMM4-1a when grown on different disaccharides. Growth 
rate and maximum OD600 is dependent on the disaccharide used for each strain. 
Notably, none of the strains grew when Xyl, GlcNAc, GalNAc, 2’FL, 3’FL or 6’SL were used as sole 












































reveal any HexNAc kinase or specific fucosidase or sialidase encoding genes. The inability of 
Lr100-23 and LrATCC 53608 to utilise Xyl contrasted with the presence of a predicted Xyl 
utilisation pathway in these two strains. However, these two strains were shown to grow in the 
presence of xylo-oligosaccharides or Xyl in MRS media (Dr. Ravindra Pal-Singh, The John Innes 
Centre, personal communication), although growth in Xyl was impaired, suggesting differences 
in the transport of Xyl and short xylo-oligosaccharides. In addition, as these strains did not grow 
in LDM-II when Xyl was used as sole carbon source, this suggests that there are additional 
components in MRS that promote growth of the bacteria on this substrate. 
 
Figure 17 Growth of L. reuteri strains in HexNAc as sole carbon source. None of the three strains was able to utilise 






















3.2.3. Bioinformatics analysis of glycosyltransferase clusters 
3.2.3.1. Identification of putative glycosyltransferases 
To identify putative protein glycosylation systems, the genomes of Lr100-23, LrATCC 53608 and 
LrMM4-1a were interrogated for the presence of clusters containing GTs: 24 annotated GTs 
were identified in Lr100-23, 21 in LrATCC 53608 and 12 in LrMM4-1a. Most of the annotated GTs 
found in all three strains belong to GT families 2 and 4, as per the CAZy database classification 
(www.cazy.org). The GT2 family contains enzymes that employ an inverting mechanism of 
glycosylation, suggesting the formation of mainly β-glycosidic bonds. Known substrates for 
members of this family include UDP-Glc, UDP-GlcNAc, UDP-GalNAc, UDP-Galf, dTDP-Rha and 
GDP-Man. In contrast, members of the GT4 family employ a retaining mechanism that leads to 
the formation of α-glycosidic linkages. Possible substrates for GT4 members include UDP-Glc, 
UDP-GlcNAc, UDP-Xyl and GDP-Man. Some predicted multidomain proteins in the three L. 
reuteri strains contain a GT1 domain at the C-terminus, in addition to the GT4 domain at the N-
terminus. The GT1 domain uses an inverting mechanism but seems to be active primarily on 
small molecules. Also, all three strains contain a single gene encoding a predicted GT28, which 
has an inverting activity and is probably involved in the biosynthesis of peptidoglycan. In 
addition, Lr100-23 and LrATCC 53608 harbour genes coding for proteins with a GT8 domain. The 
retaining mechanism of GT8 members mostly leads to the formation of α-glycosidic linkages, 
using primarily UDP-Glc and UDP-Gal. A summary of the GTs identified in Lr100-23, LrATCC 






Table 16 Summary of the GTs identified in Lr100-23, LrATCC 53608 and LrMM4-1a, as part of clusters. Genes found 
on the same row were found to be homologues with an E-value < 1.0-70. 
 Lr100-23 LrATCC 53608 LrMM4-1a 
Cluster Gene ID Domain Gene ID Domain Gene ID Domain 
1 
2500069824 GT4/GT1 LRATCC53608_0691 GT4/GT1 2502290820 GT4/GT1 
2500069825 GT4/GT1 LRATCC53608_0690 GT4/GT1 2502290819 GT4/GT1 
             
2 (EPS) 
2500069849 GT2     
2500069850 Not classified     
2500069851 Not classified     
2500069853 GT2     
2500069854 (DUF4422)     
2500069855 GT2     




    
  LRATCC53608_0666 GT2 2502290049 GT2 
  LRATCC53608_0655 Not classified 2502290056 
Not 
classified 
  LRATCC53608_0654 GT4 2502290057 GT4 
2500069867 Bacterial GT LRATCC53608_0651 Bacterial GT 2502290062 Bacterial GT 
2500069868 GT2 LRATCC53608_0650 GT2 2502290063 GT2 
2500069869 (DUF4422) LRATCC53608_0649 (DUF4422) 2502290064 (DUF4422) 
       
3 
2500070567 GT4 LRATCC53608_0089 GT4 2502291957 GT4 
2500070568 Gtf2 LRATCC53608_0090 Gtf2 2502291958 Gtf2 
       
4 (SecA2/Y2) 
2500070887 GT4 LRATCC53608_0907 GT4   
2500070893 GT4 LRATCC53608_0913 GT4   
2500070894 Gtf2 LRATCC53608_0914 Gtf2   
2500070896 GT8/DUF1792     
2500070897 GT8/DUF1792     




    
             
5 
2500070918 Bacterial GT LRATCC53608_0938 Bacterial GT   
  LRATCC53608_0939 GT4/GT1   
2500070922 GT8     
2500070923 GT2     
2500070924 GT2 LRATCC53608_0940 GT2   
  LRATCC53608_0941 GT4/GT1   
  LRATCC53608_0945 GT2   
       
       
N/A 
2500071234 GT28/GT28 LRATCC53608_1356 GT28/GT28 2502291442 GT28/GT28 
2500069382 GT2 LRATCC53608_0673 GT2 2500070923 GT2 
2500069655 GT1 or GT4 LRATCC53608_0770 GT1 or GT4 2502290385 GT1 or GT4 
  LRATCC53608_1078 GT8   
  LRATCC53608_1691 GT2 2502290343 GT2 






3.2.3.2. Glycosylation clusters in L. reuteri 
Five glycosylation clusters were identified in L. reuteri strains. The first glycosylation cluster is 
conserved between Lr100-23, LrATCC 53608 and LrMM4-1a and consists of two putative GTs 
(Figure 18). Both GTs contain a GT4 domain at the N-terminus and a GT1 domain at the C-
terminus. These genes are part of a predicted four-gene operon, which also encodes a putative 
lysylphosphatidylglycerol synthase and an uncharacterised YkuJ-like protein. This predicted 
operon is located directly downstream of the genes encoding HPr and EI, the sugar-independent 
components of the PTS system. 
 
Figure 18 Glycosylation cluster 1 is conserved in Lr100-23, LrATCC 53608 and LrMM4-1a and harbours two genes 
encoding multidomain GTs. Both GTs have a GT4 domain in the N-terminus and a GT1 domain in the C-terminus. 
The second cluster is the EPS biosynthetic cluster which is also found in all three strains (Figure 
19). This cluster is significantly larger in Lr100-23 with 11 predicted GTs, while the clusters in 
LrATCC 53608 and LrMM4-1a consist of six putative GTs. The conserved GTs between the EPS 
clusters of Lr100-23, LrATCC 53608 and LrMM4-1a include the priming GT, containing a bacterial 
GT domain, a GT (GT family 2) and a protein containing a DUF4422, which has been identified in 
GTs of C. jejuni subsp. jejuni. LrATCC 53608 and LrMM4-1a also harbour genes encoding a GT2 
and a GT4, which have no homologues in Lr100-23. Instead, the Lr100-23 EPS cluster contains 
four additional GT2 and one DUF4422 containing protein, as well as two proteins that are similar 
to putative GTs from Oenococcus oeni (2500069850 and 2500069851) and a YfhO-like protein, 
which in some cases has been annotated as a GT, but which function remains to be determined 
experimentally (Figure 19). Additional proteins predicted to be expressed by this cluster include 




determinant protein, further supporting that this cluster is involved in the biosynthesis of EPS 
(Figure 19). 
 
Figure 19 The EPS biosynthetic cluster in Lr100-23, LrATCC 53608 and LrMM4-1a. The clusters differ in the 
organisation of the genes, as well as the number of GT-encoding genes present in each cluster.  
A predicted two-GT operon constitutes the third glycosylation cluster, identified in L. reuteri 
strains (Figure 20). Each GT has a conserved DUF1975 at the N-terminus and a GT4 domain at 
the C-terminus. This operon is homologous to the gtf1-gtf2 operon in L. plantarum WCFS1, 
which was shown to be involved in a general protein O-glycosylation system, as deletion of 
either gtf1 or gtf2 resulted in the loss of protein glycosylation in more than seven identified 
glycoproteins in L. plantarum (277). The high similarity of the Lr100-23 gtf1 and gtf2 with their 
homologues from L. plantarum (E-value = 1.0-146 and 1.0-134, respectively) suggests that they may 
play a similar role in L. reuteri. In Lr100-23, LrATCC 53608 and LrMM4-1a, several predicted 






Figure 20 Glycosylation cluster 3 contains two putative GTs, similar to gtfA and gtfB from the secA2/Y2 cluster, and 
homologous to gtf1 from L. plantarum, that may be involved in protein glycosylation. 
The fourth group of GTs is only found in Lr100-23 and LrATCC 53608 and is part of the SecA2/Y2 
cluster (Figure 21). Both clusters contain genes encoding the priming pair of GTs (GtfA and GtfB), 
and GtfC, in addition to the accessory secretion proteins (Asp) 1-3, the translocases SecA2/Y2 and 
SecY2, as well as the target serine rich repeat protein (SRRP) (see section 1.3.3.3.2). Lr100-23 
also carries four additional GT-encoding genes. Of these, genes 250070898 and 250070900 
appear to be part of a single original gene, which became split by the insertion of a transposase. 
These putative GTs have a GT8 domain at the N-terminus and a DUF1792 at the C-terminus, 
showing a reverse organisation compared to the well-studied homologue dGT1 from 
Streptococcus parasanguinis FW213 (262), which contains a DUF1792 at the N-terminus and a 
GT domain at the C-terminus and was shown to mediate the third and fourth glycosylation steps 
of the fimbriae associated protein 1 (Fap1) in S. parasanguinis FW213 (264). However, while S. 
parasanguinis encodes one protein containing a DUF1792, Lr100-23 has four genes encoding 
similar proteins, suggesting a more variable glycosylation of the target serine rich repeat protein 
(SRRP). In contrast, the LrATCC 53608 cluster only contains the putative GtfA, B and C. It is 
therefore more likely to glycosylate SRR with a disaccharide, as GtfA and B mediate the first 
glycosylation step and GtfC mediate the second one, as shown for S. parasanguinis FW213 and 





Figure 21 The SecA2/Y2 cluster in Lr100-23 and LrATCC 53608. Both systems contain genes that form the core of the 
cluster (srr, secA2, secY2, asp1-3 and gtfA-B) as well as gtfC. The Lr100-23 system contains four additional 
multidomain GTs. 
Another glycosylation cluster found only in Lr100-23 and LrATCC 53608 is located downstream 
of the SecA2/Y2 cluster and contains four, or five GTs, respectively (Figure 22). It shows some 
organisational similarity with the EPS glycosylation cluster, as it contains a chain length 
determinant protein, a polymerase and several putative membrane proteins. However, no 
annotated proteins involved in export of the EPS subunits have been identified (Figure 22). In 
addition, a TDP-Rha cluster is found in that locus in Lr100-23. 
 
Figure 22 Glycosylation cluster 5 is similar to the EPS cluster, in the nature of GTs that it contains, but is not found in 
LrMM4-1a and also lacks a putative flippase 
In addition to the GTs in the clusters described above, there are other GTs spread across the 
genome of the three L. reuteri strains that do not appear to be part of any predicted 
glycosylation cluster. Of these, the most notable genes are 250069655 in Lr100-23 and its 
homologues LRATCC53608_0770 and 2502290385 in LrATCC 53608 and LrMM4-1a, 




as found in GtfA from the SecA2/Y2 cluster and Gtf1 from L. plantarum WCFS1. However, there 
is no neighbouring gene similar to GtfB or Gtf2. Deletion of the homologous gene in L. plantarum 
WCFS1 did not alter the protein glycosylation profile (274). 
Taken together this in silico analysis suggests that there are at least two putative protein 
glycosylation systems in Lr100-23 and LrATCC 53608 (glycosylation clusters 3 and 4), and at least 
one in LrMM4-1a (glycosylation cluster 3).  
3.3. Summary and Discussion 
The range of monosaccharides used in protein glycosylation is often dictated by the nature of 
the sugar nucleotides found in an organism. To identify the sugar nucleotides that L. reuteri 
strains can synthesise, we searched for genes involved in the synthesis and modification of sugar 
nucleotides. The results of the in silico analysis suggested that the three L. reuteri strains Lr100-
23, LrATCC 53608 and LrMM4-1a are able to synthesise UDP-Glc, UDP-Gal, UDP-Galf, UDP-
GlcNAc, UDP-ManNAc and GDP-Man using Glc, Fru or Gal, as starting material; Lr100-23 may be 
able to additionally synthesise TDP-Rha. Microbes have been reported to synthesise glycans that 
mimic the structure of mammalian ones (271), but this does not appear to be the case in L. 
reuteri as the three strains appear to lack the necessary enzymes to utilise GalNAc, Fuc or 
Neu5Ac, sugars commonly found in mucin O-glycans. However, these in silico results would need 
to be confirmed by profiling the sugar nucleotides synthesised by Lr100-23, LrATCC 53608 and 
LrMM4-1a using HPLC based techniques. 
The lack of genes involved in HexNAc metabolism, as well as utilisation of carbohydrates often 
found in host glycans, was confirmed by growth assays on various mono-, di- or trisaccharides 
used as sole carbon source. The results showed that the three L. reuteri strains could utilise 
lactose, maltose and sucrose with different efficiency, but none of the HexNAcs or modified 
lactose tested, thus confirming the results from the bioinformatics analysis. This suggests that 




derived glycans, which is consistent with their localisation in the GI tract (104). Transcriptomics 
studies would be required to gain further insights into the observed differential growth profile 
of the L. reuteri strains, despite sharing similar genetic potential for the utilisation of these 
carbohydrates.  
To identify putative systems involved in protein glycosylation, we searched for gene clusters 
encoding putative GTs. It is of note that as the in silico analysis focused on gene clusters 
containing GTs, the levansucrase (fructosyltransferase) of Lr100-23 (287) or LrATCC 53608 was 
not identified. This enzyme is classified as a glycoside hydrolase (GH family 68) and is involved 
in the formation of levan, an extracellular fructose polymer, by transglycosylation activity (287). 
Five clusters containing two or more putative GTs were identified in Lr100-23 and LrATCC 53608 
and three in the LrMM4-1a genome. These included a cluster responsible for EPS formation and 
a cluster of unknown function, as well as a cluster containing two GT-encoding genes highly 
similar to gtf1 and gtf2 from L. plantarum, which are involved in protein glycosylation (274). In 
addition, a SecA2/Y2cluster containing varying number of GTs was identified in Lr100-23 and 
LrATCC 53608, as previously described in (103) and (159), respectively.  
The identified glycosylation clusters gtf1/gtf2 and secA2/Y2 are both predicted to be involved in 
protein O-glycosylation. While the presence of an en bloc N-glycosylation system similar to that 
found in Campylobacter species is unlikely to be identified in Gram-positive bacteria, due to their 
different cell surface structure, the presence of a N-glycosylation system similar to that of 
Haemophilus influenza cannot be excluded. However, no genes encoding for proteins that could 
be involved in a N-glycosylation system could be identified, based on homology to the proteins 
involved in protein N-glycosylation in Gram-negative bacteria, suggesting that L. reuteri can 
probably perform O-glycosylation. 
In L. plantarum, Gtf1 and Gtf2 act together to add a α-GlcNAc moiety to various proteins 




reuteri (E-value < 1.0-130), they could act in a similar way. Similarly to L. plantarum, no 
neighbouring GTs were identified, suggesting that this modification is not further extended by 
other monosaccharides. 
The secA2/Y2 clusters in Lr100-23 and LrATCC 53608 shared a similar organisation but differed in 
the number of GTs constituting the cluster, as well as the localisation of the srr gene (at the 5’-
end in LrATCC 53608 and at the 3’-end in Lr100-23). Both systems contained GtfA, B, and C, but 
the Lr100-23 cluster contained three additional GTs and there is an insertion of a putative 
transposase to the last GT, suggesting that it is inactive. The additional GTs have a reversed 
organisation to dGT1 from S. parasanguinis FW213, which mediates the third and fourth 
glycosylation steps of Fap1 (191). These results suggest that SRRP53608 is probably glycosylated 
with a disaccharide, whereas SRRP100-23 may be glycosylated with glycans ranging from two to 
ten monosaccharides long, depending on the activity of the additional GTs present in the 
SecA2/Y2 cluster. 
In conclusion, based on the in silico analysis of L. reuteri genomes, two putative protein 
glycosylation systems were identified in Lr100-23 and LrATCC 53608 (gtf1/gtf2 and the secA2/Y2 
cluster) and one putative protein glycosylation system in LrMM4-1a (gtf1/gtf2 cluster). These 
glycosylation systems may utilise the sugar nucleotides identified by the bioinformatics analysis. 
As this analysis is based on annotation of the genomes, the presence of additional sugar 
nucleotides or further glycan modifications cannot be excluded in the L. reuteri strains analysed 
















Protein O-glycosylation in bacteria is often associated with surface or secreted proteins. For 
example, en bloc O-glycosylation in Gram-negative bacteria occurs in the periplasm and many 
of the target proteins are found on the membrane (237,272). Similarly, sequential O-
glycosylation identified in Gram-positive bacteria such as L. plantarum, Streptococcus 
parasanguinis and S. pneumoniae (260,267,277,278) occurs intracellularly and the target 
proteins are either secreted in the environment, or anchored on the surface, via specific cell-
wall anchoring motifs (see section 1.3). Our bioinformatics analysis showed that L. reuteri strains 
harbour several gene clusters containing glycosyltransferases (GTs). For example, glycosylation 
cluster 3 (see section 3.2.3.2) encodes two putative GTs, homologous to the Gtf1 and Gtf2 from 
L. plantarum WCFS1, which have been shown to be involved in protein glycosylation (274). In 
addition, L. reuteri 100-23 (Lr100-23) and ATCC 53608 (LrATCC 53608) have been found to 
harbour a functional auxiliary SecA2/Y2 system (109,159), similar to that found in pathogenic 
Gram-positive bacteria, where it has been shown to be involved in the glycosylation of large, 
serine rich repeat proteins (SRRPs) (193). These data suggest that L. reuteri has the capacity to 
carry out protein glycosylation. However, no biochemical or structural information is available 
to date on the nature of glycosylated proteins in L. reuteri strains. 
The aim of this chapter is to determine the ability of L. reuteri to perform protein glycosylation 
and to identify the major glycoproteins secreted by L. reuteri 100-23 (Lr100-23), ATCC 53608 
(LrATCC 53608) and MM4-1a (LrMM4-1a) using lectin screening and monosaccharide 





4.2.1. Lectin screening of L. reuteri secreted proteins (SM) 
To determine whether Lr100-23, LrATCC 53608 and LrMM4-1a are capable of performing 
protein glycosylation, the strains were grown in MRS or LDM-II, and the spent media (SM) 
proteins were analysed by SDS-PAGE followed by western blot using a range of fluorescein (f-)-
labelled lectins (summarised in Table 17).  
Lectins are proteins that recognise and bind on specific carbohydrate structures and they 
provide an invaluable tool in glycoprotein analysis. Most plant lectins are specific to mono-, or 
disaccharides and can be used to identify characteristic epitopes on glycoconjugates. In addition, 
mammalian lectins form part of the immune system, and some of them recognise microbial 
carbohydrate structures. 
Table 17 Specificity of plant lectins used to identify putative SM glycoproteins from L. reuteri strains, after SDS-PAGE 
and western blot. 
Lectin Abbreviation Specificity 
Concanavalin A ConA α-mannose 
Lotus tetragonolobus lectin LTL α-L-fucose 
Peanut agglutinin PNA Gal-(β-1,3)-GalNAc (T-antigen) 
Ricinus communis agglutinn RCA  Gal or GalNAc 
Sambucus nigra agglutinin SNA α-2,6-linked sialic acid 
(α-2,3-linked sialic acid with lower affinity) 
Ulex europaeus agglutinin UEA α-L-fucose (differs from LTL) 
Wheat germ agglutinin WGA GlcNAc or sialic acid 
 
Lr100-23, and LrATCC 53608 SM proteins shared a similar lectin recognition profile with specific binding of f-WGA, f-
RCA and f-SNA (Figure 23A, B, C). LrMM4-1a SM proteins showed a different lectin recognition profile with binding 
restricted to f-RCA and f-SNA (Figure 23B, C). No binding was observed with f-ConA, f-LTL, f-PNA, or f-UEA against SM 
proteins from the three strains (data not shown). More specifically, f-WGA recognised a large protein with an 
apparent molecular weight (MW) >300 kDa in Lr100-23 and LrATCC 53608, in addition to a smaller protein of ~130 
kDa and 50 kDa, respectively (Figure 23). The high MW protein band in Lr100-23 was mainly detected when the strain 
was grown in the MRS medium, whereas it was predominant when LrATCC 53608 was grown in LDM-II (Figure 23A), 
suggesting that the growth medium may influence protein secretion and/or glycosylation. In addition, western blot 
analysis of the LrATCC 53608 SM proteins with anti-SRRP53608 antibodies revealed that SRRP migrates at the same 
size as the protein recognised by f-WGA (Figure 23D), suggesting that this protein may be glycosylated with GlcNAc 
or sialic acid.  
f-RCA recognised several protein bands in Lr100-23, LrATCC 53608 and LrMM4-1a, ranging from 40 to 130 kDa (Figure 
23). Protein bands at 75 kDa and 55 kDa were shown to be recognised by f-RCA across all three L. reuteri strains, 
which could suggest that these strains share the same target proteins and glycosylation system. In addition to these 
proteins, f-RCA also recognised a high MW band at ~500 kDa, which may correspond to a mucus binding protein 
(MUB53608), the major adhesin in LrATCC 53608 (151,154). This protein was recognised by an anti-MUB53608-antibody 




f-SNA recognised SM proteins in all three strains grown in LDM-II, ranging from 20 to ~100 kDa (Figure 23C). Samples 




Figure 23 Western blot analysis of SM proteins from Lr100-23, LrATCC 53608 and LrMM4-1a cultures in MRS or LDM-
II. The blots were probed with various FITC-labelled lectins. A) f-WGA, B) f-RCA, C) f-SNA. D) LrATCC 53608 MRS SM 
probed with f-WGA or anti-SRRP antibody. E) LrATCC 53608 MRS SM probed with f-RCA or anti-MUB53608 antibody. 
Taken together, these results suggest that the glycans present on L. reuteri SM proteins may 
contain galactose (Gal) or N-acetyl-galactosamine (GalNAc), N-acetyl-glucosamine (GlcNAc) or 
sialic acid, based on RCA, WGA and SNA binding, respectively. The presence of GlcNAc and Gal 
was predicted by bioinformatics analysis (see section 3.2.1), however, no enzyme involved in 
sialic acid metabolism was identified. As there is no sialic acid in the LDM-II growth media, this 
result suggests that there may be un-annotated genes that encode proteins involved in the 
biosynthesis of sialic acid and its utilisation in protein glycosylation or that SNA recognises 
modified sugars other than sialic acid, or that the interaction is not specific. To further 
investigate if sialic acid is present in L. reuteri glycoproteins, these were treated with 




of linkage, and the reaction products were analysed by SDS-PAGE and western blot, using f-SNA 
or f-WGA. The results showed that recognition of these two lectins towards SM proteins 
remained unaltered (Figure 24).  
 
Figure 24 Treatment of L. reuteri SM proteins with neuraminidase A. 1) Lr100-23 control, 2) Lr100-23 treated, 3) 
LrATCC 53608 control, 4) LrATCC 53608 treated, 5) LrMM4-1a control, 6) LrMM4-1a treated. A) InstantBlue stained 
blot, B) f-SNA probed blot. The results show that neuraminidase A has no effect on SNA recognition of L. reuteri SM 
proteins. 
This suggests that either the sialic acid present on L. reuteri glycoproteins cannot be cleaved by 
neuraminidase A due to some modification, or that SNA interaction is not glycan mediated. To 
address this, chemical release of sialic acid was employed to SM proteins from Lr100-23, 
LrATCC53608 and LrMM4-1a cultures. Briefly, SM proteins were precipitated, mildly hydrolysed 
in acetic acid and the reaction products were labelled with 1,2-diamino-4,5-
methylenedioxybenzene (DMB). Following analysis by High Performance Liquid 
Chromatography (HPLC), no sialic acid could be detected in the samples, whereas control 
samples showed the elution and detection of sialic acids between 15 and 35 min, under the 




These data, confirmed our bioinformatics analysis that did not identified any sialic acid 
biosynthetic pathway, suggesting that SNA recognition of L. reuteri SM proteins was not specific 
and that no sialic acid is present in these proteins. 
4.2.2. Monosaccharide composition analysis of L. reuteri SM proteins 
Another approach to assess whether L. reuteri proteins are glycosylated was to carry out 
monosaccharide composition analysis of SM proteins by gas chromatography – mass 
spectrometry (GC-MS). This technique allows the identification of monosaccharides present on 
glycoproteins. To that end, Lr100-23, LrATCC 53608 and LrMM4-1a were grown in LDM-II 
medium for 18 h, SM proteins were precipitated from the SM by methanol/chloroform 
precipitation to remove free sugars and methanolysed. The released monosaccharides were re-
N-acetylated, derivatised with trimethylsilane and analysed by GC-MS.  
The results are summarised in Table 18. The major monosaccharides identified in this analysis 
were rhamnose (Rha), Fuc, xylose (Xyl), Gal, glucose (Glc) and GlcNAc (Figure 25). The strongest 
peak in all chromatograms corresponds to Glc, but shows large variation in concentration 
between the different samples. The second most intense peak corresponded to Gal, in SM 
proteins from all three L. reuteri strains. Rha was one of the major peaks in Lr100-23 SM proteins 
but was not detected in the LrATCC53608 and LrMM4-1a samples. GlcNAc was also found in all 
three strains with highest concentration in LrATCC 53608. Fuc and Xyl were identified in L. reuteri 





Table 18 Monosaccharides identified by GC-MS, after methanolysis of L. reuteri glycoproteins and derivatisation of 
the released monosaccharides with TMS. 
Monosaccharide Retention time (min) Concentration (μg / mg of protein) 
Lr100-23 WT LrATCC 53608 LrMM4-1a 
Rhamnose 5.5 37.3±7.5 - - 
Fucose 6.3 2.6±0.2 Trace - 
Xylose 7.8 0.2±0.1 Trace - 
Galactose 10.5/12.1 42.9±6.5 15.8±3.3 65±28 
Glucose 11.2/11.4 324.3±170 63±17.5 108.2±57 






Figure 25 GC-MS chromatogram of monosaccharide composition analysis of glycoproteins from Lr100-23 WT, Lr100-
23 Δgtf1, LrATCC 53608 and LrMM4-1a. The results showed the presence of Glc, Gal and GlcNAc in each strain, in 
addition to Fuc and Xyl in Lr100-23 and LrATCC 53608 and Rha in Lr100-23. 
4.2.3. Identification of L. reuteri glycoprotein candidates 
To identify the nature of the putative glycoproteins secreted by LrATCC 53608, protein bands indicated with arrows 
in Figure 23 were excised from the polyacrylamide gel and subjected to in-gel trypsin digest. The proteins were 
identified by mass spectrometry (MS). The major protein band from LrATCC 53608 that interacted with WGA was 
identified as the serine rich repeat protein (SRRP53608). As SRRP53608 has no trypsin digestion site within the serine rich 
repeat regions, the coverage of the tryptic peptides was limited to 21%. MUB53608 was also identified in this sample, 




MS as MUB53608. The MS analysis of the high MW proteins from LrATCC 53608 that interacted with RCA or WGA 
confirmed the immunoblotting data obtained from the anti-MUB53608 and anti-SRRP53608 antibodies, respectively, 
indicating that MUB53608 and SRRP53608 are putative glycoproteins. Lastly, the predominant protein in the ~75 kDa 
protein band from all three strains was found to be a predicted muramidase, homologous to Acm2, a known 
glycoprotein in L. plantarum WCFS1 (275).  
To investigate whether SRRP100-23 is glycosylated, the lectin binding profile of three L. reuteri 100-
23 mutants with an insertion mutation in asp2, gtfB or srr was determined. Asp2 encodes an 
accessory secretion protein which is involved in the secretion of SRRPs and the modification of 
GlcNAc residues found on the adhesin, whereas gtfB encodes a chaperon required for successful 
glycosylation of SRRP. Briefly, Lr100-23 WT strain and the insertion mutants were grown in MRS 
for 18 h and the secreted proteins were concentrated by spin filtration and analysed by SDS-
PAGE and western blot, using fluorescently-labelled lectins. While no major differences in the 
protein pattern were observed with InstantBlue stain (Figure 26A), differences were noted when 
the proteins were probed with f-WGA after western blot analysis. A protein band >300 kDa was 
apparent in the WT strain but was missing in the Lr100-23 Δsrr mutant, as well as the other 
mutants, suggesting that this protein is SRRP1000-23 (marked with an arrow in Figure 26B). The 
interaction with WGA, in combination with SRRP100-23’s apparent MW of >300 kDa on SDS-PAGE 
(predicted MW is 224 kDa) suggest that SRRP100-23 is glycosylated. In addition, other protein 
bands that were recognised by f-WGA were consistently found across all samples and no other 
differences were observed when the proteins were probed with f-RCA (Figure 26C) or f-SNA 
(data not shown). These results suggest that Asp2 and GtfB are dedicated to the processing of 





Figure 26 A) SDS-PAGE, followed by western blot analysis with B) f-WGA or C) f-RCA of secreted proteins from 1) 
Lr100-23 WT, 2) Δasp2, 3) ΔgtfB 4) Δsrr. The arrow indicates the SRRP100-23. 
4.2.4.  Identification and characterisation of L. reuteri glycosylation pathways 
4.2.4.1. Gtf1100-23 is involved in protein glycosylation 
Lr100-23, LrATCC 53608 and LrMM4-1a harbour a glycosylation cluster composed of two 
predicted GTs (see section 3.2.3.2), homologous to the Gtf1 / Gtf2 general protein glycosylation 
system in L. plantarum WCFS1 (274).  
To investigate the role of Gtf1 in Lr100-23, a Lr100-23 Δgtf1 deletion mutant was generated by 
Dr. Rebbeca Duar (University of Alberta, Edmonton, Canada), following the protocol described 
in (303). The role of Gtf1 in protein glycosylation was then assessed by western blot analysis of 
SM proteins from Lr100-23 WT and Lr100-23 Δgtf1 grown in MRS (Figure 27). The results showed 
that while SNA and WGA recognition remained unaffected in the Lr100-23 Δgtf1 mutant 





Figure 27 Western blot analysis of SM proteins from Lr100-23 WT (lane 1) and Lr100-23 Δgtf1 (lane 2) and probing 
with various lectins. The results show that RCA recognition of l. reuteri proteins is lost in the gtf1 mutant, but the 
recognition of SNA and WGA was not affected. 
Taken together, these results suggest that Gtf1 is involved in a general protein glycosylation 
system in L. reuteri 100-23, similar to the one found in L. plantarum WCFS-1 (274), targeting 
several secreted proteins. However, in contrast to L. plantarum, where glycoproteins interact 
with WGA and are suggested to be glycosylated predominantly with a single GlcNAc molecule 
on each glycosylation site (277), Gtf1 in Lr100-23 appears to be involved in the glycosylation of 
proteins that are specifically recognised by RCA, via a Gal or a GalNAc moiety. As no GalNAc was 
identified in the monosaccharide composition analysis, the monosaccharide that mediates RCA 
recognition is more likely to be Gal. Taken together, these data suggest that Gtf1100-23 is involved 
in the synthesis of glycans containing Gal residues. It is possible that Gtf1 transfers Gal residues 
directly, or that it adds monosaccharides that precede Gal deposition, leading to a loss of RCA 




4.2.4.2. Gtf1100-23 is involved in the synthesis of glycans containing both GlcNAc and Gal 
To identify the monosaccharides used by the Gtf1 glycosylation system, monosaccharide 
composition analysis was performed on SM proteins from Lr100-23 Δgtf1 strain, as described in 
4.2.2. Table 19 summarises the identified monosaccharides and their respective concentrations. 
The mutant strain showed reduced levels of Gal, Glc and GlcNAc (Figure 28); interestingly, both 
Gal and Glc showed a ~5-fold decrease while GlcNAc was decreased ~10-fold in the mutant 
strain. A small reduction (>1.5-fold) was observed in the concentration of Fuc and Rha. 
Table 19 Monosaccharide composition analysis of Lr100-23 Δgtf1, compared to Lr100-23 WT. 
Monosaccharide Retention time (min) 
Concentration (μg / mg of protein) 
Lr100-23 WT Lr100-23 Δgtf1 
Rhamnose 5.5 37.3±7.5 24.52±5.4 
Fucose 6.3 2.6±0.2 1.75±0.6 
Xylose 7.8 0.2±0.1 0.31±0.1 
Galactose 10.5/12.1 42.9±6.5 8.15±1.7 
Glucose 11.2/11.4 324.3±170 62.75±26.7 
GlcNAc 29.3 1.4±0.3 0.13±0.05 
 
 
Figure 28 GC-MS chromatogram of monosaccharide composition analysis of glycoproteins from Lr100-23 Δgtf1. The 




These results suggest that Gtf1100-23 is part of a glycosylation system that generates glycan 
structures containing Glc, Gal and GlcNAc residues. Based on the similarity of Gtf1 from Lr100-
23, with its homologous enzyme from L. plantarum WCFS1 (43,28%, E-value=10146), it is possible 
that Gtf1 serves as the priming GT, depositing GlcNAc residues onto the target protein, while 
additional GTs outside the gene cluster extend the glycan with Glc or Gal moieties. The presence 
of other modified sugars that were not identified by GC-MC cannot be excluded. The presence 
of Rha, Fuc and Xyl seems to be independent of Gtf1 and possibly part of glycans synthesised by 
a different glycosylation system. 
4.2.4.3. Gtf1 plays a role in aggregation of Lr100-23 
To test if the deletion of gtf1 affected the growth of Lr100-23, the OD600 of Lr100-23 WT and 
Lr100-23 Δgtf1 cultures was monitored for 24 h. Both Lr100-23 WT and the isogenic Lr100-23 
Δgtf1 mutant grew to the same level under these conditions. The wild type (WT) strain showed 
a slight increase in growth rate at 3-4 h, (α=0.05), but no other statistically significant differences 
were observed over the course of the experiment (Figure 29). This suggests that Gtf1 it is not 
required for growth in Lr100-23, under the conditions tested. 
 






















However, it was observed that while the parent strain sedimented after prolonged static 
incubation, the Δgtf1 mutant remained in suspension, which could suggest impaired 
aggregation. To further assess the aggregation properties of the Lr100-23 Δgtf1 mutant, the 
sedimentation of the bacteria was determined by spectrophotometry (304), in comparison to 
the WT strain. LrATCC 53608 and its isogenic mutant L. reuteri 1063N (Lr1063N) were used as 
controls. Lr1063N carries an insertion in the mub gene encoding the surface adhesin MUB53608, 
which resulted in an early stop codon, leading to the synthesis of a truncated MUB53608 
(tMUB1063N), which lacks the C-terminus LPxTG anchoring motif and is thus secreted to the 
growth medium but not attached onto the cell surface. As Lr1063N lacks its major adhesin, it 
fails to form aggregates or biofilms, as previously determined by flow-cytometry (151). Here, to 
measure sedimentation, Lr100-23 Δgtf1 and Lr1063N were suspended in PBS and the OD600 was 
monitored regularly for 8 h, using Lr100-23 WT or LrATCC56308 as reference, respectively.  
The results showed that the WT strains (Lr100-23 and LrATCC 53608) in the reference cell 
sedimented faster, leading to an increased OD600 measurement. This suggests that they form 
more or larger aggregates. In contrast, the mutant strains Lr100-23 Δgtf1 and Lr1063N remained 
in suspension, suggesting impaired aggregation. This observation was also confirmed by 
macroscopic visual observation of the cultures, which showed a more turbid solution for the 
mutant, compared to the WT, after 8 h (Figure 30E). The reduced aggregation capability of 
Lr1063N compared to LrATCC 53608 is consistent with previous observations by flow cytometry, 
showing that MUB53608 is involved in cell aggregation (151). When Lr100-23 WT or LrATCC53608 
sedimentation was measured, the OD600 measurements fluctuated around the baseline and 
resulted in overall similar sedimentation rate between the measuring and reference sample, as 
determined by the slope of the trendline (m = 10-4; Figure 30A and C). These results also suggest 






Figure 30 Measurement of the change in ΔOD600 of A) Lr100-23 WT, B) Lr100-23 Δgtf1, C) LrATCC 53608 and D) 
Lr1063N, using Lr100-23 WT as reference for A and B and LrATCC 53608 for C and D. E) Visual observation of the 
sedimentation of Lr100-2 WT and Lr100-23 Δgtf1, after 8 h of stationary incubation. 
4.2.4.4. Overexpression of putative glycosyltransferases involved in glycosylation of MUB 
Deletion of Gtf1 in Lr100-23 abolished the recognition of SM proteins by RCA. The high similarity 
between Gtf1 from 100-23 (Gtf1100-23) and Gtf1 from LrATCC 53608 (Gtf153608) (98% identities, E-
value = 0.0), strongly suggests that this enzyme may have a similar role in LrATCC 53608. As 
MUB53608 was shown to be recognised by RCA, it may be possible to be a glycosylation target for 
the Gtf153608/Gtf253608 glycosylation system.  
To confirm the role of these enzymes in LrATCC 53608 (and since it is difficult to transform this 
strain), Gtf153608 and Gtf253608 were heterologously expressed in E. coli BL21 (DE3) using the 
pOPINF overexpression vector. This vector allows the overexpression of N-terminal His6-tagged 
recombinant proteins, and their purification by immobilised metal ion affinity chromatography 
(IMAC). Upon induction, the proteins were successfully produced, as shown by the 
overexpressed protein bands at ~60 kDa on SDS-PAGE (Gtf153608 and Gtf253608 have a predicted 
MW of 59.7 kD and 56.8 kDa, respectively (Figure 31). After cell lysis, Gtf253608 was found in the 




IMAC, however, elution with 0.25 M imidazole led to the precipitation of the protein (data not 
shown). Therefore, the protein was eluted using EDTA, leading to depletion of Ni2+ from the 
IMAC column and elution of Gtf253608 as a soluble protein. Attempts were made to recover Gtf1 
from the inclusion bodies, following denaturation with 6 M guanidinium chloride, and re-folding. 
However, upon removal of the chaotropic agent, the protein precipitated again, preventing any 
further purification (data not shown). 
 
Figure 31 SDS-PAGE analysis of A) E. coli pOPINF_gtf1 lysate after induction and B) E. coli pOPINF_gtf2 lysates during 
IMAC purification. I) insoluble fraction, II) soluble fraction, 1) flow-through, 2) wash, 3) first elution fraction, 4) second 
elution fraction. Gtf153608 was found in the insoluble fraction and was not further purified, whereas Gtf253608 was 
found in the soluble fraction and purified by IMAC. 
Alternatively, attempts were made to co-express Gtf153608 and Gtf253608 in E. coli BL21 (DE3) using 
a pRSFDuet-1 expression system, since co-expression of insoluble proteins with their natural 
partner can help maintain proteins in solution. Upon induction, Gtf153608 and Gtf253608 were 
successfully overexpressed (Figure 32), as shown by the intense protein bands at ~58 kDa after 
SDS-PAGE, however they were both found in the insoluble fraction, after cell lysis, thus 





Figure 32 SDS-PAGE analysis of the A) soluble and B) insoluble fractions from 1) E. coli BL21 (DE3) pRSFDuet-1, 2) E. 
coli BL21 (DE3) pRSFDuet-1_gtf1 and 3) E. coli BL21 (DE3) pRSFDuet-1_gtf1/2 cell lysates. Overexpression of the 
proteins was successful, however, both proteins were found in the insoluble fraction. 
4.2.4.5. The Lr100-23 SecA2/Y2 cluster is organised into two operons 
Protein analysis of Lr100-23 insertional mutants with disrupted SecA2/Y2-associated genes 
showed that Lr100-23 harbours a functional SecA2/Y2 cluster (109). This includes eight predicted 
GTs (Figure 33A). GtfA, GtfB and GtfC have been annotated based on homology with other 
studied proteins (see section 1.4.1.2.4). GtfD and GtfE contain two GT domains, a GT4 at the N-
terminus and a DUF1792 at the C-terminus. Genes 2500070898 and 2500070900 have a GT4 
and a DUF 1792 domain, respectively, and are probably part of the same gene, which has been 
split by a transposase, hence they have been annotated as gtfF1 and gtfF2. To determine the 
transcriptional organisation of the cluster and to identify the expressed GTs, RT-PCR was 
employed. Briefly, RNA extracted from Lr100-23was used to synthesise cDNA. The cDNA was 
then used as a template in PCR reactions, whereas RNA was used as a negative control. The 
primers used in the PCR reactions were specifically designed to target the intergenic regions of 




Initially, random hexameric nucleotides were used for the synthesis of cDNA. When this cDNA 
was used a template for the RT-PCR, reactions 1-3, 5, and 9-12 gave bands of the expected size 
(Figure 33B). This would suggest the presence of three operons (gtfC-asp2, asp3-secA2/Y2 and 
gtfBC-term-Tnase) and five independent genes (gtfA, gtfB, gtfF2, RTase and srr). In all secA2/Y2 
clusters studied so far, the transcriptional organisation varies, but the core genes (secY2-gtfB) 
are always linked into a single operon (189,305), in contrast to the findings for the Lr100-23 
cluster. As it is possible that the random primers used for the cDNA synthesis did not accurately 
target the entire cluster, gene specific primers were used for the synthesis of cDNA from the 
genes that did not produce RT-PCR products. When the gene-specific cDNA was used as a 
template, reactions 4, 6-8 and 12-14 gave bands of the expected size, whereas reaction 15 was 
the only one that did not yield any product. Taken together, these results suggest that the 
SecA2/Y2 cluster from Lr100-23 is organised into two operons: one spanning genes gtfC-RTase 
and a monocistronic operon containing srr alone. This was unexpected as the insertion of two 
exogenous genes (Tnase and RTase) could have introduced transcriptional terminator 






Figure 33 A) schematic representation of the Lr100-23 SecA2/Y2 cluster. B) RT-PCR analysis of the Lr100-23 SecA2/Y2 
cluster, using cDNA synthesised by random hexameric primers or C) gene-specific reverse primers. The lane numbers 
correspond to the intergenic regions noted on A 
4.2.4.6. The LrATCC 53608 SecA2/Y2 cluster is organised into a single operon 
RT-PCR analysis of the SecA2/Y2 cluster from Lr100-23 showed that the genes in this cluster are 
expressed, while the change in the recognition of SRRP100-23 by WGA in Lr100-23 insertion 
mutants of secA2, asp2 and srr shows that the glycosylation system is active. Similarly, the 
interaction of SRRP53608 with WGA suggests that the LrATCC 53608 SecA2/Y2 glycosylation system 
is also functional. To characterise the transcriptional organisation of the SecA2/Y2 cluster, RT-
PCR was used to amplify the intergenic regions of the genes composing the cluster, as described 
for Lr100-23 above. The primers used in the PCR reactions were specifically designed to target 
the intergenic regions of the genes in the cluster (Figure 34A).  
The PCR reactions yielded products of the expected size for each targeted sequence, apart from 
the reaction targeting the intergenic region between secY2 and asp1 (Figure 34B, lane 4). This 
would suggest the presence of two distinct operons, one spanning genes from srr to SecY2 and 
a second one spanning from asp1 to gtfB. However, given that the intergenic region between 
secY2 and asp1 is only two nucleotides long and does not contain a transcription termination 
sequence and a promoter for the second operon, it is more likely that a complex secondary 
structure in this region prevented cDNA synthesis. It is worth noting that the primer pair 
targeting the intergenic region between asp1 and asp2 gave a non-specific band in the RNA 
control, although the product intensity was significantly higher in the cDNA sample. All other 
reactions gave a negative result in the RNA control, suggesting that this is unlikely to be due to 
DNA contamination. Taken together, these results suggest that the SecA2/Y2 cluster in LrATCC 
53608 is organised into a single operon. In addition, based on the number of GTs expressed in 
the operon, these data suggest that SRRP53608 is probably glycosylated with disaccharide 
moieties, as, based on previous studies, GtfA and GtfB are predicted to initiate glycosylation, 




section 1.4.1.2.4). When the cDNA from the stationary phase was used, no PCR product was 
obtained (data not shown), suggesting downregulation of the expression of this cluster under 
these conditions.  
 
 
Figure 34 Analysis of the secA2/Y2 gene cluster in LrATCC 53608 A) Schematic representation of the secA2/Y2 gene 
cluster. The numbers correspond to the PCR reactions analysed by electrophoresis. B) Agarose electrophoresis of the 
intergenic PCR products. The results suggest that the cluster is composed by a single operon. 
4.2.4.7. Biochemical characterisation of GTs from the SecA2/Y2 cluster by differential 
scanning fluorimetry (DSF) 
4.2.4.7.1. Overexpression of the SecA2/Y2 associated glycosyltransferases  
Based on studies on homologous glycosylation clusters in streptococcal and staphylococcal 
systems, GtfA and GtfB are predicted to work together to initiate glycosylation of the SRRP by 
the addition of GlcNAc residues, whereas GtfC is predicted to mediate the second glycosylation 




activity, GtfA GtfB and GtfC from LrATCC 53608 were heterologously expressed in E. coli BL21 
(DE3), using the pOPINF vector. After induction, all three proteins were successfully produced, 
as determined by SDS-PAGE (Figure 35). GtfB53608 was found in the insoluble fraction, preventing 
further purification and characterisation. GtfA53608 and GtfC53608 were found in the soluble 
fraction and further purified by IMAC, using EDTA for the elution, to avoid protein precipitation. 
 
Figure 35 SDS-PAGE analysis of A) E. coli BL21 (DE3) pOPINF_gtfA, B) E. coli BL21 (DE3) pOPINF_gtfC lysates during 
IMAC purification and C) E. coli BL21 (DE3) pOPINF_gtfB lysate after induction of the overexpression system. 1) flow-
through fraction, 2) wash fraction, 3) first elution fraction, 4) second elution fraction. I) insoluble fraction, II) soluble 
fraction. 
4.2.4.7.2. UDP-GlcNAc stabilises GtfC53608 
Based on homology with functionally characterised homologues, GtfA and GtfC are expected to 
mediate the first and second step in glycosylation of SRRP53608. In the studied staphylococcal and 
pneumonococcal SecA2/Y2 systems, GtfA adds a GlcNAc residue onto the SRRP and based on 
homology (~44% identity, E-value > 10-150), GtfA from LrATCC 53608 is expected to have a similar 
activity. In addition, since SRRP53608 was found to interact with WGA, it is possible that the 
glycans that modify the adhesin have a terminal GlcNAc moiety. As GtfC53608 is the only GT 
present in the cluster that is predicted to extend the glycan, UDP-GlcNAc is likely to be the donor 




interaction with UDP-GlcNAc was assessed by differential scanning fluorimetry (DSF), which can 
be used to measure the melting temperature (Tm) of a protein. Interactions of proteins with 
their ligands often lead to increased stabilisation of the protein, and this is reflected by an 
increased Tm. This approach indicated an interaction between UDP-GlcNAc and GtfC53608, but 
not GtfA53608. GtfC53608 showed a UDP-GlcNAc-concentration dependent increase in Tm, from 
42oC in the absence of the ligand to 47oC in presence of UDP-GlcNAc 4 mM (Figure 36B). No 
change was recorded for GtfA53608, showing a constant Tm of ~38oC across all UDP-GlcNAc 
concentrations tested (Figure 36A). The absence of recognition of UDP-GlcNAc by GtfA53608 is 
intriguing, as crystal structures of GtfA from S. pneumoniae and S. gordonii show UDP-GlcNAc 
binding, independent of GtfB (266,267). As GtfA acts synergistically with GtfB, it is possible that, 
in solution, binding of UDP-GlcNAc to GtfA requires both proteins, or that the binding of UDP-
GlcNAc to GtfA may not be sufficient to stabilise the enzyme under the conditions tested by DSF. 
 
Figure 36 Melt curves of A) GtfA53608 and B) GtfC53608, in the presence of increasing concentration of UDP-GlcNAc. The 
ligand appears to stabilise GtfC53608, but not GtfA53608. 
The specificity of GtfC interaction was further tested against UDP, UDP-Gal, and UDP-Glc. The 
results showed a concentration dependent increase in Tm for all ligands tested (Figure 37). 
However, the interaction with UDP-GlcNAc at concentrations up to 4 mM caused the greater 
increase in Tm compared to the other ligands, suggesting that there is a preference of the 
enzyme towards this sugar nucleotide. At concentrations > 4 mM, UDP caused the greatest 
increase in Tm. As UDP is smaller than the other ligands, it may be able at high concentrations 






Figure 37 Increase in the Tm of GtfC53608 from LrATCC 53608 in the presence of increasing concentrations of different 
ligands. 
DSF was also used to investigate the binding dependency of GtfC53608 activity to metal ions, in 
the presence or absence of UDP-GlcNAc. In the presence of 4 mM UDP-GlcNAc, the Tm of 
GtfC53608 was increased by 3oC (Figure 38B), whereas in the presence of 5 mM of the divalent 
ions (Mg2+, Mn2+, Ca2+), the Tm increased by 2.5oC (Figure 38A). However, when both the sugar 
ligand and the ions were present, the Tm of GtfC53608 increased by 7oC, suggesting that divalent 
ions may be required for optimum binding. The requirement of divalent ions is well established 
in Leloir GTs, and some examples have been recently reported prokaryotic systems. For 
example, the dGT1-mediated glycosylation of Fap1 in S. parasanguinis is enhanced by divalent 
ions (262), whereas, using DSF, a glucosyltransferase from Clostridium difficile showed a 11oC 
increase in Tm, when both the sugar substrate and Mn2+ were present, also suggesting the 
dependency of the GT enzymatic activity on divalent ions (307). However, no divalent ions have 
been identified enzymatically or in the crystal structures of GtfC from other microorganisms so 
far (263). It is worth noting that GtfC53608 does not contain a DxD motif; it does, however contain 
a DxE motif, which could facilitate binding of the divalent ions, as shown for a GT from the S. 

























Figure 38 Melt peaks of GtfC53608 in the presence of A) divalent ions only or B) UDP-GlcNAc and divalent ions. 
4.2.4.7.3. GtfC100-23 is preferentially stabilised by UDP-Glc 
GtfC100-23 is predicted to mediate the second step in SRRP100-23 glycosylation, similarly to GtfC53608. 
To determine the acceptor specificity of GtfC100-23 (cloned and expressed by Prozomix, UK), DSF 
was employed, as described above for GtfC53608. Incubation of GtfC100-23 with UDP-Glc led to an 
increase of the Tm of up to 3oC, whereas as incubation with other ligands had a milder effect, 
when their concentration was < 4 mM, (Figure 39), indicating a stronger interaction between 
the enzyme and UDP-Glc. In contrast, at concentrations > 4 mM, UDP led to the highest increase 
in Tm, as previously observed for GtfC53608. 
 
Figure 39 Increase in the Tm of GtfC100-23 in the presence of increasing concentrations of different UDP ligands. The 
results show a preference for UDP-Glc. 
DSF was also employed to determine the effect of divalent ions in the stability of GtfC100-23. The 
enzyme was incubated with Mg2+, Mn2+, or Ca2+ alone, or in the presence of UDP-Glc and the melt 
peaks showed that the ions had very small effect on the stability of the protein, as determined 





















enzymatic activity of GtfC100-23. Interestingly, the DxE motif identified in GtfC53608, is also 
conserved here, but the effect of ions in the stability of GtfC100-23 is not as strong as for GtfC53608. 
 
Figure 40 Melt peaks of GtfC100-23 in the presence of A) divalent ions or B) UDP-Glc and divalent ions. 
4.3. Summary and discussion 
The presence of glycosylation clusters homologous to those involved in protein glycosylation in 
pathogenic Gram-positive bacteria and L. plantarum WCFS1 in the genome of Lr100-23, LrATCC 
53608 and LrMM4-1a suggests that these strains are capable of performing protein sequential 
O-glycosylation. These include the SecA2/Y2 glycosylation system which is dedicated to the 
glycosylation of SRRPs and a general glycosylation system composed of two putative GTs, Gtf1 
and Gtf2. To assess the ability of L. reuteri strains to carry out protein glycosylation, lectin 
screening of SM proteins from L. reuteri cultures was first used. The interaction of SM proteins 
from Lr100-23, LrATCC 53608 and LrMM4-1a with lectins such as RCA and WGA suggests that 
these strains can modify their proteins with glycans containing GlcNAc and/or Gal. SNA, a sialic 
acid-specific lectin, was also found to bind SM proteins from Lr100-23, LrATCC 53608 and 
LrMM4-1a, however, further investigation with neuraminidase A and HPLC analysis showed that 
this interaction was not carbohydrate mediated. In addition, monosaccharide composition 
analysis of secreted SM proteins revealed the presence of Gal, Glc and GlcNAc in the three L. 
reuteri strains analysed, as well as Xyl and Fuc in SM proteins from Lr100-23 and LrATCC 53608, 
and Rha in Lr100-23. Glc was identified as the strongest peak in all three samples. The high 
abundance of Gal in Lr100-23, LrATCC 53608 and LrMM4-1a is in agreement with the lectin 
screening showing strong interaction of RCA with SM proteins from all three L. reuteri strains. In 




and Xyl was not expected, as no genes involved in the synthesis of GDP-Fuc or UDP-Xyl were 
identified in the bioinformatics analysis. This suggests that there may be un-annotated genes 
involved in the biosynthesis of these sugar nucleotides or that their presence in SM proteins is 
due to a different mechanism, such as a transglycosylation reaction. In addition, no binding was 
observed when UEA was tested against SM proteins from Lr100-23 or LrATCC 53608. This could 
be due to the low concentration of Fuc, which may be below the detection limit of f-UEA. The 
presence of GlcNAc is in agreement with the bioinformatics analysis that revealed enzymes 
involved in the biosynthesis of UDP-GlcNAc in these three L. reuteri strains. The low 
concentration of GlcNAc in Lr100-23 and LrMM4-1a compared to LrATCC 53608 is also in 
agreement with the lectin screening that showed weak or no WGA binding against SM proteins 
from Lr100-23 and LrMM4-1a, respectively. The presence of Rha in Lr100-23 SM proteins is 
consistent with the bioinformatics analysis, that showed the presence of a TDP-Rha biosynthesis 
cluster in this strain.  
To further identify the nature of the putative glycoproteins, immunoblot and MS analysis of 
proteins recognised by lectins was carried out. MUB53608, a high MW and the major adhesin from 
LrATCC 53608 (151,154), and SRRP53608 were identified as putative glycoproteins recognised by 
RCA and WGA, respectively. As there was no antibody against SRRP100-23, lectin blotting analysis 
of Lr100-23 WT and Lr100-23 Δasp2, ΔgtfB or Δsrr mutants was used, demonstrating that 
SRRP100-23 is also glycosylated. Studies on homologous clusters from Streptococci or 
Staphylococci have shown that SRRPs are the target proteins of this cluster (see section 
1.3.3.3.2). Similarly, our analysis of the Lr100-23 ΔgtfB mutant showed that the Gtf is dedicated 
to the glycosylation of SRRP. The secA2/Y2 cluster of Lr100-23 and LrATCC 53608, differs in the 
length of the SRRP encoded from each strain, as well as the number of GTs present (Figure 33A 
and Figure 34A). To determine the transcriptional organisation of the two clusters, RT-PCR was 
performed to amplify the intergenic regions from cDNA. The results showed that the SecA2/Y2 




glycosylation and secretion of SRRP, and a second one containing the target protein SRRP. In 
contrast, the SecA2/Y2 cluster from LrATCC 53608 is organised into a single operon. Studies on 
SecA2/Y2 clusters from Streptococcus salivarius JIM8777 and S. pneumoniae TIGR4 show that the 
transcriptional organisation of this cluster is highly variable between strains (189,305). However, 
it is clear that the core genes encoding the proteins for the secretion system, as well as the 
priming GTs, GtfA and GtfB, are usually organised in the same operon.  
While the Lr100-23 cluster expresses seven GTs, four of which contain two distinct GT folds each, 
the LrATCC53608 one contains only three GTs. Considering that GtfA and GtfB, present in both 
clusters are required for the first glycosylation step with GlcNAc, SRRP53608 is expected to be 
glycosylated with a disaccharide, while glycosylation of SRRP100-23 appears to be more complex. 
In order to get some information on the specificity of GtfC, the enzyme that is predicted to 
mediate the second glycosylation step of SRRP, DSF was employed. The results suggested that 
despite their high sequence similarity, GtfC53608 and GtfC100-23 have different activities: GtfC53608 
showed stronger interaction with UDP-GlcNAc, in the presence of divalent ions, while GtfC100-23 
interacted stronger with UDP-Glc, and the divalent ions tested did not have a significant effect 
on the binding of the enzyme. Taken together, these results suggested that SRRP53608 is 
glycosylated with a di-GlcNAc, while the core disaccharide of SRRP100-23 is likely to be GlcNAc-Glc. 
In addition to MUB53608 and SRRPs, a muramidase, homologous to the glycosylated Acm2 from 
L. plantarum WCFS1 was identified as a putative glycoprotein recognised by RCA in all three L. 
reuteri strains, suggesting that this protein may be glycosylated by a conserved glycosylation 
system.  
To assess the role of Gtf1 in Lr100-23, SM proteins from a Lr100-23 Δgtf1 deletion mutant were 
tested for interaction with RCA or WGA. The results showed a complete loss of RCA recognition 
in the mutant, while the recognition of WGA remained unaffected. This suggests that Gtf1 is also 




decrease in Gal, Glc and GlcNAc in the Lr100-23 Δgtf1 mutant. This suggests that Gtf1 is involved 
in the synthesis of glycans containing these three monosaccharides. The presence of modified 
monosaccharides that were not identified by GC-MS cannot be excluded. The reduction in Gal 
concentration is in agreement with the western blot analysis, showing that the affinity of RCA (a 
Gal-specific lectin) towards Lr100-23 glycoproteins is lost when gtf1 is deleted. Gtf1 has high 
homology with the L. plantarum WCFS1 homologue that is involved in protein glycosylation. In 
L. plantarum WCFS1, the synergistic action of two GTs, Gtf1 and Gtf2, is required for protein 
glycosylation with GlcNAc residues (274), therefore it is likely that the function is conserved in 
L. reuteri 100-23, with Gtf1 transferring GlcNAc residues onto protein targets. Other GTs may be 
responsible for the subsequent attachment of Gal residues. In addition, while Gtf1 was not 
essential for bacterial growth under controlled, laboratory conditions in Lr100-23, it was shown 
to be involved in bacterial aggregation. This suggests that either the glycans found on surface 
glycoproteins act as ligands for surface, lectin-type bacterial adhesins, or that loss of 
glycosylation may lead to impaired secretion of proteins involved in aggregation and/or biofilm 
formation. Attempts to characterise heterologously expressed Gtf1 and Gtf2 from LrATCC 53608 
were not successful, as Gtf1 was found to be insoluble when expressed in E. coli independently, 
while both enzymes were found to be insoluble when co-expressed. Further experiments are 
required to determine the enzymatic activity of these proteins, and confirm their glycosylation 
targets.  
MUB, SRRP and muramidase have been previously shown to mediate the adhesion of 
Lactobacilli to mucin and/or the epithelium of their host (109,144,151,156). Glycosylation of 
these adhesins may suggest a role for the glycans in the adhesion mechanism of L. reuteri strains, 
as reported for pathogenic bacteria (see section 1.4.1.2.4), underscoring the importance of 






Characterisation of the 







In the previous chapter, we identified SRRP100-23, SRRP53608 and MUB53608, the major adhesins of 
L. reuteri 100-23 (Lr100-23) and ATCC 53608 (Lr1ATCC 53608), respectively, as putative 
glycoproteins. 
MUB53608 is a long, multidomain protein of a predicted molecular weight (MW) of 353 kDa. 
However, it migrates at ~500 kDa on SDS-PAGE (154). This aberrant migration is indicative of 
post-translational modifications. In addition, it has been shown to interact with C-Type lectins, 
such as Dectin-2 and DC-SIGN, that are part of the mammalian immune system (175). Both 
Dectin-2 and DC-SIGN recognise mannose-containing glycans (308), while DC-SIGN can also 
recognise fucose (309,310), suggesting that MUB53608 is glycosylated. 
SRRPs are the target proteins of the SecA2/Y2 glycosylation and secretion system see section 
1.3.3.3.2). Often, more than one SRRPs are found in each cluster, however, in most cases, only 
one srr gene is considered to be functional, while the other ones are annotated as pseudo-genes. 
While this cluster is well studied in pathogenic strains of streptococci and staphylococci, little is 
known about its role in the physiology of commensal bacteria. SRRPs are long surface proteins 
composed of an unusually long N-terminal signal peptide (~90 aa), followed by a short alanine-
serine-threonine (AST) domain, a first serine rich repeat region (SRR-1), the binding region (or 
basic region; BR), a second, longer serine rich repeat region (SRR-2) and lastly an LPXTG 
anchoring motif. Many differences can be observed between SRRPs of different origins, as well 
as within the same organism. These differences are mostly located in the number and 
composition of the serine rich repeats in SRRP-1 and SRRP-2, as well as the composition of the 
BR region. For instance, SRRP100-23 has 101 10-amino acid long serine-rich repeats, whereas 
SRRP53608 only contains 22 (Figure 41) (159). In addition, the BR regions of the two SRRPs only 





Figure 41 Schematic representation of SRRP from Lr100-23 and LrATCC 53608. 
These adhesins are both predicted to be surface anchored by an LPXTG anchoring motif. Sortase 
A, the surface-bound enzyme responsible for the anchoring of the proteins onto the surface, 
cleaves the peptide bond between Thr and Gly in the LPXTG motif and forms a peptide bond 
between the Thr and the N-terminal Gly in the Gly5 motif found in the cell wall (Figure 42). 
 
Figure 42 Anchoring of surface proteins via the LPXTG anchoring motif. The arrow points at the peptide bond formed 
between Thr and Gly. The Gly5 motif is underlined. Adapted from (174). 
The aim of this work is to characterise the glycans found on L. reuteri adhesins identified as 





5.2. Results and discussion 
5.2.1. Characterisation of SRRP100-23 glycosylation pattern 
5.2.1.1. Purification of SRRP100-23 
To determine the nature of the glycans present on SRRP100-23, the adhesin was purified from L. 
reuteri culture. Briefly, L. reuteri 100-23 was grown in LDM-II, supplemented with maltose, for 
18 h. After concentration and dialysis of the SM, SRRP100-23 was purified by affinity 
chromatography, using an agarose-bound WGA column, taking advantage of the lectin 
recognition results described in section 4.2.3. After washing of the column, bound proteins were 
eluted with 0.5 M GlcNAc. The collected fractions were analysed by SDS-PAGE (Figure 43). The 
major purified protein migrated at a MW >300 kDa. MS analysis of the gel revealed that SRRP100-
23 was the fifth most strongly identified protein, with a score of 472 and coverage of 8%. Other 
surface proteins, including Lsp (Large Surface Protein, Accession no. 2500070581, score: 1225, 
coverage: 22%) were also identified. However, the score for SRRP100-23 is underestimated, as the 
serine-rich repeat regions (accounting for ~65% of the total protein) contain no trypsin digestion 
sites, preventing their identification by MS due to the size of the resulting peptides.  
These results suggest that either the identified surface proteins are also glycosylated with 
GlcNAc residues, but the abundance of the glycans is below the detection limit of WGA on a 
western blot, or that these surface proteins interact with SRRP, leading to co-purification by 
WGA-affinity chromatography. A smaller protein at 130 kDa was also co-purified in much lower 
yield. This was expected from earlier results showing that WGA recognised a protein band of 
this size after western blot analysis of the secreted proteins from Lr100-23 (see section 4.2.1). 
MS analysis identified this protein as an LPXTG- anchored peptidase (accession no. 2500070874, 
score: 1088, coverage: 40%) of a predicted MW of 100 kDa, suggesting that this may also be a 
putative glycosylation target. The elution fractions containing SRRP100-23 were pooled and 




chromatography supported the results showing that WGA interacts with SRRP100-23 in a glycan-
mediated interaction. 
 
Figure 43 Purification of SRRP100-23 by WGA affinity chromatography. Lane 1) starting material, Lanes 2-4) wash 
fractions, Lanes A-C) elution fractions. 
5.2.1.2. SRRP100-23 is glycosylated with HexNAc1Hex2 moieties 
Previous studies on SRRPs from pathogenic organisms have shown that these proteins are O-
glycosylated on serine residues (191,269). To identify the glycans present on SRRP100-23, the 
purified protein was subjected to β-elimination, and the released glycans were permethylated 
and analysed by MALDI-ToF. The spectra showed a characteristic peak at 738 Da, that 
corresponds to HexNAc1Hex2, and fragmentation of this ion species suggests it is a linear glycan 
structure (Figure 44). As the MS analysis of the purified SRRP100-23 identified multiple large 
surface proteins in the sample, it is possible that this glycan structure was also present in these 
proteins. To confirm that this is an SRRP100-23-specific glycan, the same glycomics analysis was 
performed on SM proteins from Lr100-23 WT and Lr100-23 ΔgtfB mutant, shown to have lost 
the WGA affinity to SRRP100-23. The results showed that the peak at 738 Da was missing in the 
mutant sample, while the rest of the spectra was identical (data not shown). Taken together, 





Figure 44 A: MS spectrum of the released and permethylated O-glycans from SRRP100-23. B) Fragmentation spectrum 
of the peak at 738 Da. The data suggest the presence of HexNAc1Hex2 moieties on SRRP100-23. 
5.2.1.3. Monosaccharide composition analysis of SRRP100-23 
To determine the nature of the monosaccharides constituting SRRP100-23 glycosylation, sugar 
analysis was performed on purified proteins by GC-MC, after methanolysis, N-acetylation and 
TMS-derivatisation of the released methyl-glycosides. The results showed mainly the presence 
of Glc, as well as smaller amounts of Gal, GlcNAc and Rha (Figure 45). Based on the MALDI-ToF 
analysis, it was expected that Hex and HexNAc would be found in a 2:1 ratio. However, the total 
amount of Hex molecules is more than 100 times higher than GlcNAc. This could suggest the 
glycosylation of SRRP100-23 with single Glc or Gal residues, which are not retained by the 
graphitised carbon cartridges used for desalting the samples during preparation and therefore 




In addition, no deoxy-hexose was identified in the MALDI-ToF analysis, so the presence of Rha 
was not expected. It may be that only a small fraction of the glycans carries a Rha residue, which 
will be below the detection limits of MALDI-ToF, under the conditions tested.  
 
Figure 45 Extracted chromatogram of ions 173.1 and 204.1 (main ions produced upon fragmentation of HexNAc and 
Hex, respectively) after GC-MS analysis of the monosaccharides found on SRRP100-23. The results show the excess of 
Glc, and the presence of Gal, GlcNAc and Rha. 
5.2.2. Characterisation of SRRP53608 glycosylation pattern 
5.2.2.1. Purification of SRRP53608 and MUB53608 
In the previous chapter, we identified MUB53608 and SRRP53608 as putative glycoproteins in L. 
reuteri ATCC 53608. These are high molecular weight proteins, both migrating at >300 kDa on 
SDS-PAGE. MUB53608 generally shows higher expression levels in MRS, whereas SRRP53608 
production is enhanced in LDM-II growth medium. However, as MRS is a semi-defined medium 
containing yeast derived glycans, LDM-II was chosen for bacterial growth and purification of 
both proteins. MUB53608, in addition to other glycoproteins from L. reuteri ATCC 53608 was found 
to interact with RCA, whereas WGA was found to specifically bind SRRP53608. To purify the two 
adhesins, L. reuteri was grown for 24 h in LDM-II media and proteins were precipitated in 
ammonium sulphate. After resuspension, proteins were extracted in a triple phase partitioning 
system using tert-butanol and an increasing concentration of ammonium sulphate. After three 
cycles of extraction, the proteins were analysed by SDS-PAGE. MUB53608 and SRRP53608 were both 
found in the second fraction (Figure 46A), which was then further separated by gel filtration (see 




respectively, MUB53608 and SRRP53608 both co-eluted in the void volume of the column 
(approximately 2 MDa) (Figure 46B). This may be due to their extended protein fold, which will 
increase their hydrodynamic volume in solution (311). The two proteins were separated by 
affinity chromatography, using an agarose-bound WGA column. MUB53608 was recovered from 
the flow-through and wash fractions, whereas SRRP53608 was retained on the column and eluted 
with high concentration of GlcNAc, the cognitive sugar for WGA, therefore confirming the ability 
of SRRP53608 to interact with WGA in a glycan-mediated manner. Slot blot analysis of the wash 
and elution fractions showed that the two glycoproteins could be successfully separated (Figure 
46C), as differentially recognised by f-WGA or f-RCA. The identity of the two proteins was further 
confirmed by anti-SRRP56308 and anti-MUB53608 antibodies, as well as mass spectrometry (MS) 
(data not shown). 
 
Figure 46 Purification of MUB53608 and SRRP53608 from LrATCC 53608 bacterial culture SM. A) SDS-PAGE analysis of 
protein extracts collected after three rounds of triple phase partitioning (TPP) (I-III). B) Gel filtration chromatogram 
of the protein separation from fraction II. C) SDS-PAGE of fractions collected after separation of fraction II from the 





5.2.2.2. SRRP53608 is glycosylated with di-HexNAc moieties 
To identify the glycans present in SRRP53608, purified SRRP53608 was subjected to reductive β-
elimination. The chemically released glycans were then permethylated and analysed by Matrix 
Assisted Laser Desorption/Ionisation Time of Flight Mass Spectrometry (MALDI-ToF). The 
analysis revealed a single peak at 575 Da, which corresponds to the mass of a reduced, 
permethylated sodiated di-N-acetylhexosamine (HexNAc) (Figure 47A). Further fragmentation 
of this species confirmed the nature of the glycan, as it produced two main peaks at 282 and 
316 Da, corresponding to a non-reducing and a reducing terminal HexNAc (Figure 47B).  
 
Figure 47 A) MS spectrum of the released and permethylated O-glycans from SRRP53608. B) Fragmentation spectrum 
of the main peak at 575 Da. The data suggest the presence of diHexNAc moieties on SRRP53608. 
5.2.2.3. The SRRP53608 glycans are comprised of GlcNAc molecules 
The bioinformatics analysis, as well as the monosaccharide composition analysis of the 
LrATCC53608 SM proteins, and the interaction of WGA with SRRP53608, all suggest that the di-




nature of the glycan residues, the carbohydrate content of purified SRRPP53608 was further 
analysed by GC-MS. After methanolysis of SRRP53608, the released sugars were re-N-acetylated 
and derivatised with trimethylsilane (TMS). The GC-MS chromatogram showed a single HexNAc 
peak with a retention time (~29 min) corresponding to that of GlcNAc (Figure 48). Glucose was 
also detected (data not shown), but as no hexose was identified in the MALDI-ToF analysis, this 
was attributed to contamination. The GC-MS results supported the previous bioinformatics and 
monosaccharide composition analyses that identified no HexNAc other than GlcNAc (see section 
4.2.2). In addition, this result suggests that GtfC from L. reuteri ATCC 53608 is distinct from GtfCs 
characterised from other organisms, as in all cases studied so far, GtfC was shown to use UDP-
Glc as the sugar donor for the second glycosylation step of SRRPs (see section 1.4.1.2.4). 
 
Figure 48 GC-MS analysis of SRRP53608 monosaccharides. MS trace of monosaccharide-characteristic ions at 173 and 
204 Da. 
5.2.2.4. The GlcNAc moieties of SRRP53608 are α-linked 
In homologous glycosylation clusters, GtfC was shown to belong to the GT family 4, which 
contains GTs with a retaining mechanism (www.cazy.org) (306), therefore generating α-
glycosidic bonds (Figure 14).  
To determine the conformation of the GlcNAc residue in SRRP53608, purified SRRP53608 was 
treated with enzymes specific for α- or β-linkages, i.e. a commercially available, β-N-acetyl-




thetaiotaomicron, produced in-house. Briefly, an overexpression vector containing the GH89 
gene fused to a His6 tag sequence, was transformed into E. coli BL21 (DE3). After induction of 
the gene expression in Auto Induction Media, soluble recombinant α-GlcNAcase was obtained 
and purified by IMAC (Figure 49).  
 
Figure 49 Purification of GH89 α-GlcNAcase by IMAC. 1) starting material, 2) flow-through, 3) wash fraction 1, 4) wash 
fraction 2, 5) elution fraction 1, 6) elution fraction 2. 
The specific activity of the IMAC-purified enzyme was assessed using οNP-α-GlcNAC and found 
to be ~350 U/ml of purified protein (one unit of enzyme hydrolyses 1.0 nmole of o-nitrophenyl-
α-D-GlcNAc to o-nitrophenol and D-GlcNAc in 1 h, at pH 6.5 and 37°C). 
The reaction products of the enzymatically treated SRRP53608 were analysed by western blot, 
probed with f-WGA or anti-SRRP53608 antibodies. When SRRP53608 was treated with α-GlcNAcase 
at 25oC, 37oC or 42oC, deglycosylation products were observed (Figure 50A), suggesting that the 
GlcNAc moieties found on SRRP53608 are α-linked. The deglycosylation products were recognised 
by the anti-SRRP53608 antibodies, but not by f-WGA, suggesting that they are fully deglycosylated. 
Treatment with an excess of β-N-acetyl-hexosaminidasef under the same conditions did not 
produce any deglycosylated products (Figure 50B) whereas treatment with both enzymes 





Figure 50 Enzymatic deglycosylation of SRRP53608 using α-GlcNAcase, β-N-acetyl-hexosaminidasef or both. Top set: 
Western blot analysis of enzymatic deglycosylation products using anti-SRRP53608 antibody. Bottom set: Western blot 
analysis of enzymatic deglycosylation products using f-WGA. A,I) Treatment with α-GlcNAcase, Β,ΙΙ) Treatment with 
β-N-acetyl-hexosaminidasef. C,III) Treatment with both enzymes. 1) α-GlcNAcase control, 2) SRRP53608 control, 3) 
reaction performed at 25oC,4) reaction performed at 37oC, 5) reaction performed at 42oC. The results show 
deglycosylation products when SRRP53608 is treated with α-GlcNAcase. Fully glycosylated SRRP53608 is still present after 
enzymatic deglycosylation. 
However, the α-GlcNAcase treated protein migrated at ~220 kDa, therefore higher than the fully 
deglycosylated SRRP53608 which has a predicted MW 116 kDa, based on amino acid composition. 
This could be due to the presence of sugars that are not recognised by WGA, or cleaved by the 
N-acetyl-glucosaminidases used in this assay. For instance, it was recently shown in S. gordonii 
M99 that Asp2 could modify GlcNAc residues on SRRP with an additional O-acetyl group (O-
AcGlcNAC) and that the modified sugar could not be identified by WGA (204). The use of similar 
monosaccharides has been reported in S. agalactiae H36b and S. salivarius JIM8777 (189,269). 
As the catalytic residues are conserved in Asp2 from L. reuteri ATCC 53608 (Figure 51), it is 
possible that SRRP53608 also carries O-AcGlcNAc residues, which could account for the aberrant 
mobility of the deglycosylated protein on SDS-PAGE. However, this modification is lost under 
the conditions used for glycomics or sugar composition analysis, so O-AcGlcNAc it is not 





Figure 51 Alignment of the Asp2 sequence from L. reuteri and Streptococcus sp. flanking the catalytic residues 
(highlighted in green). 
In addition, despite the detection of deglycosylation products, f-WGA was still found to bind to 
protein bands corresponding to native SRRP53608 (Figure 50 I, III). The lack of complete 
deglycosylation with α-GlcNAcase may be due to the substrate specificity of the enzyme, which 
may not be optimum for this epitope, or to high levels of glycosylation, providing little 
accessibility to the enzyme.  
GlcNAc is one of the constituents of the bacteria cell wall, and WGA is often used to label Gram-
positive bacteria. In order to exclude the possibility that WGA recognises cell wall debris that 
could be attached to the C-terminus of SRRP53608, the adhesin was treated with lysostaphin, a 
peptidase that targets the Gly5 anchor motif (see Figure 42) between the cell wall and the surface 
proteins (174). Treatment with lysostaphin alone did not alter the mobility of SRRP53608 in SDS-
PAGE (Figure 52A). In addition, lysostaphin treatment did not change the recognition of 
SRRP53608 by f-WGA (Figure 52B), suggesting that the interaction is mediated by the SRRP53608 
glycans and not by cell wall debris. This is also supported by the fact that WGA binding is specific 
to SRRP53608 and does not recognise other predicted cell surface anchored proteins from LrATCC 






Figure 52 A) SDS-PAGE analysis of SRRP53608 (1) following treatment with lysostaphin (2), α-GlcNAcase (3) or both (4). 
B) Western blot analysis of the same reactions, using f-WGA. The results show deglycosylation products when 
SRRP53608 is treated with α-GlcNAcase, but no effect with lysostaphin. 
5.2.2.5. SRRP53608 is resistant to proteolysis by GluC 
Having identified that SRRP53608 is glycosylated, we were interested in identifying the 
glycosylation sites, using liquid chromatography-mass spectrometry (LC-MS) after proteolytic 
digestion. In most proteomics studies, trypsin is used as the protease of choice, as it generally 
generates peptides long enough to provide information for sequencing and characterisation of 
the proteins and their modifications. However, in silico digest of SRRP53608 with trypsin showed 
that the reaction generates large peptides, up to 71 kDa, as there are no lysine residues within 
the SRRP regions. In contrast, each repeat terminates with a glutamic acid, which would make it 
a preferential substrate for the endoproteinase GluC (312). However, upon treatment of a 
SRRP53608 with GluC in solution, the analysis of the reaction products by western blotting, using 
f-WGA and anti-SRRP53608 antibodies showed that the adhesin remained intact, showing 
increased resistance to proteolysis. In contrast, treatment of a truncated MUB53608 from L. reuteri 
1063N (tMUB1063N) under the same conditions led to completely digestion (Figure 53). This 
prevented further characterisation of SRRP53608 glycosylation sites. Glycans have been widely 





Figure 53 Western blot analysis of purified SRRP digested with GluC, using A) f-WGA, or B) anti-SRRP53608 antibodies. 
C) Western blot analysis of purified tMUB1063N digested with GluC, using f-GSL-1 B4. 
5.2.3. Characterisation of MUB53608 glycosylation pattern 
5.2.3.1. The interaction of MUB53608 with RCA is glycan mediated  
MUB53608 was previously shown to interact with RCA, a galactose specific lectin. To confirm that 
the interaction between RCA and MUB53608 is glycan-mediated, SM proteins from LrATCC 53608 
culture were loaded onto an RCA affinity column. After washing of the unbound proteins, lactose 
was used to elute proteins that interacted with RCA. All unbound proteins eluted in the first two 
wash fractions. MUB53608 was identified by immunoblot and MS analysis in all fractions (wash 
and elution) collected (data not shown), but was found to be the predominant protein in the 
elution fractions, as determined by SDS-PAGE (Figure 54). The fact that MUB53608 was retained 
by RCA and eluted by lactose suggests that the interaction between the two proteins is glycan-
mediated. MUB53608 found in the flow-through and wash fraction was also recognised by RCA 
(data not shown).  The presence of MUB53608 in the wash fractions therefore may be due to a 
saturation of the RCA column, or to insufficient time allowed for the interaction between the 
two proteins. These parameters would need to be optimised to increase the separation 





Figure 54 SDS-PAGE analysis of fractions collected after RCA affinity chromatography of LrATCC 53608 SM proteins. 
Most proteins are eluted in the flow-through and wash fractions, while MUB53608 is retained and eluted after addition 
of lactose.  
Force spectroscopy was also used to directly measure the interaction of RCA with MUB53608. The 
analysis showed interactions between MUB53608 and RCA between 150 and 250 pN. When 
galactose was added as a competitive ligand, the frequency of adhesion events was decreased. 
This is in agreement with the affinity chromatography results with RCA that showed glycan 





Figure 55 A) Force maps, B) Frequency histograms and C) graphic representation of the interaction between MUB53608 
and RCA, as measured by force spectroscopy. The results show reduced interaction upon the presence of lactose as 
a competing sugar. 
5.2.3.2. MUB53608 carries a terminal α-galactose moiety 
The interaction of MUB53608 with RCA suggests that the adhesin is glycosylated with Gal moieties. 
To identify the conformation of this sugar, purified MUB53608 was treated with α-, or β-
galactosidase, exoglycosidases specific for Gal residues with the specified conformation. The 
reaction products were then analysed by western blot, using f-RCA. RCA binding was abolished 
when MUB53608 was treated with α-, but not β-galactosidase (Figure 56), suggesting the presence 





Figure 56 A) SDS-PAGE analysis or B) western blot analysis of purified MUB53608 using f-RCA, after treatment with α- 
or β- galactosidase,  
However, as RCA has only been reported to bind β-Gal moieties, equal amounts of MUB53608 was 
also probed with other galactose-specific lectins, such as Griffonia simplicifolia Lectin I isolectin 
B4 (GSL-I B4), Maackia amurensis lectin I (MAL I) and Maclura pomifera lectin (MPL) (Table 20). 
Table 20 Gal-specific, FITC-labelled plant lectins used to probe MUB53608, after western blot analysis. 
Lectin Abbreviation Specificity Fluorescein/ 
protein ratio 
Ricinus communis agglutinn RCA  Gal or GalNAc 6:1 
Griffonia simplicifolia Lectin I 
isolectin B4 
GSL-I B4 α-Gal 2.5:1 
Maackia amurensis lectin I MAL I Galβ-1,4-GlcNAc 8.9:1 
Maclura pomifera lectin MPL Galβ-1,3-GalNAc 3.9:1 
In addition to RCA, only the α-Gal specific lectin GSL-I B4 was found to bind MUB53608, whereas 
no binding was observed with the β-Gal specific MAL I and MPL (Figure 57). Probing with GSL-I 
B4 gave a stronger intensity, despite a lower fluorescein/protein ratio compared to RCA, 
suggesting a stronger interaction.  
Together, these data suggest that MUB53608 carries terminal α-Gal moieties. α-Galactose is the 
terminal sugar found on the “α-Gal epitope” (Galα-1,3-Galβ-1,4-GlcNAc), a widely expressed 
epitope in mammals that has also been found in bacteria and parasites and is highly 
immunogenic in humans (313). However, MUB53608 was not recognised by an anti-α-Gal 
antibody, raised against the mammalian “α-Gal epitope” (data not shown), suggesting that the 




treatment abolishes the binding of RCA to MUB53608. If the Galα-1,3-Galβ-1,4-GlcNAc epitope 
was present, treatment of α-galactosidase would have exposed a β-linked Gal, leading to greater 
interaction between MUB53608 and RCA.  
 
Figure 57 Western blot analysis of purified MUB53608 using fluorescein labelled lectins specific for galactose. 
5.2.3.3. MUB53608 interacts with human intelectin-1 (h-Int1) 
Human intelectin 1 (h-Int1) is a calcium dependent, X-type lectin  that recognises carbohydrates 
carrying terminal 1,2-diol groups (314). As LrATCC 53608 harbours genes that are necessary for 
the synthesis of UDP- Galf, a known ligand of h-Int1, and MUB53608 was shown to contain Gal 
residues, hInt-1 was tested for its ability to bind MUB53608, by force spectroscopy or slot blot. In 
the presence of Ca2+ ions, hInt-1 produced multiple adhesion events which were reduced upon 
addition of EGTA, as shown in the force maps (Figure 58A). In particular, interaction of hInt-1 
with MUB53608 resulted in adhesion events ranging from 100 to 500 pN (Figure 58B and C, green 
line). When EGTA was added to the mixture, the frequency of the adhesion events decreased 
(Figure 58B and C, purple line), but did not go down to baseline levels (Figure 58A, red-blue). 
These results suggest that binding of h-Int1 to MUB53608 is mainly mediated by glycans found on 
MUB53608, but that there is also protein-protein interaction, although to a lesser degree. Slot blot 
analysis also showed binding of MUB53608 to h-Int1 in the presence of Ca2+ or EGTA, with stronger 





Figure 58 A) Force maps of the interaction of hInt-1 with MUB53608, in PBS with CaCl2 or EGTA. B) Force histograms. C) 
Force spectroscopy curves, showing the interaction of MUB53608 with h-Int1 in the presence of Ca2+. When EGTA is 
added, the frequency and force of the adhesion events dropped. D) Slot blot analysis of the interaction of h-Int1 with 
MUB53608. In presence of Ca2+ the interaction is strong, while addition of EGTA reduced the amount of lectin that binds 
onto the protein.  
5.2.3.4. Glycomics analysis of MUB53608 
To structurally characterise the glycans found on MUB53608, these were chemically released by 
β-elimination and analysed by MALDI-ToF, after permethylation. The generated MS spectra 
were not reproducible between experiments, and fragmentation of the major peaks did not 
yield ions or fragmentation patterns characteristic to glycans making it difficult to identify 
potential glycan structures. A peak at 534 Da, corresponding to a HexNAc1Hex1 structure, was 




confirm the annotation. In addition, the peak at 534 Da was often masked by a dominant ion at 
531 Da, making it difficult to conclusively identify the ion at 534 Da as a glycan. It is possible that 
the linkages formed between the glycan and MUB53608 are different to those formed during O-
glycosylation, making the chemical release and subsequent analyses not a suitable approach to 
determine the glycosylation of MUB53608. However, if MUB53608 is a glycosylation target of the 
Gtf1/Gtf2 glycosylation system, as suggested in section 4.2.4.4, it is more likely that glycans are 
attached to the adhesin with an O-linked GlcNAc. 
 
Figure 59 Example of MS spectrum obtained from the analysis of MUB53608 glycans after chemical release and 
permethylation. 
To identify the monosaccharides present in MUB53608 glycans, these were analysed by GC-MS, as 
described for the SRRPs. The analysis showed that the MUB53608 fraction contains Gal, Glc, 
GlcNAc and traces of Xyl and Fuc (Figure 60). The presence of Gal is in agreement with the lectin 
assays that showed recognition of MUB53608 by RCA, whereas Xyl, Gal, Glc and GlcNAc had been 
earlier identified in the analysis of proteins from the spent media of LrATCC 53608 cultures. 
Therefore, MUB53608 is likely to be glycosylated with glycans containing GlcNAc, Glc and Gal, 
while Xyl and Fuc may also be present in smaller amounts, or due to insufficient purification of 





Figure 60 Extracted chromatogram of ions 173.1 and 204.1 (main ions produced upon fragmentation of HexNAc and 
Hex, respectively) after GC-MS analysis of the monosaccharides found on MUB53608. The results show the presence of 
Fuc, Xyl, Glc, Gal, and GlcNAc. 
5.3. Summary and discussion 
Microbial appendages like flagella and pili are used by bacteria to adhere onto host tissue. These 
structures have been shown to be glycosylated in most cases, however, these are absent in L. 
reuteri, an important member of the gut microbiota. Instead, L. reuteri species produces long, 
fibre-like adhesins, to mediate binding onto the host's surface. L. reuteri ATCC 53608 has been 
shown to produce a long multidomain mucus binding protein, MUB53608 (154,156), in addition to 
a serine rich repeat protein, SRRP53608 (159), that belongs to a class of adhesins often found in 
Gram-positive bacteria (176). SRRP100-23 was also identified in L. reuteri 100-23, where it was 
shown to be involved in biofilm formation and required for successful colonisation in mice (109). 
In this work, we identified MUB53608, SRRP53608 and SRRP100-23 as the main glycoproteins in LrATCC 
53608 and Lr100-23 strains. Here, we aimed to characterise the glycans found on these adhesins. 
Our glycomics analysis of the purified SRRPs suggested that SRRP53608 is glycosylated with di- 
HexNAc moieties, while SRRP100-23 is glycosylated with linear Hex2HexNAc1 glycans. 
Monosaccharide composition analysis of SRRP53608 identified GlcNAc as the sole HexNAc. This 
confirmed the hypothesis that SRRP53608 is glycosylated with di-GlcNAc residues and is in 
agreement with the DSF analysis of GtfC53608, the enzyme that mediates the second step in SRRP 
glycosylation. This is unlike any other studied SRRPs, as in most cases the second 




with an α-N-acetyl-glucosaminidase resulted in the formation of deglycosylated products, 
suggesting that the GlcNAc residues are α-linked. Although the exact linkage is unknown, the 
GlcNacα-GlcNac epitope has been previously identified in the O-antigen of E. coli O101 (315) and 
Shigella dysenteriae type 4 (316) and a surface polysaccharide of Acinetobacter baumannii O16 
(317). This epitope has also been reported in structures deposited in the GlyTouCan glycan 
repository (318), although no information on their origin is available. 
Taken together, the results from the monosaccharide composition and western blot analysis of 
SRRP100-23, and the DSF analysis of GtfC100-23 suggest that the glycan present on SRRP100-23 is Glc-
Glc-GlcNAc. Based on the DSF assay with GtfC100-23, that showed greater interaction of the 
enzyme with UDP-Glc, than with UDP-Gal, as well as monosaccharide composition analysis of 
SM proteins from Lr100-23 showing Gal and Glc as the only hexoses present, and lectin affinity 
assays that show no interaction between SRRP100-23 and RCA. Such trisaccharide structure is also 
found in the reducing end of the SRRP glycans from S. parasanguinis FW213 (191)). It is worth 
noting that the nature of this trisaccharide contradicts the recognition of SRRP2100-23 by WGA. It 
is possible that glycosylation is not always complete, and that WGA binds to GlcNAc residues that 
have not been further extended by GtfC. Further studies with a combination of glucosidases and 
N-acetyl-glucosaminidases are therefore needed to confirm the exact nature and structure of 
these glycans. In addition, the identification of a trisaccharide for SRRP100-23 was surprising, as 
the GT content of the SecA2/Y2 cluster in Lr100-23 strain suggested a more complex glycan. This 
may be due to inactive enzymes, but further studies are required to analyse the role of the 
additional GTs present in the secA2/Y2 cluster. 
Purified MUB53608 was found to interact with RCA, a Gal specific lectin, similarly to other secreted 
proteins from LrATCC 53608, suggesting it may be a target protein of a general glycosylation 
system. This interaction was shown to be glycan-mediated by force spectroscopy and RCA affinity 




of the glycan, MUB53608 was treated with galactosidases, and western blot analysis of the 
products using lectins revealed that the Gal residues were α-linked. Terminal α-Gal is part of a 
highly immunogenic epitope in humans, that is abundant in other mammalian tissues (319). In 
addition, h-Int1 was found to recognise MUB53608. h-Int1 is a Ca2+-dependent secreted lectin, 
expressed in intestinal goblet and Paneth cells (320), able to distinguish microbial from host cells, 
as it recognises carbohydrates not naturally found in mammals (314). Apart from Gal, sugar 
analysis of MUB53608 revealed the presence of Glc, GlcNAc, Xyl and Fuc. However, glycomics 
analysis of MUB53608 failed to characterise the glycans present. This could be due to the presence 
of a linkage that is not cleaved chemically by β-elimination, the method of choice for chemical 
deglycosylation of proteins, or the presence of further modified glycans that may interfere with 
the analysis of the data. 
Table 21 summarises the glycans identified in SRRP100-23, SRRP53608 and MUB53608. 
Table 21 Summary of the identified glycosylated adhesins and their glycans 
Strain Adhesin Glycan identified Putative pathway 
Lr100-23 SRRP100-23 Glc-Glc-GlcNAc SecA2/Y2 
LrATCC 53608 SRRP53608 GlcNAcα-GlcNAc SecA2/Y2 
LrATCC 53608 MUB53608 N.D. 














To date, the role of protein glycosylation in bacteria has been extensively studied in pathogens, 
underscoring the importance of glycans in colonisation, virulence and survival of bacterial 
pathogens (250,321,322). However, knowledge on protein glycosylation in commensal bacteria 
is still at its infancy. Here we used L. reuteri as a model organism to gain insights into the protein 
glycosylation pathways of gut commensal probiotic strains. L. reuteri is a widespread gut 
symbiont found in many vertebrate hosts and one of the first to colonise the human GI tract 
(323). As such, it plays a pivotal role in the host’s health and physiology. Many studies have used 
L. reuteri strains as probiotics in humans, mice and pigs, demonstrating their beneficial effects 
in the health and well-being of individuals (see section 1.2). Adhesion of the bacteria to the 
host’s tissue is considered a key step in colonisation. This adhesion is often mediated by 
adhesins, which specifically bind to components of the host’s surface. The aim of this project 
was to identify putative glycoproteins expressed by L. reuteri 100-23 (rat isolate), ATCC 53608 
(pig isolate) and MM4-1a (human isolate) and to characterise the nature of the glycans present 
on these proteins.  
To that end, a variety of approaches were employed. First, a bioinformatics analysis was carried 
out to identify putative enzymes involved in the synthesis of sugar nucleotides, the building 
blocks of glycans, as well as putative glycosylation pathways in L. reuteri strains. Following this 
in silico analysis, lectin affinity screening combined with mass spectrometry was used to identify 
putative glycoproteins secreted by L. reuteri strains. This included the analysis of deletion or 
insertion L. reuteri mutants of putative glycosyltransferases (GTs) or genes encoding proteins 
with a putative role in protein glycosylation. Following the identification of putative 
glycoproteins, the adhesins were purified and the glycans were determined by analytical 
techniques such as gas chromatography - mass spectrometry (GC-MS) or matrix assisted laser 
desorption/ionisation - time of flight mass spectrometry (MALDI-ToF), force spectroscopy and 




The bioinformatics analysis suggested the ability of Lr100-23, LrATCC 53608 LrMM4-1a to utilise 
a very limited number of carbohydrates, mainly simple sugars, as carbon source. Differences 
were observed in between these L. reuteri strains in their ability and efficiency to utilise certain 
monosaccharides, which may be the result of co-evolution between the host and the bacteria, 
reflecting a difference in the diet of the respective host. It is also worth noting that no enzymes 
involved in the utilisation of host glycans were identified, suggesting that L. reuteri is dependent 
on dietary  carbohydrates, in agreement with studies showing that this species has evolved and 
diversified from free-living ancestors (104). 
The bioinformatics analyses also suggested that using these simple sugars, L. reuteri had the 
potential to produce a number of activated sugars (i.e. sugar nucleotides) that could be involved 
in cell wall and exopolysaccharide (EPS) synthesis, or protein glycosylation. While the 
biosynthetic pathways of sugar nucleotides were conserved among Lr100-23, LrATCC 53608 and 
LrMM4-1a strains, Lr100-23 was also found to harbour genes responsible for the expression of 
enzymes involved in TDP-rhamnose (Rha), which the other strains lacked. However, further 
analysis is required to provide biochemical evidence on the range of sugar nucleotides used by 
these L. reuteri strains.  
In addition, the analysis of the Lr100-23, LrATCC 53608 and LrMM4-1a genomes revealed the 
presence of five putative glycosylation pathways. Four of them were conserved across the three 
L. reuteri strains, including an EPS glycosylation cluster and a two-glycosyltransferase (GT) 
cluster (gtf1/gtf2) that could be involved in protein glycosylation, based on its homology with a 
general glycosylation system found in L. plantarum WCFS1 (274). The fifth glycosylation cluster 
was identified as the SecA2/Y2 gene cluster which is conserved in Lr100-23 and LrATCC53608, but 
absent from LrMM4-1a. Such clusters have been shown to be dedicated to the expression of 
proteins involved in the glycosylation and secretion of serine-rich repeat proteins (SRRPs) in 




pathogenic bacteria, but which have recently been identified in commensal species (109,176). 
The SecA2/Y2 clusters in Lr100-23 and LrATCC 53608 differ by the number of GT-encoding genes, 
as well as the localisation of the srr gene (encodes the SRRP) within the cluster, which may 
suggest that the two clusters were acquired independently, or that the cluster was acquired by 
a common ancestor and diversified during evolution events (159). The different number of GTs 
also suggests a diverse SRRP glycosylation pattern between Lr100-23 and LrATCC 53608 SRRPs. 
To test the hypothesis that the products of the gtf1/gtf2 and of the secA2/Y2 clusters were 
involved in protein glycosylation, a deletion mutant of gtf1 and insertion mutants of gtfB, asp2 
and srr (genes found in the secA2/Y2 cluster encoding a GT, an accessory secretion protein and 
SRRP, respectively) were generated in Lr100-23 and analysed for their ability to perform protein 
glycosylation. Western blot analysis of the proteins found in the spent media (SM) after growth 
of Lr100-23 WT and the mutants using  lectins suggested that these genes are involved in protein 
glycosylation. In particular, deletion of gtf1 resulted in loss of RCA recognition (a galactose-
mediated interaction) to several SM proteins, supporting the hypothesis that Gtf1 is involved in 
protein glycosylation. In addition, it suggested that glycans synthesised by this glycosylation 
system contain a terminal Gal residues. This is in contrast to the reported role of Gtf1 from L. 
plantarum WCFS1, where its target proteins are recognised by WGA (a GlcNAc specific lectin) 
(274). In addition, protein glycosylation mediated by Gtf1 in Lr100-23 appears to affect 
aggregation of the cells with the WT strain showing higher aggregation capability than the Lr100-
23 Δgtf1 deletion mutant. While further experiments are required to elucidate the cause of this 
phenotype, it may be that the glycans normally found on the secreted glycoproteins are involved 
in cell-cell interactions and bacterial aggregation, or that the lack of glycosylation leads to 
impaired secretion or attachment to the cell-surface of components required for aggregation. It 
has been previously shown that protein glycosylation is important in bacterial aggregation and 




difficult to uncouple the events leading to this phenotype. As close homologues of this gene are 
found in LrATCC 53608 and LrMM4-1a, it is probable that Gtf1 has a similar role in these strains. 
In contrast, western blot analysis of the Lr100-23 insertional mutants of gtfB, asp2 and srr 
showed that WGA recognition of a high molecular weight protein, corresponding to SRRP100-23, 
was abolished, while RCA recognition remained unaffected. This suggests that the proteins 
encoded from gtfB and asp2 are dedicated to the glycosylation and secretion of the SRRP100-23, 
respectively. This is in agreement to secA2/Y2 clusters from other organisms, where the enzymes 
encoded by this system are exclusively involved in the processing of their respective SRRPs 
(190,199,324). Interestingly, an LPxTG-surface anchored protein, found to be recognised by 
WGA, was not affected by either deletion of gtf1 or mutation of gtfB, also suggesting the 
presence of a different glycosylation pathway in Lr100-23.  
Western blot analysis of SM proteins from cultures of LrATCC 53608 and LrMM4-1a using RCA 
showed a similar lectin recognition pattern as for Lr100-23. In contrast, only proteins from the 
Lr100-23 and LrATCC 53608 SM were recognised by WGA. These high molecular weight proteins 
from Lr100-23 and LrATCC 53608 were further identified by MS as the SRRP100-23 and SRRP53608 
(recognised by WGA) and MUB53608 (recognised by RCA). MUB53608 and SRRPs are large surface 
adhesins and protein structures like pili and flagella that have a similar role in adhesion and 
colonisation are often found to be glycosylated in pathogens (166,240,325,326). Additionally, a 
protein identified as a muramidase was recognised by RCA across the three L. reuteri strains. 
This protein had the highest similarity to Acm2, a known glycoprotein from L. plantarum WCFS1 
and a known target of the Gtf1/Gtf2 glycosylation system (275).  
SecA2/Y2 clusters have been primarily identified and studied in oral pathogenic bacteria (see 
section 1.3.3.3.2), and this is the first time that such a glycosylation system is studied in gut 
microbes. RT-PCR analysis of the secA2/Y2 clusters from LrATCC 53608 and Lr100-23 revealed a 




into a single operon that spans from srr to gtfB. Notably, this cluster contains only three putative 
GTs. In contrast, the Lr100-23 cluster is organised into two operons, one spanning from gtfC, the 
first gene of the cluster, to Lr_70901, a gene encoding a reverse transcriptase, and containing 
seven GTs, and a second one that consists of the srr gene alone. The transcriptional organisation 
of the two clusters, although different, suggests a tight and coordinated control of the gene 
expression in both organisms. 
Following identification of MUB53608, SRRP53608 and SRRP100-23 as putative glycoproteins, the 
adhesins were purified by affinity chromatography, taking advantage of their specific binding to 
lectins, and their glycans were analysed by MALDI-ToF and GC-MS. The glycan present on 
SRRP53608 was identified by MALDI-ToF and GC-MS analysis as a GlcNAc-GlcNAc disaccharide 
(Figure 61). GlcNAc was found to be in α-configuration, after enzymatic treatment of SRRP100-23 
with a α- or β-specific N-acetyl-glucosaminidases. SRRP100-23 was found to be glycosylated by 
linear GlcNAc1Hex2 moieties. GC-MS analysis of SRRP100-23 suggested that the hexoses are likely 
to be Glc or Gal (Figure 61).  
The presence of a disaccharide in SRRP53608 is in agreement with the number of GTs encoded by 
the LrATCC 53608 SecA2/Y2 cluster. In all secA2/Y2 clusters from pathogenic bacteria studied to 
date, GlcNAc has been found at the reducing end, as the product of the combined activity of 
GtfA and GtfB, the most conserved and essential GTs of the cluster. However, in the pathogenic 
systems, Glc has been identified as the second residue added to the extending glycan, which 
contrasts with the observation of a second GlcNAc being present in the SRRP53608 glycans. This 
finding suggests that GtfC53608, the enzyme mediating the second glycosylation step uses UDP-
GlcNAc as the donor substrate, in contrast to other studied GtfCs that use UDP-Glc. To 
investigate this hypothesis, and as no suitable acceptor was available, a differential scanning 




the presence of UDP-GlcNAc compared to UDP-Glc, supporting the nature of the GlcNAc-GlcNAc 
glycan structure identified by MALDI-ToF. 
Although MS analysis suggested that SRRP100-23 was glycosylated with trisaccharide moieties, a 
larger glycan was expected based on the number of GTs encoded by the Lr100-23 secA2/Y2 
cluster. Using DSF, we showed that GtfC100-23 had stronger interactions with UDP-Glc, compared 
to UDP-Gal, suggesting that GtfC adds a Glc residue onto the extended glycan. The third 
glycosylation step of SRRP in S. parasanguinis FW213 and S. pneumoniae TIGR4 is mediated by 
a GT containing a DUF1972 (268). The Lr100-23 secA2/Y2 contains three genes encoding such 
enzymes. In addition, GlyD, the respective GT in S. pneumoniae TIGR4 has been shown to use 
both UDP-Glc and UDP-Gal as donor substrates for the glycosylation of the SRRP (268). This may 
also be the case for the Lr100-23 DUF1972-containing genes. However, further experiments are 
required to identify the exact substrate specificity of each enzyme, to allow a thorough 





Figure 61 Model of pathways leading to SRRP53608 and SRRP100-23 glycosylation. 
Here, it is worth noting that DSF was shown to be able to distinguish the different specificities 
of GtfC from Lr100-23 and LrATCC 53608, without the requirement of an acceptor substrate. 
This could have a useful application when analysing unknown GTs or other carbohydrate binding 
enzymes for binding specificity.  
While the mechanism of SRRP glycosylation appears to be conserved among bacterial species, 
their glycan structures are very diverse. For example, SraP, the staphylococcal SRRP, is predicted 
to be glycosylated with single GlcNAc residues (190), while Fap1 in S. parasanguinis FW213 is 
glycosylated with Glc-GlcNAc-(Rha-Glc)-Glc-GlcNAc moieties (191) (see section 1.4.1.2.4). In 
contrast, SRRP100-23 and SRRP53608 are glycosylated with GlcNAc-Glc-Glc (or -Gal) and GlcNAc-
GlcNAc moieties, respectively. However, it is not clear what drives this diversification of the 
glycans. It could be the localisation of the bacteria, as streptococcal and staphylococcal species 




difference in pathogenic or immune-tolerant responses that leads to modifications of the 
glycans. In addition, future work could focus on elucidating the role of glycosylation in the 
binding specificity and interaction of SRRP100-23 and SRRP53608 with the host. 
MUB53608 was identified as a glycoprotein that was recognised by RCA. Thus, it was hypothesised 
that the Gtf1/Gtf2 general glycosylation system was also responsible for the glycosylation of this 
adhesin in LrATCC 53608. To further investigate this hypothesis, Gtf153608 and Gtf253608 were 
cloned and heterologously expressed in E. coli. However, as Gtf153608 was found to be insoluble 
under the conditions tested, the glycosylation system and its putative target proteins could not 
be further characterised. The interaction between MUB53608 and RCA suggests the presence of a 
Gal residue, which present was also confirmed by GC-MS. However, the glycan structure of the 
glycans present on MUB53608 could not be elucidated by MALDI-ToF mass spectrometry. 
Treatment with conformation-specific galactosidases showed that this Gal residue is α-linked. 
α-Linked Gal is part of an immunogenic epitope that is recognised by IgE antibodies and induces 
allergic reactions in humans (327). In addition, using force spectroscopy and slot blot assays, 
MUB53608 was shown to interact with human intelectin 1 (h-Int1, a human lectin that recognises 
galactofuranose (Galf) residues. LrATCC 53608 harbours the necessary genes responsible for the 
synthesis of UDP- Galf, which could be used for protein glycosylation. Galf, often found in 
microbial EPS, was found to be highly immunogenic when interacted with monocyte-derived 
dendritic cells, in a DC-SIGN dependent manner (328). Therefore, the presence of Galf residues 
in MUB53608 is in line with recent work showing that this adhesin interacts with DC-SIGN (175). 
Surface adhesins are important contributors of host-microbe interactions (175,329–331). 
Recent studies showed that gut commensal and probiotic bacteria also utilise these adhesins to 
interact with components of the host immune system and regulate the immune responses in a 
strain-dependent manner (91,116,175,329,332). While the exact nature of these interactions 
remains unknown, the involvement of host lectins suggests that bacterial carbohydrates play an 




from L. rhamnosus interacted with DC-SIGN via the glycan moieties (280). The carbohydrate 
epitopes identified as part of this work could, in part, account for the immunomodulatory 
properties of LrATCC 53608. 
Many efforts are geared towards engineering bacteria to synthesise glycoproteins. For this 
reason, glycosylation systems are extensively studied and characterised for their sugar donor 
specificity, the number and nature of acceptor proteins, as well as the glycosylation sites of the 
target proteins. Most knowledge so far comes from studies carried out with Gram-negative, 
pathogenic bacteria, such as C. jejuni (see section 1.4.1.2). Here we showed the presence of 
Gtf1/Gtf2 and SecA2/Y2 glycosylation systems in Lr100-23 and lrATCC 53608. The work with the 
Lr100-23 mutants showed that the target proteins for each system are distinct, with no 
redundancy or overlapping observed. As the priming GT pairs (Gtf1/Gtf2 and GtfA/GtfB) interact 
with their target proteins via a DUF1975 in order to initiate the glycosylation (274,333,334), it 
would be interesting to identify the amino acids that dictate the substrate specificity. 
Understanding how this priming GTs work, will boost the exploitation of Gram-positive bacteria 
in the field of glycoengineering. The O-glycosylation mechanism mediated by the Gtf1/Gtf2 and 
the SecA2/Y2 cluster offers certain advantages compared to en bloc N-, or O- glycosylation, which 
may increase its applicability in the future. Firstly, it can be functional in both Gram-negative 
and Gram-positive bacteria. The different types of en bloc glycosylation require the inner 
membrane of the Gram-negative bacteria, where the glycan is assembled on a lipid carrier, and 
the periplasmic space, where protein glycosylation takes place (208,209). In contrast, this type 
of O-glycosylation occurs in the cytoplasm, directly onto the target protein (275,335). While 
identified in Gram-positive bacteria, this glycosylation machinery has been shown to be 
functional in the Gram-negative E. coli (191). In addition, the genetic manipulation of engineered 
microorganisms may be easier, due to the decreased size of exogenous DNA transferred, as less 
genes are required for this type of glycosylation (no flippase, or oligosaccharyl-transferase are 




for glycosylation, compared to the en bloc glycosylation systems which only target proteins in 
the periplasmic space. The study of such glycosylation systems in gut commensal bacteria can 
provide invaluable tools in the engineering of novel glycoproteins for industrial and 
pharmaceutical applications. In addition, future work is required to identify the sites of 
glycosylation in the glycoproteins identified in this work, by glycoproteomics analysis, in order 
to understand the acceptor specificity of the enzymes involved in the glycosylation process and 
the requirements of the target glycoproteins. 
The growing interest around gut microbiota and probiotics has led to important insights into the 
mechanisms underpinning the interaction between bacteria and their host. Carbohydrate 
structures surrounding the bacterial cells play a crucial role in this interaction and are often used 
by the host to distinguish between symbiont and pathogenic species. However, it is important 
to also acknowledge the importance of glycans found on adhesins, as these proteins are one of 
the first bacterial components to come in contact with the host. Studies on the role played by 
the glycosylation of the adhesins in successful colonisation and in mediating pro- or anti-
inflammatory properties are therefore required to further our mechanistic understanding of the 
health benefits of these bacterial species. In addition, unravelling the nature of the glycans used 
in protein glycosylation could provide novel ways of designing or selecting probiotic strains. The 
knowledge generated from these studies can also be used to improve ongoing efforts to 
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